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Abstract
The CD2 molecule is a cell surface glycoprotein expressed on rat T cells which 
has numerous functions including the provision of a TCR-independent pathway of T 
cell activation, costimulation in T cell activation via the TCR, intercellular adhesion 
and the transmission of negative signals. Murine studies have shown that targeting 
the CD2 molecule with mAb has potent immunological effects including the 
prolongation of allograft survival. In this project I have assessed the effects of the 
mouse anti-rat CD2 mAb 0X34 and 0X55 in transplant models. 0X34 proved to be 
more effective than 0X55 in the low responder Lewis to DA strain combination, and 
this prolonged graft survival was associated with greater depletion of CD4 T cells by 
0X34. Analysis of the time course and distribution of depletion in different 
lymphocyte compartments suggested that host factors are also involved in 0X34- 
mediated depletion. Despite the potent effects of 0X34 in transplant models it has 
little effect on in vitro allogeneic models compared to those of anti-CD4 mAb. In 
particular 0X34 does not affect proliferation and release of Thi cytokines in the 
MLR and does not prevent anti-TCR-mediated T cell activation. The principal effect 
of 0X34 appears therefore to be depletion of T cells, an effect which is not 
reproduced in in vitro systems. 0X34 mAb was also found to have a synergistic 
action with both the anti-CD4 mAb 0X38 and CTLA4g- Both of these combinations 
were able to induce permanent allograft survival in the high responder DA to Lewis 
combination. Graft survival in these models is associated with abrogation of the anti- 
globlin response combined with profound and prolonged T cell depletion. Evidence 
is presented therefore that, in contrast to murine studies, the principle effect of anti- 
CD2 mAb in rat transplant models is immunosuppression by T cell depletion 
mediated by the delivery of negative signals.
ii
Acknowledgements
I would like to thank my supervisors, Dr Eleanor Bolton and Professor Andrew 
Bradley, for initially conceiving the project and for their advice and technical 
support, and Dr Hilary Armstrong for teaching me the techniques of cellular assays 
used in this work and for her constant help in designing and performing experiments. 
Thanks are also due to Dr Bryon Jaques for teaching me the technique of the 
abdominal rat cardiac allograft and for his initial work on anti-CD4 mAb, on which 
this project is partially based. Technical help was also provided by Mr J Casey, who 
performed some of the transplant experiments using the PVG rat strain, Dr H 
Ahmiedat who performed a number of experimental controls with DA strain rats and 
Dr I Newman for his help with MLR experiments. Lastly I would like also to thank 
Professor Philip Stell for his valuable help with statistical analysis and Dr Elizabeth 
Lim for her constructive criticism and help with computing problems.
Declaration
The data presented in this thesis represent original work performed by the 
author at the Department of Surgery, Western Infirmary, Glasgow between August 
1994 and June 1997. All experiments were performed by the author unless otherwise 
attributed in the text.
Contents
Abst r a c t .............................................................................................................................i
A cknow ledgem ents.....................................................................................................n
D e c l a r a t io n ................................................................................................................................m
Co n ten ts .......................................................................................................................... iv
List of fig u r es ............................................................................................................. x v
List of t a b l e s ...............................................................................................................x x
1 INTRODUCTION................................................................................... 1.1
1.1 T h e  h is t o r y  o f  e x p e r im e n t a l  t r a n s p l a n t a t io n ....................................... 1.1
1.2 T h e  c e l l u l a r  t h e o r y  o f  g r a f t  r e je c t io n ......................................................1 .2
1.3 E f f e c t o r  m e c h a n is m s  in  a l l o g r a f t  r e j e c t io n .......................................... 1 .6
1.3.1 Lymphocyte subsets in graft rejection...............................................1.6
1.3.2 CD4 and CD8 T cell effector functions.............................................1.6
1.3.3 Mechanisms o f graft destruction by T cells.................................... 1.10
1.3.4 Patterns o f  cytokine secretion by helper T cells........................... 1.12
1.3.5 Other immune mechanisms o f  graft destruction........................... 1.12
1.4 T h e  m o l e c u l a r  b a s is  o f  a l l o r e c o g n it io n .................................................1 .13
1.4.1 The T cell receptor complex............................................................ 1.14
1.4.2 The Major Histocompatibility Complex..........................................1.14
1.4.3 Antigen presentation......................................................................... 1.16
1.4.4 CD4 and CD8....................................................................................1.17
1.5 C o s t i m u l a t i o n  in  T  c e l l  a c t i v a t i o n .............................................................. 1 .17
1.5.1 The CD28/CTLA4-B7 pathway o f costimulation.......................... 1.19
1.6 Th e  C D 2  m o l e c u l e ...................................................................................................... 1 .24
1.6.1 Historical background......................................................................1.24
1.6.2 Structure and cellular relations....................................................... 1.24
1.6.3 Distribution.......................................................................................1.25
1.6.4 CD2 ligands.......................................................................................1.26
1.6.5 Functional properties o f CD 2 ......................................................... 1.26
1.7  St r a t e g ie s  t o  in d u c e  a l l o g r a f t  t o l e r a n c e ; n e o n a t a l  t o l e r a n c e  
....................................................................................................................................................................... 1.33
1.8 M o n o c l o n a l  a n t ib o d ie s  in  t r a n s p l a n t  t o l e r a n c e ............................. 1.35
1.8.1 Antibody structure............................................................................ 1.36
1.8.2 The mechanism o f immunosuppression by monoclonal antibody in 
animal models o f transplantation................................................  1.37
1 .9  ANTI-CD4 MONOCLONAL ANTIBODIES IN ANIMAL MODELS OF 
TRANSPLANTATION............................................................................................................................  1 .42
1.9.1 General immunological effects o f anti~CD4 mormclonal antibody 
therapy.................................................................................................................. 1.43
L9.2 Influence o f  anti-CD4 therapy on allograft survival..,,..................... 1,44
1.9.3 Depleting and non-depleting anti-CD4 antibody regimens 1.46
1.9.4 Differential effects o f  anti-CD4 mAb on CD4 subsets....................1.48
1.9.5 Induction o f  non-classical tolerance by anti-CD4 mAb therapy in 
transplant models................................................................................................. 4.49
1 .10  ANTT-CD2 MONOCLONAL ANTIBODIES IN EXPERIMENTAL 
TRANSPLANTATION............................................................................................................................  1 .54
1.10.1 Anti-CD2 monoclonal antibody therapy in murine models o f 
transplantation......................................................................................................1.54
1.10.2 Anti-CD2 monoclonal antibody therapy in rat models o f  
transplantation......................................................................................................1.56
1.10.3 Mechanisms o f  action o f  anti-CD2 mAb therapy in rodent studies 
................................................................................................................................1.57
1.10.4 Anti-CD2 mAb therapy in primate models....................................1.59
1.11 B l o c k a d e  o f  t h e  CD28-B7 p a t h w a y  in  e x p e r im e n t a l  
TRANSPLANTATION..................................................................................................  1.60
1.11.1 Construction ofCTLAJg ................................................................1.60
1.11.2 Immunological effect o f  CTLA4g therapy.....................................1.60
1.11.3 CTLA4g therapy in transplant models..........................................1.62
1.11.4 Mechanism o f tolerance induction by CTLAl4g therapy............. 1.64
1.12 H ig h  a n d  l o w  r e s p o n d e r  r a t  s t r a in s  in  t r a n s p l a n t  m o d e l s  ...1.67
1.13 A im s  o f  t h is  p r o je c t .........................................  1.70
2 MATERIALS AND METHODS......................................................... 2.73
2.1 M e d ia  u s e d  w it h  l y m p h o c y t e  p r e p a r a t io n s ............................................ 2.73
2.1.1 Wash medium:...................................................................................2.73
2.1.2 Culture medium:............................................................................... 2.73
2.2 M a in t e n a n c e  o f  h y b r id o m a s ..............................................................................2.73
2.2.1 Monoclonal antibodies used in in vitro and in vivo experiments. 2.74
2.2.2 Preparation o f monoclonal antibodies............................................ 2.74
2.2.3 Characterisation o f  monoclonal antibody...................................... 2.75
2.3 E x p e r im e n t a l  a n i m a l s ............................................................................................ 2.75
2.3.1 Heterotopic heart transplantation................................................... 2.75
2.4 Pr e p a r a t io n  o f  c e l l  s u s p e n s io n s ......................................................................2.76
2.4.1 Preparation o f purified CD4 T cells................................................2.77
2.4.2 Preparation o f  Concanavalin A transformed lymphoblasts (Con A 
blasts).................................................................................................................... 2.77
2.5 A s s a y  o f  a n t ib o d y -in d u c e d  c e l l u l a r  a c t iv a t io n ............................... 2.77
vii
2 .6  T h e  m ix e d  l y m p h o c y t e  r e a c t io n  (M L R )......................................................2 .7 8
2 .7  IL 2 ASSAY........................................................................................................................... 2 .7 9
2 .8  y lF N  ASSAY........................................................................................................................ 2 .7 9
2 .9  P r e p a r a t io n  o f  t a r g e t  c e l l s  f o r  c y t o t o x ic it y  a s s a y s ....................2 .8 0
2.10 In  v itro  g e n e r a t i o n  o f  c y t o t o x i c  T  l y m p h o c y t e s  (C T L s ) ........... 2 .8 0
2 .11  C T L -m e d ia t e d  c y t o t o x ic it y  a s s a y ..............................................................2 .81
2.11.1 NK cell-mediated cytotoxicity assay..............................................2.82
2 .1 2  Fl o w  c y t o m e t r ic  a n a l y s is  o f  l y m p h o c y t e  a n t ig e n  e x p r e s s io n
AFTER IN VIVO MONOCLONAL ANTIBODY THERAPY..............................................................2 .8 2
2 .1 3  Fl o w  c y t o m e t r ic , a n a l y s is  o f  e l im in a t io n  o f  c ir c u l a t in g
ANTIBODY AFTER INTRAVENOUS ADMINISTRATION..............................................................2 .8 3
2 .1 4  Fl o w  c y t o m e t r ic  d e t e c t io n s  o f  c ir c u l a t in g  a n t ig l o b u l in
RESPONSE AFTER INTRAVENOUS ADMINISTRATION OF MONOCLONAL ANTIBODY. 2 .8 4
2 .1 5  D e t e r m in a t io n  o f  t o t a l  c ir c u l a t in g  l e u k o c y t e  n u m b e r ........... 2 .8 6
2 .1 6  A n t ib o d y -m e d ia t e d , c o m p l e m e n t -d e p e n d e n t  c y t o t o x ic it y  a s s a y  
 2 .8 6
2 .1 7  M o n o c l o n a l  a n t ib o d y -m e d ia t e d  a n t ib o d y -d e p e n d e n t  c e l l u l a r  
CYTOTOXICITY.......................................................................................................................................2 .8 7
2 .1 8  S t a t ist ic a l  a n a l y s i s ..............................................................................................2 .8 7
2.18.1 Parametric data.............................................................................. 2.87
2.18.2 Non-parametric data......................................................................2.88
3 EFFECT OF MONOCLONAL ANTIBODY THERAPY ON 
SURVIVAL OF CARDIAC ALLOGRAFTS IN HIGH AND LOW 
RESPONDER STRAIN RATS.............................................................................3.89
3.1 S t u d y  o b je c t iv e : ..........................................................................................................3 .8 9
3 .2  S t u d y  d e s ig n :..................................................................................................................3 .8 9
Vlll
3 .3  Su r v iv a l  o f  c a r d ia c  a l l o g r a f t s  in  u n t r e a t e d  a n i m a l s ................ 3 .9 0
3 .4  E x p e r im e n t s  t o  a s s e s s  t h e  a b il it y  o f  m o n o c l o n a l  a n t ib o d y
THERAPY TO PROLONG ALLOGRAFT SURVIVAL IN LOW RESPONDER RATS..................3 .91
3.4.1 Effect o f 0X34 and 0X55 therapy on survival o f  Lewis allografts in 
DA strain rats....................................................................................................... 3.91
3.4.2 Anti-CD2, anti-CD4, anti-TCR and CTLA4g therapy all induce 
long-term allograft survival in DA rats..............................................................3.93
3 .5  E x p e r im e n t s  t o  a s s e s s  t h e  a b il it y  o f  t a r g e t in g  a c c e s s o r y
MOLECULES TO PROLONG ALLOGRAFT SURVIVAL IN HIGH RESPONDER RATS...........3 .9 4
3.5.1 Combination therapy in the prolongation o f  allograft survival in 
high responder strain rats. .............................       3.95
3 .6  C o n c l u s io n s  a n d  d is c u s s io n  o f  r e s u l t s ......................................................3 .9 9
3.6.1 Monoclonal antibody therapy in low responder DA rats.............. 3.99
3.6.2 Monoclonal antibody therapy in high responder Lewis andPVG rats 
..............................................................................................................................3.101
4 THE COMPARATIVE EFFECT OF ANTI-CD2 MONOCLONAL 
ANTIBODY ON IN VITRO LYMPHOCYTE FUNCTIONS......................... 4.105
4.1  S t u d y  o b j e c t iv e ........................................................................................................ 4 .1 0 5
4 .2  S t u d y  d e s ig n ................................................................................................................ 4 .1 0 6
4 .3  A n a l y s is  o f  t h e  e f f e c t  o f  m o n o c l o n a l  a n t ib o d y  o n  a s s a y s  o f  T
CELL FUNCTION: T  CELL ACTIVATION......................................................................................4 .1 0 8
4.3.1 Anti-CD2 monoclonal antibody as a mitogen..............................4.108
4.3.2 Effect o f  anti-CD2 monoclonal antibody on the mixed lymphocyte 
reaction...............................................................................................................4.109
4.3.3 Effect o f CTLA4g on the mixed lymphocyte reaction................. 4.112
4.3.4 Analysis o f  the effect o f monoclonal antibody on assays o fT  cell
function: anti-TCR antibody mediated activation............................................4.113
4 .4  A n a l y s is  o f  t h e  e f f e c t  o f  m o n o c l o n a l  a n t ib o d y  o n  a s s a y s  o f  T  
c e l l  f u n c t io n : c y t o k in e  p r o d u c t io n ..............................................................................4 .1 1 5
4.4.1 Influence o f  monoclonal antibody on IL2 production in MLR 
supernatants........................................................................................................4.115
4.4.2 Influence o f monoclonal antibody on jdFN production in MLR 
supernatants........................................................................................................4.117
4.4.3 Cytokine production by anti-TCR stimulated lymphocytes 4.118
4 .5  A n a l y s is  o f  t h e  e f f e c t  o f  m o n o c l o n a l  a n t ib o d y  o n  a s s a y s  o f  T  
c e l l  f u n c t io n : l y m p h o c y t e  e f f e c t o r  f u n c t io n s .................................................... 4 .1 1 9
4 .6  A n a l y s is  o f  t h e  e f f e c t  o f  m o n o c l o n a l  a n t ib o d y  o n  a s s a y s  o f  
N a t u r a l  K il l e r  c e l l  f u n c t io n s ........................................................................................ 4 .1 2 2
4 .7  A n a l y s is  o f  t h e  a b il it y  o f  m o n o c l o n a l  a n t ib o d y  t o  l y s e  T  c e l l s
BY COMPLEMENT FIXATION......................................................................................................... 4 .1 2 3
4 .8  A n a l y s is  o f  t h e  a b il it y  o f  m o n o c l o n a l  a n t ib o d y  t o  l y s e  T  c e l l s  
BY PROMOTING ADCC...................................................................................................................4 .1 2 4
4 .9  C o n c l u s io n s  a n d  d is c u s s io n  o f  r e s u l t s ..................................................4 .1 2 5
4.9.1 Direct mitogenic effect o f monoclonal antibody...................... 4.125
4.9.2 Influence o f monoclonal antibody on mixed lymphocyte reactions 
..............................................................................................................................4.125
4.9.3 Influence o f monoclonal antibody on anti-TCR mediated T cell 
activation.............................................................................................................4.127
4.9.4 Influence o f  monoclonal antibody on mitogen-induced cytokine 
elaboration..........................................................................................................4.127
X4.9.5 Influence o f  monoclonal antibody on CTL generation and function
..............................................................................................................................4.129
4.9.6 Influence o f  monoclonal antibody on NK cell function in in vitro 
assays..................................................................................................................4.131
4.9.7 Mechanisms o f monoclonal antibody-mediated cellular lysis.... 4.132
5 THE COMPARATIVE IN VIVO EFFECTS OF ANTI-CD2 
MONOCLONAL ANTIBODY THERAPY..................................................... 5.135
5.1 St u d y  o b j e c t iv e .........................................................................................................5.135
5.1.1 Pharmacokinetics o f anti-CD2 mAb therapy............................... 5.135
5.1.2 Pharmacodynamics o f  anti-CD2 mAb therapy.............................5.136
5.2 St u d y  d e s ig n .................................................................................................................5.136
5.3 D is t r ib u t io n  o f  t h e  CD2 m o l e c u l e ..............................................................5.139
5.4 D is t r ib u t io n  o f  t h e  B7 m o l e c u l e ..................................................................5.140
5.5 P h a r m a c o k in e t ic s  o f  m o n o c l o n a l  a n t ib o d y  t h e r a p y ..................5.146
5.5.1 Distribution o f 0X34 after intravenous administration.............. 5.146
5.5.2 Elimination o f 0X34 and 0X38 by DA and Lewis strain rats after 
intravenous injection..........................................................................................5.149
5.5.3 Distribution o f CTLAflg after intravenous injection....................5.154
5.5.4 Elimination o f 0X34 by Lewis strain rats after intravenous injection 
in combination with CTLAflg........................................................................... 5.154
5.6 P h a r m a c o d y n a m ic s  o f  0X34 m o n o c l o n a l  a n t ib o d y  t h e r a p y  5.157
5.6.1 Effect on lymphocyte populations o f intravenous 0X34 therapy in 
DA rats.................................................................................................................5.157
5.6.2 Comparison o f  the depleting effect o f 0X55 and 0X34 in DA strain 
rats...................................................................................................................... 5.161
XI
5.6.3 Comparison o f the depleting effect o f 0X34 with 0X38 in high and
low responder strain rats................................................................................. 5.163
5.6.4 Effect on lymphocyte populations o f intravenous CTLAflg therapy. 
............................................................................................................................ 5.166
5.6.5 Dose effect on saturation o f  the CD2 molecule after 0X34 therapy 
............................................................................................................................ 5.167
5.6.6 Effect o f  anti-CD2 monoclonal antibody on CD2 expression.... 5.168
5.6.7 CD2 modulation induced by in vitro culture with monoclonal 
antibody............................................................................................................. 5.168
5.7 E f f e c t  o n  l y m p h o c y t e  p o p u l a t io n s  o f  c o m b in e d  0X34 a n d  0X38 
m o n o c l o n a l  a n t ib o d y  t h e r a p y ....................................................................................... 5.171
5.7.1 Modulation o f leukocyte antigens in Lewis rats by combined 0X34 
and 0X38 monoclonal antibody therapy........................................................5.175
5.8 E f f e c t  o n  ly m p h o c y t e  p o p u la t io n s  o f  c o m b in e d  CTLA4IG a n d  
0X34 MONOCLONAL ANTIBODY THERAPY...........................................................5.177
5.8.1 Comparative CD4 T cell depletion in Lewis rats after OX34-based 
regimes...............................................................................................................5.179
5.9 C o n c l u s io n s  a n d  d is c u s s io n  o f  r e s u l t s ................................................. 5.180
5.9.1 CD2 antigen expression in lymphocyte subsets...........................5.180
5.9.2 B7 antigen expression on activated, but not tolerant B cells......5.181
5.9.3 Distribution o f 0X34 monoclonal antibody after intravenous 
administration................................................................................................... 5.181
5.9.4 Elimination o f  mAb in high and low responder strain rats........ 5.182
5.9.5 Elimination o f mAb in high responder strain rats treated with 0X34 
and CTLA4g..................................................................................................... 5.184
5.9.6 Monoclonal antibody mediated cellular depletion..................... 5.185
Xll
5.9.7 Differential depletion o fT  cell subsets by anti-CD2 mAb........... 5.187
5.9.8 Dose effect in mAb-mediateddepletion.........................................5.189
5.9.9 Comparison o f depleting effects o f  0X34 and 0X 55 .................. 5.189
5.9.10 Comparison o f  the depleting effects o f 0X34 and 0X38 in DA and 
Lewis rats............................................................................................................5.191
5.9.11 Assessment o f  the depleting effect ofCTLAflg ...........................5.191
5.9.12 The effect o f  anti-CD2 mAb on NK cells.................................... 5.191
5.9.13 Anti-C.D2 monoclonal antibody mediated ligand saturation... 5.193
5.9.14 Effect o f 0X34 monoclonal antibody on CD2 expression.........5.194
5.9.15 Effect o f combined 0X34 and 0X38 therapy on lymphocyte 
populations.........................................................................     5.196
5.9.16 Effect o f combined 0X34 and 0X38 on lymphocyte antigen 
expression...........................................................................................................5.197
5.9.17 Effect o f combined 0X34 and CTLAflg on lymphocyte populations 
and antigen expression......................................................................................5.198
6 ANALYSIS OF ALLOREACTTVITY IN TRANSPLANTED 
ANIMALS TREATED WITH ANTI-CD2 MONOCLONAL ANTIBODY. 6.199
6.1 S t u d y  o b j e c t iv e ........................................................................................................ 6 .1 9 9
6.1.1 Assessment o f  transplant tolerance................................................6.199
6.1.2 Analysis o f mechanisms o f  transplant tolerance...........................6.199
6 .2  S t u d y  d e s ig n .................................................................................................................6 .2 0 0
6 .3  D e m o n s t r a t io n  o f  t r a n s p l a n t  t o l e r a n c e ..............................................6 .2 0 2
6 .4  A n a l y s is  o f  m e c h a n is m s  o f  t r a n s p l a n t  t o l e r a n c e  in  D A  s t r a in  
r a t s ........................................................................................................................................................ 6 .2 0 4
6.4.1 Assessment o f  alloreactivity o f  lymphocytes from DA strain rats 
treated with 0X34 on in vitro stimulation........................................................ 6.204
xiii
6.4.2 Analysis o f cytokine production in mixed lymphocyte reactions using 
tolerant DA strain responders.......................................................................... 6.204
6.4.3 Assessment o f  alloreactivity o f  lymphocytes from DA strain rats 
treated with CTLAAg on in vitro stimulation...................................................6.207
6.4.4 Proliferative responses o f tolerant Lewis rats treated with 0X34 and 
0X38..................................................................................................................  6.208
6.4.5 Cytokine production by lymphocytes from tolerant Lewis rats treated 
with 0X34 and0X38.........................................................................................6.209
6.4.6 Proliferative responses o f tolerant Lewis rats treated with 0X34 and 
CTLA4g..............................................................................................................6.211
6 .5  A n a l y s i s  o f  a l l o - s p e c i f i c  e f f e c t o r  m e c h a n is m s  in  t o l e r a n t  L e w is  
RATS AFTER THERAPY WITH 0 X 3 4  AND 0 X 3  8 ....................................................................6 .2 1 3
6.5.1 Assessment o f allospecific CTL in tolerant Lewis rats.................6.213
6.5.2 Assessment o f alloantibody production by tolerant Lewis rats after 
therapy with 0X34 and0X38........................................................................... 6.214
6 .6  C o n c l u s io n s  a n d  d is c u s s io n  o f  r e s u l t s ................................................. 6 .2 1 7
6.6.1 Demonstration o f  transplant tolerance.........................................6.217
6.6.2 Analysis o f proliferative responses in transplanted rats. .......... 6.218
6.6.3 Analysis o f  cytokine production in MLR experiments..................6.219
6.6.4 Analysis o f  effector mechanisms in tolerant Lewis rats after therapy 
with 0X34 and 0X38 .......................................................................................  6.220
7 SUMMARY......................................................................................... 7.221
7.1 T h e  jn  vivo  p r o p e r t ie s  o f  a n t i-C D 2  m A b ................................................. 7 .2 2 1
7 .2  T h e  i n  v itro  p r o p e r t ie s  o f  a n t i-C D 2  m A b .................................................7 .2 2 3
7 .3  C o m b in a t io n  t h e r a p y  in  h ig h  r e s p o n d e r  Le w is  s t r a in  r a t s  .... 7 .2 2 5
7 .4  F in a l  s y n o p s is ..............................................................................................................7 .2 2 6
7.4.1 Future pospects 
REFERENCES
XV
List of figures
Figure 2.1 In vitro generation of allo-CTL................................................................. 2.81
Figure 2.2 Positive and negative controls in flow cytometry experiments 2.83
Figure 2.3 Positive and negative controls in flow cytometric detection of circulating
mAb in rat serum..................................................................................................2.84
Figure 2.4 Flow cytometric detection of circulating antiglobulin response 2.85
Figure 3.1 Survival of cardiac allografts in untreated control ra ts...........................3.90
Figure 3.2 Effect on graft survival in DA rats o f pre-operative 0X34 therapy 3.92
Figure 3.3 Effect on graft survival in DA rats of pre-operative 0X55 or high dose
0X34 therapy....................................................................................................... 3.92
Figure 3.4 Effect on graft survival in DA rats of post-operative 0X34 therapy.... 393 
Figure 3.5 0X34, 0X38 and CTLAdg induce permanent graft survival in DA rats
................................................................................................................................3.94
Figure 3.6 0X34, 0X38 and CTLAdg fail to induce permanent allograft survival in
Lewis rats..............................................................................................................3.95
Figure 3.7 Combination therapy with 0X34 and R73 in Lewis rats........................3.96
Figure 3.8 Combination therapy with 0X34 and R73 in PVG rats..........................3.98
Figure 3.9 Combination therapy with 0X34 and 0X38 in Lewis rats.................... 3.98
Figure 3.10 Combination therapy with 0X34 and CTLAJg in Lewis rats............. 399
Figure 4.1 Effect of 0X34 compared to 0X38 and CTLAjIg on proliferation in MLR
experiments........................................................................................................ 4,110
Figure 4.2 Dose effect of 0X34 in MLR experiments.......................................... 4.111
Figure 4.3 Dose effect of 0X55 in MLR experiments.......................................... 4.111
Figure 4.4 Dose effect of CTLAdg in MLR experiments using DA and Lewis strain 
responders......................................................................................................... 4.112
xvi
Figure 4.5 0X34 and CTLAdg are unable to inhibit T cell activation via TCR.. 4.114 
Figure 4.6 Dose effect of 0X34 in anti-TCR mAb mediated proliferation
experiments.......................................................................................................4.114
Figure 4.7 Effect of mAb on IL2 production by lymphocytes in the MLR 4.116
Figure 4.8 Effect of dose range of anti-CD2 mAb on IL2 production by lymphocytes
in the MLR........................................................................................................4.116
Figure 4.9 Influence of 0X34, 0X55, 0X38 and CTLAdg on ylFN production by
anti-TCR stimulated lymphocytes.................................................................. 4.118
Figure 4.10 Influence of dose range of 0X34 on ylFN production by anti-TCR
stimulated lymphocytes...................................................................................4.119
Figure 4.11 Effect of 0X34 on the in vitro induction of CTL.............................. 4.120
Figure 4.12 Effect of 0X34 on the lytic capacity of allo-CTL............................. 4.121
Figure 4.13 Effect of 0X34 on the in vitro amplification of NK activity 4.122
Figure 4.14 Effect of 0X34 on the lytic capacity of NK cells............................. 4.123
Figure 4.15 Assessment of the ability of mouse mAb to fix rat complement in vitro
............................................................................................................................4.124
Figure 4.16 Assessment of the ability of mouse mAb to promote ADCC by NK cells
in vitro............................................................................................................... 4.125
Figure 5.1 Distribution of the CD2 molecule on lymphoid cell subsets................5.141
Figure 5.2 Distribution of CD2 on T cells..............................................................5.142
Figure 5.3 CD2 is not expressed by B cells............................................................. 5.143
Figure 5.4 CD2 expression on T cell subsets........................................................... 5.144
Figure 5.5 Labelling with 0X34 by peritoneal macrophages.................................5.144
Figure 5.6 B7 expression on non-T cells from a rat rejecting an allograft 5.145
Figure 5.7 B7 expression on non-T cells in tolerant Lewis rats........................... 5.145
XVII
Figure 5.8 Saturation of binding sites on LNCs and thymocytes after 0X34 therapy
............................................................................................................................. 5.147
Figure 5.9 Saturation of binding sites on LNCs after low dose 0X34 therapy.... 5.148 
Figure 5.10 Failure of DA strain rats to produce IgG antiglobulins against either
0X34 or 0X38 fourteen days after administration......................................... 5.151
Figure 5.11 Lewis strain rats produce IgG antiglobulins against 0X38 but not 0X34
fourteen days after administration................................................................... 5.152
Figure 5.12 Lewis strain rats but not DA strain rats produce IgG antiglobulins against
0X34 twenty-one days after administration...................................................5.153
Figure 5.13 T cell depletion by 0X 3 4 .................................................................... 5.157
Figure 5.14 Preferential depletion of CD4 T cells by 0X 34 .................................. 5.158
Figure 5.15 Relative preponderance of B cells after 0X34 therapy..................... 5.159
Figure 5.16 Effect of dose of 0X34 on lymphocyte depletion............................. 5.160
Figure 5.17 Effect of 0X34 therapy on NK cell function.....................................5.162
Figure 5.18 Depleting effect of 0X55 therapy.......................................................5.162
Figure 5.19 Total circulating leukocyte count in DA rats treated with 0X34 or 0X38
..............................................................................................................................5.164
Figure 5.20 Total circulating leukocyte count in Lewis rats treated with 0X34 or
0X38................................................................................................................... 5.164
Figure 5.21 Depletion of CD4 T cells in DA rats treated with 0X34 or 0X38... 5.165 
Figure 5.22 Depletion of CD4 T cells in Lewis rats treated with 0X34 or 0X38 5.166
Figure 5.23 0X34 mAb-mediated modulation of the CD2 molecule.................... 5.169
Figure 5.24 Expression of the CD2 molecule after intravenous therapy with 0X55 
..............................................................................................................................5.170
Figure 5.25 Lymphocyte depletion in Lewis rats treated with 0X34 and 0X38. 5.172
XV111
Figure 5.26 T cell depletion in Lewis rats treated with 0X38, 0X34 or both
modalities............................................................................................................5.173
Figure 5.27 CD4 T cell depletion in Lewis rats treated with 0X38, 0X34 or both
modalities............................................................................................................5.173
Figure 5.28 CD8 T cell population in Lewis rats treated with 0X38, 0X34 or both
modalities............................................................................................................5.174
Figure 5.29 Proportion of monocytes in Lewis rats treated with 0X34 and 0X38
............................................................................................................................. 5.175
Figure 5.30 Differential re-expression of CD2 and CD4 after dual therapy with 0X34
and 0X38 in Lewis rats .................................................................................... 5.176
Figure 5.31 Total circulating leukocyte count in Lewis rats treated with 0X34 and
CTLA4Ig..............................................................................................................5.178
Figure 5.32 Lymphocyte subset frequencies in transplanted Lewis rats (n=5) treated
with 0X34 and CTLAftg.................................................................................. 5.178
Figure 6.1 Survival of second transplants in DA strain rats treated with 0X34
(2x5mg/kg) preoperatively................................................................................ 6.203
Figure 6.2 Survival of second transplants in Lewis strain rats treated with 0X34 and
0X 38...................................................................................................................6.203
Figure 6.3 Proliferation of cells from naive and tolerant DA rats after therapy with
0X34 on in vitro stimulation with donor antigen............................................6.206
Figure 6.4 Production of Thi cytokines by cells from tolerant and naive DA rats on in
vitro stimulation with donor antigen.................................................................6.206
Figure 6.5 Proliferation of cells from naive and tolerant DA rats after therapy with
CTLAftg on in vitro stimulation with donor antigen...................................... 6.207
Figure 6.6 Proliferation of cells from tolerant Lewis rats after therapy with 0X34 and 
0X38 on in vitro stimulation with donor antigen............................................6.208
XIX
Figure 6.7 Production of IL2 by cells from tolerant Lewis rats after therapy with
0X34 and 0X38 on in vitro stimulation with donor antigen....................... 6.209
Figure 6.8 Production of IL2 by cells from tolerant Lewis rats after therapy with 
0X34 and 0X38 on in vitro stimulation with donor antigen and third party
antigen............................................................................................................... 6.210
Figure 6.9 Production of ylFN by cells from tolerant Lewis rats on in vitro
stimulation with donor antigen....................................................................... 6.211
Figure 6.10 Proliferation of cells from Lewis rats with long surviving grafts after 
therapy with 0X34 and CTLAJg on in vitro stimulation with donor antigen
 6.212
Figure 6.11 Generation of donor-specific allo-CTL by tolerant Lewis rats treated
with 0X34 and 0X 38...................................................................................... 6.214
Figure 6.12 Generation of donor-specific cytotoxic alloantibody by tolerant Lewis
rats treated with 0X34 and 0 X 3 8 .................................................................. 6.215
Figure 6.13 Generation of donor-specific alloantibody of IgM subclass by tolerant
Lewis rats treated with 0X34 and 0X38........................................................6.216
Figure 6.14 Generation of donor-specific alloantibody of IgG subclass by tolerant
Lewis rats treated with 0X34 and 0X 38........................................................6.216
Figure 6.15 Generation of donor-specific alloantibody of IgG and IgM subclass by 
tolerant Lewis rats treated with 0X34 and 0X38 during the induction of 
transplant tolerance...........................................................................................6.217
XX
List of tables
Table 2.1 Reagents used in transplant experiments...................................................2.74
Table 4.1 Direct mitogenic effect of 0X34 compared to R73.............................. 4.109
Table 4.2 Influence of 0X 34,0X 55,0X 38 and CTLAdg on ylFN production in the
MLR....................................................................................................................4.117
Table 5.1 Elimination of 0X34 and 0X38 by DA and Lewis rats.......................5.150
Table 5.2 Effect of CTLA^g on elimination of 0X34 in Lewis rats...................5.155
Table 5.3 Abrogation of anti-globulin response by CTLAJg and graft survival. 5.156 
Table 5.4 Estimation of labeling with 0X34 and R73 on residual cells after 0X34
therapy.................................................................................................................5.161
Table 5.5 Differential effect of 0X55 therapy on T cell subsets............................5.163
Table 5.6 Comparison of CD4 number in Lewis and DA rats after therapy with
0X 34...................................................................................................................5.166
Table 5.7 Estimation of B cell frequency at 24 hours in untransplanted DA rats
treated with CTLAdg (2.5mg/kg).....................................................................5.167
Table 5.8 Comparison of CD4 T cell depletion by OX34-based regimes.............5.179
1.1
1 Introduction
1.1 The history of experimental transplantation
Although mediaeval surgeons have been depicted attempting limb 
transplantation in humans (1) the earliest recorded work in English of systematic 
attempts at experimental transplantation were made by John Hunter in the 18th 
Century (2). During his investigations into the process of inflammation Hunter 
included a number of experiments on tissue and organ transplantation in cocks and 
humans. Although these experiments generally failed and Hunter did not distinguish 
between auto, alio and xenotransplantation he firmly established animal 
experimentation as a tool in transplant research.
In the early 19 Century tumour biologists made many useful observations on 
the viability of transplanted tumours in rodents. For example it was noticed that adult 
animals have complete immunity to proliferation of transplanted tumours from a 
different species and that a spontaneous tumour arising in white mice was 
transmissible to all other members of an in-bred closed colony but not to other mice 
(3).
Efforts were made initially to explain tumour immunity by analogy to classical 
bacterial immunity. Many attempts were made to demonstrate cytolytic antibody in 
immune animals but no immune serum was shown to be capable of inhibiting tumour 
growth. This led to the suggestion by JB Murphy in 1926 that graft rejection may be 
due to a cellular reaction on the part of the host (4).
The first demonstration that successful tumour transplantation depends on 
donor and host sharing a tissue antigen, which is absent from resistant hosts, was 
made by Gorer in 1937 (5). Gorer had earlier shown that albino strain mice possess
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an antigen (which he called antigen II, later H-2) on their erythrocytes, which is 
absent from a black strain (6). In a series of tumour transplants between F2 hybrids 
Gorer showed that the presence of the antigen on the erythrocytes of both hosts and 
donors was essential for successful transplantation. In these experiments Gorer was 
fortunate in using mice as experimental models which, very unusually, express MHC 
antigens on mature erythrocytes. Gorer demonstrated that the barrier to successful 
transplantation is an antigenic difference between donor and host. This could only be 
demonstrated at the time using serological methods, Gorer therefore became an 
advocate of the antibody-mediated model of allograft rejection, a model which 
persisted until the later work of Medawar.
The techniques of organ grafting were initially perfected by Alexis Carrel. In 
1905 Carrel demonstrated the feasibility of organ transplantation by grafting the 
kidney of a small dog into its neck (7) and later published a large series of renal 
allografts in cats (8). All animals ultimately died following this procedure, although 
one animal survived for 29 days. Carrel established beyond doubt that vascularised 
organ transplantation was a technical possibility and paved the way for organ 
transplantation in clinical practice.
1.2 The cellular theory of graft rejection
The Second World War provided the impetus for Medawar’s research into skin 
transplantation. The first of Medawar’s studies of skin graft rejection was a case 
report of a patient with extensive bums treated with a combination of skin autografts 
and allografts in Glasgow Royal Infirmary in 1942 (9). Fifty pinch grafts of each 
type were used (the donor was the patients brother) and 15 days after the first set of 
allografts a ‘second set’ of allografts were taken from the same donor. The autografts 
therefore provided a control against which to assess changes in the allografts. The
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tempo of the first and second set responses suggested an active immune reaction was 
responsible for graft rejection. Medawar then repeated these experiments in great 
detail in a large number of outbred rabbits (10). This paper was the first to use graft 
survival curves and median survival time to illustrate differences in graft survival. It 
was shown that allografts failed to survive and that the speed of the necrosing 
process depended on the mass of transplanted skin. Characteristic of the 
inflammatory process was an intense infiltrate of lymphocytes and monocytes, which 
were visible to the naked eye in stained sections as a black band within the dermis. 
This paper also confirmed the specificity of the graft reaction, as a second set of 
grafts applied from the original donor demonstrated shorter survival. Furthermore the 
site of grafting the second set did not significantly affect the outcome of the graft, 
suggesting that the sensitisation was a generalised phenomenon. Medawar concluded 
that the mechanism of elimination of foreign skin ‘belongs to the general category of 
actively acquired immunity’.
Gorer’s demonstration of transplantation antigens and anti-H2 antibodies (11) 
lead to a belief that transplant rejection was predominantly antibody mediated. 
Medawar however demonstrated that epithelium cultured by flotation in vitro 
proliferated and coalesced equally on serum from specifically immunised or naive 
rabbits (12). Convincing evidence for the role of lymphocytes in graft rejection came 
with the development of the technique of adoptive transfer of serum and cells 
between animals of an identical strain. In 1953 Avrion Mitchison showed that 
accelerated rejection of skin grafts could be transferred passively to naive mice by 
the intraperitoneal inoculation of lymph node cells from immune animals (13). 
Inoculations of serum were ineffective (14). These results were later greatly extended 
by Billingham using skin grafts in mice (15). These workers found that sensitised 
regional lymph node cells were particularly effective at transferring immunity.
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Another technical advance which was useful in the ‘cellular versus humoral’ debate 
was the development of cellulose millipore chambers, which permit diffusion of 
humoral but not cellular components. It was shown in that tumour allografts, which 
are normally rapidly destroyed in sensitised hosts, are able to survive indefinitely in 
such animals if they were cultured lin vivo ’ inside a diffusion chamber (16).
The role of lymphocytes in graft rejection became clear in the 1960s when 
Govaerts performed a series of kidney allografts in dogs and removed thoracic duct 
lymph (which contains a very high percentage of small lymphocytes (17)) from these 
animals after they had rejected their grafts (18). The contained cells were then shown 
by histological methods to be cytotoxic for a culture of renal epithelial cells from the 
second kidney of the donor. Further definition of the role of lymphocytes in the 
initiation of immune responses was made by Gowans who demonstrated that 
depletion of small lymphocytes from an animal by thoracic duct drainage severely 
impaired its ability to generate antibody and DTH responses (19) and by Terasaki 
who fractionated the leukocyte elements of blood into monocytes, polymorphs and 
lymphocytes and showed that the lymphocyte component was responsible for 
producing the splenomegaly characteristic of graft-versus-host disease when adult 
cells were injected into newborn chicks (20).
It was therefore becoming recognised that small lymphocytes are involved in 
many aspects of immunity and are fundamental to the allograft response. Of 
considerable importance was the chance discovery of the mixed leukocyte reaction in 
1964 (21). During an experiment to assess the morphology of lymphocytes from 
leukaemic patients cells from two different patients were inadvertently mixed. It was 
noticed that in this culture some cells grew in size and went into mitosis. These 
experiments were then extended to include white cell fractions from normal 
volunteers and it was noted that only lymphocytes from genetically distinct
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individuals were able provoke the reaction, and that this blast transformation of 
lymphocytes could be assessed by the incorporation of tritiated thymidine. As 
genetic studies showed that the magnitude of the MLR response tended to correlate 
with the degree of genetic disparity between individuals (22) it was conjectured that 
this reaction had some similarities to the allograft reaction and could be used as a 
predictive assay of the likelihood of graft rejection between individual patients (23).
Using vital dyes to quantitate the cytotoxic activity of lymphocytes it was 
shown by culturing lymph node cells from sensitised rats with donor strain 
lymphocytes that there was an exponential reduction in the number of surviving 
target cells with increasing concentration of effector cells (24, 25). From these 
experiments it was deduced that approximately 1-2% of lymph node cells from an 
allosensitised animal are capable of specific cytotoxicity and that antiserum has an 
inhibitory effect on cellular cytotoxicity in keeping with the phenomenon of 
enhancement. Measurement of cytotoxicity became much easier after the 
development of a quantitative assay in 1968. Brunner devised a technique of 
‘labelling’ target cells with 51Cr by incubating the cells with radioactive sodium 
chromate. Lysis of the target cell then causes release of the radiolabel, which can be 
measured in the supernatant (26).
Proof of the theory that the MLR is a complete model for alloreactivity came 
with the demonstration that effector cells can also be generated in vitro. The 
specificity of this response was confirmed when it was shown that after culture of 
cells in the MLR effector cells are generated which are capable of lysing cells 
expressing the sensitising antigen but not third party cells (27,28).
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1.3 Effector mechanisms in allograft rejection
1.3.1 Lymphocyte subsets in graft rejection
The importance of T cells in allograft rejection was first demonstrated in 1962 
when it was noted that mice thymectomised at birth fail to reject skin allografts (29). 
Thymus grafting in such tolerant mice restored allograft rejection. Further 
characterisation of the subset of lymphocytes responsible for allograft rejection came 
with the use of adoptive transfer techniques in irradiated animals (13). Using this 
technique BM Hall assessed the ability of different lymphocyte subsets to restore the 
ability to reject a vascularised allograft. Lymphocytes in various doses were prepared 
from lymph nodes, spleen, thymus and thoracic duct lymph. Affinity purification 
techniques were used to separate Ig bearing cells. From these experiments it was 
concluded that recirculating, long lived T cells were primarily responsible for 
allograft rejection (30). Thymocytes had a poor restorative capacity and removing 
the thymus from a donor animal increased its ability to transfer graft rejection on a 
numerical basis, suggesting that recent thymic emigrants diluted the effector cell 
precursors.
1.3.2 CD4 and CD8 T cell effector functions
After the demonstration in 1975 that T lymphocytes could be divided into two 
phenotypically distinct subsets which correlate with distinct helper and cytotoxic 
functions (31), the role of each in graft rejection was investigated. The allograft 
rejection mechanism is potentially either antigen specific (due to cellular 
cytotoxicity) or antigen non-specific (due to a DTH response). Early workers had 
noted a histological similarity between rejected skin allografts and the lesions of 
delayed-type hypersensitivity, suggesting they are mediated by similar mechanisms
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(32). However with the demonstration of lymphocytes directly cytotoxic to 
allografted cells in vitro (33) it was assumed that cytotoxic T lymphocytes are the 
primary effector cells. The first challenge to this theory of allograft rejection was 
made by Loveland et al in 1981 (34). Using thymectomised, irradiated and bone- 
marrow reconstituted (ATXBM) mice they tested the ability of different subsets of 
lymphocytes to restore allograft rejection. Sensitised donor cells were depleted of 
either Lyt 1+ or Lyt 2+ lymphocytes using the appropriate monoclonal antibodies 
prior to adoptive transfer, on the assumption that Lyt 1 corresponded with the helper 
phenotype and Lyt 2 with the cytotoxic phenotype. Depletion of Lyt 2+ cells had no 
effect on the ability of donor cells to restore allograft rejection whereas depletion of 
Lyt 1+ cells from the donor inoculum largely abrogated subsequent graft rejection 
(35). From these experiments the authors concluded that cytotoxic T cells are not 
responsible for allograft rejection. (It has subsequently been shown that Lytl is a 
poor marker for Th cells being expressed at a low level on Tc cells. L3T4 is a more 
specific phenotypic marker corresponding to CD4 (36)). Further work in this field 
used either the adoptive transfer of subset-depleted lymphocytes or direct depletion 
of lymphocytes in experimental animals with monoclonal antibodies. Using a similar 
technique to Loveland et al Dallman transferred depleted lymphocytes to ATXBM 
rats prior to skin grafting (37), using the mAh W3/25 as a marker for helper cells and 
0X8 for cytotoxic T cells. Results accorded with those of Loveland in that removal 
of cytotoxic T cell precursors from the donor inoculum did not affect its ability to 
mediate destruction of the graft whereas removal of T helper cells led to prolonged 
graft survival, suggesting a DTH mechanism of graft rejection. Grafts from animals 
depleted with 0X8 were however infiltrated with 0X8+ cells suggesting incomplete 
depletion of CD8 cells. Lowry used a similar technique with vascularised cardiac 
allografts in rats and found that whilst W3/25+ cells were the most efficient on a per-
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cell basis, 0X8+ cells were also able to transfer graft rejection independently (38). 
Using monoclonal antibodies to deplete either L3/T4+ (Th phenotype) or Lyt2+ (Tc 
phenotype) cells in vivo Cobbold in 1984 also showed that cells with L3/T4 
phenotype were the major promoters of allograft rejection, in that anti-L3/T4 therapy 
allowed prolonged graft survival whereas anti-Lyt2 had no impact on rejection (39). 
In a later work however the same authors found a role for Tc cells (40). Firstly they 
found that a combination of anti-L3/T4 and anti-Lyt2 mAb to be more potent than 
anti-L3/T4 mAb alone. Secondly it was noted that the accelerated rejection of 
allografts in primed animals is mediated by Tc cells, in that use of anti-Lyt2 mAb in 
such animals was more effective than anti-L3/T4. Furthermore this priming of Tc 
cells was dependent on the presence of L3/T4+ cells. This evidence pointed to a 
plurality of rejection mechanisms and co-operation between T cell subsets in 
generating a rejection response.
Much of the work supporting DTH as an exclusive mechanism for allograft 
rejection is theoretically flawed. Firstly rodents generate poor DTH responses so 
results using these as experimental subjects cannot be generalised to other animals. 
Secondly there is no in vitro assay of DTH activity so that its involvement can only 
be inferred by exclusion of other mechanisms. In addition the level of 
immunosuppression of ATXBM animals and the degree of subset depletion in mAb 
treated animals was shown to be far from complete, and the direct correlation 
between phenotype and function to be over simplistic. The T cell deficiency in 
ATXBM rodents and in nude (athymic) mice is limited to the Th cell subset and the 
presence of residual cytotoxic T cell precursors which can be induced with EL2 (41) 
or cellular helper stimuli (42) has been demonstrated. To overcome the potential 
problem of incomplete T cell depletion in these animals adoptive transfer 
experiments have been performed using ATXBM rats grafted with skin from a minor
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MHC incompatible donor. The advantage of this technique is that the precursor 
frequency of Tc for minor MHC products is many orders of magnitude lower than 
for major MHC products, so the presence of specific CTLp is much less likely. In 
these experiments Class I MHC antigens act as restriction elements for minor MHC 
reactive cytotoxic T cells (43). A major role for Tc in these models has been shown 
by the fact that adoptive transfer of L3/T4+ cells produced a very slow type of 
allograft rejection (>25 days), which could be restored to normal tempo by the 
addition of Lyt2+ cells (33). Furthermore Lyt2+ T cells capable of mediating 
rejection of allogeneic tissue have been cloned (44). In these experiments DTH was 
excluded as a mechanism as irradiation of hosts (thereby eliminating host helper cells 
as a source of inflammatory mediators) did not prevent rejection. Perhaps the most 
compelling demonstration of a role for Tc in allograft rejection came from 
experiments using allophenic mice (mosaics formed by the fusion of two blastomeres 
of differing genotype which are therefore tetraparental (45)). If skin from such an 
animal is transplanted to either pure parental strain, cellular elements within the graft 
expressing antigens of the other strain are rejected in a highly specific manner. This 
can be demonstrated using strains of differing colour, where the destruction of 
foreign melanoblasts is shown by the loss of hair colour in the surviving graft (46).
The debate over the phenotype of cell responsible for allograft rejection 
changed with the demonstration of MHC restriction in allograft rejection (47), with 
CD4 cells reacting to class II targets but not class I whilst the reverse is true for CD8  
cells (with few exceptions). Furthermore there is no surface marker which uniquely 
identifies Th cells. Cytotoxic CD4 T cells and CD8  T cells able to produce EL2 and 
provide their own help have been identified (47). More illuminating has been the 
characterisation of cellular functions in allograft rejection. Rosenberg performed a 
series of adoptive transfer experiments in which purified CD4 or CD8  T cells were
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transferred into nude mice allografted with skin of determined antigenicity. The 
ability of the transferred cells to generate Th and Tc responses in vitro against the 
specific determinants was tested by limiting dilution analysis. Without exception in a 
large series of experiments successful graft rejection only occurred in the presence of 
both detectable helper and cytolytic functions (48) (49). The presence of such ‘dual 
function’ lymphocytes has been shown more recently in adoptive transfer 
experiments using SCID (severe combined immune deficient) mice, a very stringent 
model of immunosuppression, in which either CD4 or CD8  cells can successfully 
transfer graft rejection (50). It is however probable that situations in which CD8  cells 
are able to provide their own help for cytotoxic functions are unusual and arise only 
in contrived laboratory models.
1.3.3 Mechanisms of graft destruction by T cells
There are two principle methods by which T cell subsets kill target cells, both 
leading to the fragmentation of cellular DNA typical of apoptosis (51). The principle 
method of cell lysis employed by CTL involves the secretion of the lytic protein 
perforin which occurs in a specific manner after binding with a cognate target cell. 
Release of perforin occurs by exocytosis and is a Ca2+ dependent process. Secreted 
perforin alone induces lysis without fragmentation of DNA, and penetration of the 
cell with serine proteases called granzymes via perforin pores follows to complete 
DNA breakdown (52). In addition the cell-surface receptor Fas can transduce signals 
which also lead to apoptotic cell death, which is thought to be a major regulatory 
mechanism in T cell homeostasis (53). Experiments with perforin knock-out mice 
revealed residual cytotoxicity against MLR target cells by CTL, which is abolished 
when FAS deficient cells (from lpr mice) are used, suggesting that CTL can also 
induce apoptosis by the FAS pathway (54). The contribution of these two pathways
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to graft destruction has also been addressed. PCR and immunohistochemistry reveals 
upregulation of Fas and Fas-ligand in rejecting allografts (55, 56). However the 
cytotoxicity of graft infiltrating cells cultured from biopsies from human allografts 
undergoing acute rejection can be inhibited by the addition of concanamycin A (an 
inhibitor of the perforin/granzyme system) but not anti-Fas antibodies to the culture 
medium (56). The Fas system may therefore function to regulate the proliferation of 
T cells in a graft rejection response rather than the lysis of target cells. Further 
evidence for this comes from experiments where allografts were performed using 
both FAS-ligand deficient recipients and Fas deficient donor mice; in both groups 
grafts were rejected at control rates (55). However the immune-privileged status of 
Sertoli cells of the testis is thought to be due to the induction of apoptosis in reactive 
T cells by a FAS-dependent mechanism (57).
In vivo CD4 cells have the additional function of providing help for B cells and 
macrophages. Analysis of the mediators of macrophage function by amplification of 
the transcripts for iNOS (inducible nitric oxide synthase) and TNFa (Tumour 
Necrosis Factor a) has shown a marked increase during murine cardiac allograft 
rejection (55), implying that DTH mechanisms are also induced during the graft 
response.
Thus the debate over the primary effector cell in allograft rejection has come 
full circle since Loveland and McKenzie first raised doubts about the exclusive role 
of cellular cytotoxicity, a theory that was itself a rebuttal of an earlier DTH 
dependent mechanism postulated by Brent. The argument can to some extent be 
resolved by adopting the broader perspective that many mechanisms may be 
involved in allograft rejection, the model under study dictating which is dominant. In 
the absence of any arm of the immune response in a particular experimental setting
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the remaining mechanisms ‘take over’ the role of graft rejection. However central to 
all mechanisms is secretion of cytokines, normally a preserve of the CD4 T cell.
1.3.4 Patterns of cytokine secretion by helper T cells
Stimulation of the immune system often leads to a response in which either 
cellular or humoral components predominate. For example it has been noted that the 
DTH response to nominal antigen injected subcutaneously can be greatly diminished 
by intravenous injection of the same antigen and subsequent generation of a humoral 
response, and the reverse inhibition also occurs (58). Cytokines play a crucial role in 
determining the dominant type of immunity. During the early stages of an immune 
response T cells make a wide range of cytokines. In vitro studies however have 
shown that after repeated stimulation T cell clones can be differentiated into two 
subsets according to their production of cytokines promoting DTH (Thi) or humoral 
immunity (Th2) (59). Thi cells typically secrete high levels of TL2, yTFN and TNF- 
p while Th2 cells secrete IL4, IL5, IL6  and IL13 (60). In murine studies these T cell 
clones appear to be phenotypically identical whereas studies in the rat have shown 
that a high level of expression of the antigen 0X22 is typical of the Thi subset (61). 
As outlined in section 1.9.5 the Thi/Th2 dichotomy has been studied in detail in the 
context of allograft tolerance.
1.3.5 Other immune mechanisms of graft destruction
The contribution of T cells to the rejection of allografts has been discussed in 
detail. Other cellular compartments are also capable of responding to allografts and 
may play a role in graft rejection.
As outlined in section 1.2 Medawar (12) and Mitchison (13) showed that 
immune serum is not able to effect graft destruction either in culture or after passive
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transfer in murine studies. There are however circumstances in which B cells can be 
destructive to organ grafts. Sensitisation of high responder strain Lewis rats by skin 
grafting induces the production of cytotoxic antibody which leads to hyperacute 
rejection on passive transfer to a naive host (62). Similarly host sensitisation and the 
production of cytotoxic antibody is a major problem in clinical renal transplantation 
(63). Kidney allografts in these recipients are rejected in a hyperacute manner, an 
outcome which is prevented by performing a cytotoxic antibody ‘crossmatch’ prior 
to transplantation. In rat transplant models where host and recipient differ only at the 
class I locus graft rejection is also mediated by the production of alloantibody (64). 
However in less contrived fully MHC mismatched allograft models graft rejection 
can proceed with normal tempo in the absence of B cells (65).
Natural killer cells are a also potent source of cytotoxicity, although their 
activity does not depend on an MHC interaction and NK sensitive target cells tend to 
be of tumour origin (6 6 ). Analysis of graft infiltrating cells in cyclosporine-treated 
rats has shown that grafts can survive indefinitely in the presence of high levels of 
non-specific cellular cytotoxicity (67). NK cells appear not to participate in the 
rejection of organ grafts although they are known to be involved in the rejection of 
bone marrow transplants (6 8 ).
1.4 The molecular basis of allorecognition
Central to the alloimmune response as demonstrated above is the T cell. The 
immune response in allograft rejection is initiated when a T cell recognises a foreign 
protein antigen in the context of an MHC molecule. The structures involved in this 
process are briefly outlined below.
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1.4.1 The T cell receptor complex
The T cell receptor (TCR) for antigen was first identified by generating 
monoclonal antibodies against surface structures on T cell clones. By subtraction 
against B-lymphoblastoid clones antibodies targeted against unique T cell structures 
were produced. Immunoprecipitation experiments then identified a heterodimeric 
molecule of 90 kD, consisting of a a and a p chain linked by a disulphide bond (69). 
Each a or p chain resembles an immunoglobulin (ig) light chain being composed of 
a series of Ig domains with the addition of a membrane anchor. The cytoplasmic 
domain of TCR molecules is very short, only 5 to 15 amino acids in length (70). In a 
similar fashion to Ig molecules certain amino-acid sequences involved in domain- 
domain interactions are highly conserved (71) whereas the hypervariable sequences 
are confined to loops projecting from the N terminal end (analogous to the V domain 
of Ig) (72), where they are available for interaction with the peptide-MHC complex. 
The TCR dimer is not itself responsible for signal transduction but is non-covalently 
associated with a complex of invariant polypeptides called the CD3 complex, which 
subserves this function. The CD3 subunits include three related proteins (y, 8  and e), 
which exhibit Ig-like extracellular domains and an unrelated peptide, the £ chain, 
which has a very short extracellular region of only nine amino-acids (70). The TCR 
complex is expressed as four dimers, the clonotypic a/p dimer dictates ligand 
binding specificity whereas the CD3 dimers y s, 8  8  and mediate signal 
transduction (73).
1.4.2 The Major Histocompatibility Complex
The Major Histocompatibility Complex (MHC) encodes a series of antigens 
first identified on mouse erythrocytes which, when shared by host and donor
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animals, allow the successful transplantation of tumour grafts (5). They were initially 
referred to as ‘transplantation antigens’ to reflect their association with allograft 
rejection before their basic function was understood. Their immunological role 
became clearer with the demonstration of MHC restriction in 1974 (74). Zinkemagel 
and Docherty showed that, when specifically immunised, only syngeneic strains 
generated high levels of cytotoxicity against virus infected target cells. This suggests 
that cytotoxic T cells only interact with their target cells when they share MHC 
antigens. The role of MHC products in antigen presentation became clearer when the 
structure of the MHC class 1 antigen was described in 1987 (75). Soluble HLA-A2 
was produced by papain digestion of a human lymphoblastoid cell line which was 
then crystallised and analysed by X-ray diffraction. This class 1 molecule consist of a 
membrane-inserted heavy chain divided into three domains (ai, a 2 and 013) and a 
non-covalently associated light chain (p2 microglobulin). Crystallography showed 
that HLA-A2 consists of two pairs of structurally similar domains: a i has the same 
tertiary fold as a 2, while 0C3 has the same tertiary fold as p2 microglobulin (p2 m). The 
a i and a 2 domains each consist of an anti-parallel P-pleated sheet spanned by a long 
a-helical region. These two domains are paired to create an eight-stranded P-pleated 
sheet dividing two a-helices, forming an antigen-binding groove. Evidence that this 
groove is involved in antigen binding comes from an analysis of the position of 
polymorphic residues in the a i and a 2 domains. The majority of these residues lie 
either on the floor of the groove or the sides of the a  helices facing into the groove 
where they are available for antigen binding (76). Some polymorphic residues are 
also on the top surface of the a  helices facing solvent where they may contact with 
the T cell receptor. MHC class II molecules are known to have an analogous 
structure, but are composed of a heavy a  chain divided into a i and a 2 domains and a 
lighter p chain, divided into pi and p2 domains, with both chains inserting into the
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cell membrane (77). In a similar fashion to class I molecules, an antigen-binding 
groove is formed by a  helices spanning a P-pleated sheet, formed by the membrane- 
distal a i and Pi domains. In contrast to class I molecules however this groove is open 
at both ends allowing the presentation of larger peptides (up to 24 amino acids). In 
addition there is evidence that the class II heterodimer is itself expressed as a dimer 
at the cell surface (77).
1.4.3 Antigen presentation
The MHC molecules are responsible for presenting protein antigens to T cells, 
the antigen being degraded and presented as short linear peptides (78). Despite their 
overall similarity in structure, specific differences account for the distinct functions 
of the two classes of MHC molecules. MHC class I molecules present peptides 
produced by degradation of endogenously synthesised proteins (79). In contrast,
MHC class II molecules bind peptides generated by a degradation pathway of 
exogenous protein (80), although many of these peptides are themselves degradation 
products of other MHC molecules. Furthermore MHC class I molecules present 
peptides to CD8 + T lymphocytes while class II molecules present antigenic peptides 
to CD4+ T lymphocytes (81). When a specific T cell interacts with a MHC-peptide 
complex a signal cascade mechanism is initiated resulting in T cell activation and a 
specific immune response (82, 83). The two classes of MHC molecules therefore 
direct different antigenic pools to different pathways: class I molecules interact 
directly with cytotoxic effector cells to eradicate altered cells while class II 
molecules present circulating antigen to T helper cells to generate a more generalised 
immune reaction (52).
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1.4.4 CD4 and CD8
CD4 and CD8  were initially described as markers of T cells with distinct 
effector functions, following which CD4 was found to be expressed by MHC class 
H-restricted T cells and CD8  by MHC class I-restricted T cells (84). CD4 is a 55-kDa 
monomeric membrane glycoprotein composed of four extracellular Ig-like domains, 
a hydrophobic transmembrane region and a long cytoplasmic tail (85). The 
cytoplasmic tail is associated with the protein tyrosine kinase p56lck whose activity is 
responsible for initiating the intracellular tyrosine cascade in response to TCR 
triggering (8 6 ). The CD4 molecule forms an aggregate with the TCR complex, for 
which CD4 acts as the signal transduction mechanism. The CD4 molecule binds to 
the invariant P2 domain of MHC class IT, where it increases the avidity of the MHC- 
TCR interaction, leading to increased tyrosine phosphorylation. T cell activation is 
dependent on the activity of the CD4 coreceptor as shown by the ability of anti-CD4 
mAb to inhibit T cell activation (87). CD8  is a disulphide-bonded heterodimer of two 
polypeptides each with a single Ig-like domain, which binds to an invariant part of 
MHC class I (the 013 domain) (8 8 , 89). In a similar manner to CD4, CD8  is thought to 
stabilise the TCR-Class I MHC complex.
1.5 Costimulation in T cell activation
The mechanism outlined above of cognate recognition of an antigen-MHC 
complex by the TCR is in itself insufficient to lead to the stimulation of a T cell. The 
need for multiple signals to induce T cell proliferation was initially predicted on 
purely theoretical grounds in 1970 (90). Bretscher and Cohn believed that tolerance 
to self-antigen arose not from genetic coding but by the ‘paralysis’ of self-reactive 
lymphocytes. This presumption would require within the lymphocyte the ability to be
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either activated or inactivated by immunological stimuli. As available evidence 
suggested that antibody-forming cells had only one receptor for antigen, this theory 
required the presence of a ‘second signal’ to induce activation, whilst absence of that 
signal would lead to paralysis. The authors explained their theory in terms of the 
emerging concepts of B-T cell interactions and adduced as evidence the requirement 
of certain haptens to be conjugated to carrier molecules to induce activation.
The physical requirement for two signals to induce allogeneic stimulation of 
lymphocytes was demonstrated by Lafferty and co-workers. Experimentally they 
demonstrated that ultraviolet irradiation of allogeneic stimulator cells in a MLR 
abrogated the proliferative response (91). It was postulated that a second ‘inductive 
stimulus’ was required to activate cells, which was destroyed by UV irradiation. This 
hypothesis was developed into a more general theory of allostimulation in which the 
‘inductive stimulus’ is provided by haematogenous cells within the graft, rather than 
parenchymal cells, and removal of these cellular elements, for example by in vitro 
culture prior to transplantation, overcomes the barrier to transplantation (92). The 
critical role of APC in T cell activation was later demonstrated when the proliferative 
response of T cells stimulated in the experiments described above could be restored 
by the addition of culture supernatants of macrophages stimulated by enterotoxin. 
This soluble costimulator molecule was later shown to be IL1 (93), although in other 
experimental systems costimulation requires contact with a cell surface molecule.
The model of Bretscher and Cohn predicted that not only should antigen 
recognition in the absence of a second signal fail to stimulate the lymphocyte, it 
should also lead to subsequent unresponsiveness to that antigen. Further experiments 
were performed using purified T cell clones stimulated either by immobilised anti- 
CD3 antibodies (94) or by antigen presented on chemically modified APC (95).
These experiments confirmed the requirement for a second signal in T cell activation,
1.19
as addition of allogeneic APC to these cultures at the time of initial presentation 
allowed cellular proliferation. Furthermore it was noted that T cells stimulated in 
these experiments lost the ability to respond to specific antigen on later restimulation, 
even in the presence of normal APC. These cells were shown to be viable by their 
ability to respond in the presence of IL2. This specific non-responsiveness was 
termed anergy. A crucial aspect of these experiments is that the costimulatory signal 
is provided by different cells to those presenting antigen. This suggests a separate 
signalling pathway to that associated with the TCR. This is in marked contrast to 
costimulatory activity provided by other molecules such as CD2 (see below), which 
appear to have a functional interaction with the TCR.
The cellular mechanism by which viable T cells become anergic in this system 
has been further characterised. Firstly anergy-induction is an active process which 
requires MHC recognition (96) and leads to a rise in intracellular calcium. Secondly 
the cellular deficit appears to lie at the level of induction of the IL2 gene, as IL2 
mRNA is not detectable in anergic T cell clones (97, 98). Lastly addition of 
exogenous EL2 at the time of antigen presentation in some systems may overcome 
the need for costimulatory signals (99).
1.5.1 The CD28/CTLA4-B7 pathway of costimulation
1.5.1.1 Historical background
The CD28 molecule was identified initially by immunisation of rodents with 
activated T cells and subsequent somatic hybridisation to produce a myeloma clone. 
The resultant mAb labelled an activation antigen on the T cell surface, which was 
shown to be able to transmit activation signals (100). Likewise the CTLA4 molecule 
was identified initially by its presence on activated T cells, by constructing cDNA
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libraries of activated T cells followed by subtractive hybridisation against cDNA of 
resting T cells (101). Similarly the B7 molecule was identified as an activation 
antigen on B cells as part of a screening process of hybridoma clones after in vivo 
immunisation ( 1 0 2 ).
1.5.1.2 Structure and expression
CD28 and CTLA* exist as disulphide-linked homodimeric glycoproteins of 41- 
43 kDa (103). Before their functional roles were identified it was noted that CTLA4 
and CD28 share similar amino-acid sequence homology and overall intron-exon 
organisation, suggesting they may subserve similar functions (104). CD28 and 
CTLA4 are coexpressed on activated subsets of both CD4 and CD8  T cells (105). 
CD28 is constitutively expressed on T cells and is upregulated on activation via the 
TCR (105). CTLA4 however is not expressed on resting T cells but is induced after 
activation, reaching maximal levels 48 hours after activation (106). The close 
relationship between CD28 and CTLA4 is shown by the observation that CD28 
expression is crucial for upregulation of CTLA4 and anti-CD28 mAbs alone are 
capable of accelerating CTLA4 expression (103). Conversely ligation of CD28 with 
either anti-CD28 mAbs or B7-transfected cells leads to downregulation of CD28 
mRNA levels and surface expression (107). Therefore during the time period of 
maximal CTLA4 expression CD28 expression is declining, this reciprocal expression 
is important in terms of the function of the two molecules.
1.5.1.3 Regulation of T cell activation by CD28 and CTLA4
As described earlier Jenkins demonstrated that T cells stimulated via the TCR 
alone became functionally inactivated, and one of the ‘second signals’ required to 
prevent this was shown to be mediated by the CD28-B7 pathway. In an early 
experiment a T cell clone resistant to stimulation via TCR alone was induced to
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proliferate on addition of allogeneic B7-expressing B-lymphoblasts. Furthermore 
addition of anti-CD28 or anti-B7 mAb was able to reverse this proliferation (108). 
More direct evidence for the involvement of this pathway in T cell activation came 
with the development of B7-transfectants (109, 110). These cells allowed definition 
of the binding kinetics between B7 and CD28 and further established the role of B7 
in the costimulation and specific upregulation of IL2 transcripts in T cells stimulated 
via the TCR. In keeping with the predictions of Bretscher and Cohn it has been 
shown that blockade of the CD28/B7 pathway not only inhibits T cell activation but 
also leads to specific hypo-responsiveness, in that cells stimulated under these 
conditions remain unresponsive to specific antigen for variable time periods after the 
initial exposure whilst retaining the ability to respond to third party antigen ( 1 1 1 )
(112) (113). However a failure of these experiments based on thymidine 
incorporation after costimulation with CD28 is that they do not distinguish increased 
activation from prolonged survival. Whilst the presence of increased IL2 transcripts 
after activation does indicate increased cellular activation other more recent work 
suggests that CD28 signalling may function by preventing activation-induced cell 
death. Firstly anti-CD28 mAb has been shown to inhibit y-irradiation induced 
apoptosis and increase expression of the survival gene Bcl-xi (114); secondly CD28 
deficient mice show increased cell death after anti-CD3 mediated activation (115).
In view of the homology in structure between CD28 and CTL A* it was 
predicted that CTLA4 would also bind B7. This was shown to be the case when the 
construct CTLAftg (see below) was shown to bind B7-transfectants with 20-fold 
greater affinity than CD28Ig, and was also shown to inhibit proliferative responses in 
the MLR, in a similar manner to blockade of CD28 (113) (116). This may result 
however from blockade of either the CD28 or CTLA4 pathway, as each shares the 
same B7 family of ligands. More direct targeting of the CTLA4 molecule itself with
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antibody however has variable results. Monovalent Fab fragments of anti-CTLA* 
mAb, which do not cross-link the CTLA4 molecule, are able to augment T cell 
proliferation whereas whole anti-CTLA4 mAb are able to inhibit anti-CD3 mediated 
proliferation even in the presence of optimal CD28-mediated costimulation (117). 
This suggests that the primary role of CTLA4 may be in negative regulation and 
would fit neatly with the upregulation of CTLA4 after T cell activation. CD28 and 
CTLA4 therefore may have opposing effects and the response of a T cell to activation 
via the TCR depends partly on the dynamic competition between CD28 and CTLA4 
mediated signals (118).
1.5.1.4 The B7 family of molecules
A second ligand for CTLA4 was discovered when it was noted that anti-B7 
mAb minimally inhibits proliferation in the MLR whereas CTLAJg causes maximal 
inhibition (119), suggesting the presence of further ligands for CD28. The two known 
B7 molecules, B7-1 (CD80) and B7-2 (CD8 6 ), are expressed only on activated APCs 
and B cells (120). The B7 molecules have a different temporal relationship after B 
cell activation, in that B7-2 is upregulated very rapidly after activation of the B cell 
whereas B7-1 expression reaches maximal expression after 48 hours (121).
1.5.1.5 Differential T cell requirements for costimulation
The role of the CD28 pathway in the stabilisation of IL2 mRNA and 
subsequent promotion of T cell survival has been well demonstrated. More recently 
however CD28 signalling has been shown to have more diverse effects on T cell 
cytokine secretion as the absence of CD28-mediated signals induces a bias toward a 
Thi phenotype in naive T cells. Initial in vilro evidence for this came from the 
demonstration that purified human T cells stimulated by a wide variety of non- 
cellular stimuli including anti-CD2, anti-CD3, IL2 or lectins only produce IL4 if
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anti-CD28 mAb are included (122). Further experiments showed that although 
purified T cells stimulated by mitogens in the presence of CD28-mediated signals 
produce both 1L2 and 1L4, after repeated cycles of CD28 stimulation the levels of 
supernatant IL4 increased whilst those of IL2 decreased (123). The pathways for 
production of IL2 and IL4 appear to be closely linked, in that IL2 production is a 
prerequisite for IL4 production. T cell clones stimulated by specific peptide-MHC 
complexes in the presence of splenic APC elaborate both IL2 and IL4. Blockade of 
the CD28 pathway with CTLAftg in this model abrogates production of both 
cytokines, however addition of exogenous IL2 restores the production of IL4 (124).
A positive feed-back circuit also exists to amplify costimulatory signals. TL4 
produced by Th2 cells is able to upregulate the expression of B7-1 and B7-2 by 
splenic B cells, thereby providing further costimulatory signals to T cells (125). In 
vivo evidence supports the role of CD28 in the generation of TI12 responses. CD28 
knockout mice develop T and B cells normally but have reduced basal levels of Ig 
and low titres of IgGl, and show diminished Ig class switching after virus infection, 
but retain normal DTH responses (126). The importance of CD28-mediated signals 
in T cell-B cell co-operation is further demonstrated by the ability of CTLAftg to 
prevent in vivo priming for humoral responses against protein antigens (127). 
Furthermore mice transgenic for a soluble form of CTLA4 , which blockades CD28- 
mediated signals, are again able to generate helper-T cells as shown by lymphokine 
production but have profoundly inhibited antibody production (128). Lastly the agent 
CTLA4lg when administered to mice is able to abrogate the production of antibody 
to SRBC (129). The generation of Tl^-type responses (in mice and humans) seems 
therefore to depend crucially on the delivery of CD28-mediated signals. Whether 
CD28 delivers signals for IL4 production distinct from its role in enhancing 1L2 
production is not clear.
1.6 The CD2 molecule
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As the effect of targeting the CD2 molecule with mAb forms the substance of 
this thesis this antigen will be described in detail.
1.6.1 Historical background
The CD2 molecule was first identified as an adhesion molecule when anti-CD2 
mAb were shown to block rosetting of leukocytes with SRBC, a technique which 
was used to identify human T cells (130,131).
1.6.2 Structure and cellular relations
CD2 is a 50-55-kDa glycoprotein (131). Crystalographic studies of soluble 
forms of rat and human CD2 have revealed a structure composed of two protein 
domains, an intervening linker region and an extended C terminal tail with overall 
dimensions of 20x25x75 A (132). NMR spectroscopy confirms that the protein 
domains are composed of anti-parallel B-pleated sheets, placing the protein within 
the class of the immunoglobulin superfamily (133). The ligand binding 
characteristics lie purely with the membrane-distal domain 1 (134). The linker region 
provides up to 2 0 ° of orientational flexibility between domains 1 and 2 , which may 
assist with ligand binding and also adds 17A to the length of the molecule, making 
the complex between CD2 and its ligand CD58 (humans) or CD48 (rodents) a similar 
size to the peptide-MHC-TCR complex (135). The C-terminal portion contains a 
hydrophobic transmembrane portion which anchors CD2 to the cell membrane (136) 
and a long cytoplasmic tail composed of unique, repeating proline residues. This 
portion has been shown to be essential for the signalling function of CD2, in that 
transfected mutants lacking the cytoplasmic portion are unable to subserve a 
signalling function (137).
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The CD2 molecule appears to be able to associate with other cell-surface 
proteins in a dynamic fashion. The first association noted was with CD3. 
Immunoprecipitation and deletion experiments of detergent lysates revealed that 40% 
of human CD2 is associated with the CD3 complex (138). The forces involved are 
weak however as the experiment was very dependent on the detergent used and the 
association was not strong enough to permit comodulation. The proximity of CD2 to 
CD3 suggests that CD2 may be involved in regulation of cellular signals transmitted 
by CD3. Further evidence for this came with the demonstration that the cytoplasmic 
portion of CD2 associates with the tyrosine kinases p56lck and p59fyn, molecules 
involved in phosphorylation during signalling events (139). Further 
immunoprecipitation experiments in both mouse (140) and human (141) revealed 
weak, non-covalent linkages between CD2 and CD45. CD45 provides tyrosine 
phosphatase activity which regulates the protein tyrosine phosphorylation 
characteristic of the cascade of intracellular signalling events (142). The association 
of CD2 in a loose complex involving CD3 and CD45, together with the presence of a 
long cytoplasmic tail with a protein tyrosine kinase function, suggest that the CD2 
molecule has a more complex function than simple inter-cellular adhesion and may 
be involved in the regulation of cellular activation.
1.6.3 Distribution
CD2 is expressed on T and NK cells in humans (131), rats (143) and mice 
(144). Variations exist between species in that CD2 is also expressed on murine B 
cells (144) and murine and rat macrophages (143). CD2 is one of the earliest markers 
of thymocyte development, and its expression correlates with the maturational state 
of the thymocyte, in that the majority of CD4-ve CD8 -ve cells express low levels of 
CD2, double-positive thymocytes express intermediate levels and all single positive
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cells express high levels (144). The expression of both CD2 and its ligand CD48 is 
upregulated on T cell activation, and this upregulation remains stable forming a 
marker of memory T cells (145). CD2 expression is also widely conserved across 
species, with homologous molecules identified in pigs (146), sheep (147) and non­
human primates (148).
1.6.4 CD2 ligands
The first ligand identified for human CD2 was the SRBC receptor termed T11 
target structure (T1 ITS). Mab binding studies later defined this as identical to LFA-3 
(149), later termed CD58, which is widely expressed by both haematopoetic and 
non-haematopoetic tissues. The ligand for rat CD2 is the structurally related 
molecule CD48 (150), which has a more limited distribution restricted to lymphoid 
cells (151). The molecules CD2, CD48 and CD58 are structurally similar and are 
related to the carcinoembryonic antigen family of IgSF molecules (135). CD48 binds 
to domain 1 of CD2 and this interaction can be blocked by both 0X34 mAb (anti- 
CD2) and 0X45 (anti-CD48) (150). The kinetics of the interaction between CD2 and 
its ligands have been studied and reveal that the interaction is one of very low 
affinity, but very fast dissociation rate (152, 153). This may be required to facilitate 
intercellular contacts in rapidly moving cells and the low affinity may be necessary 
to prevent the molecules being avulsed from the cell membrane.
1.6.5 Functional properties of CD2
The CD2 molecule has been implicated in a variety of cellular functions, which 
will be considered separately although they may be different aspects of a single 
cellular process.
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1.6.5.1 Intercellular adhesion
The ability of CD2 to adhere to its physiological ligands in solution and to 
SRBC has been outlined above. The adhesion function of CD2 was assessed 
separately from its other functions by transfecting hamster fibroblasts with CD2 
cDNA. These cells then showed increased non-physiological conjugate formation 
with a CD48-expressing mastocytoma cell line, which could be blocked with specific 
anti-CD2 mAb (154). However the small size of CD2 and its ligand compared to 
other leukocyte adhesion molecules (such as integrins and selectins) argues against 
this being its primary role (135).
1.6.5.2 T cell activation
The initial evidence that CD2 has a more active function than simple inter­
cellular adhesion came with the recognition that combinations of different anti-CD2 
mAbs or anti-CD2 mAb plus soluble LFA-3 could stimulate T cells in both humans
(155) and rats (143) in the absence of signalling via the TCR. These studies revealed 
that there are three functionally significant epitopes on the CD2 molecule, termed 
T11 i-Tl I3 in the human. T111 was identified as the ligand-binding site as mAb to 
this epitope prevented resetting with srbc. A combination of mAb targeting the non­
overlapping epitopes T112 and T113 induced marked T cell activation, measured by 
3H-Thymidine incorporation and 1L2 production (155). Furthermore CD2-mediated 
signalling required the presence of the CD3-TCR complex, as modulation of this 
complex completely abrogated CD2-mediated T cell proliferation. Similar results 
were obtained in the rat, where three non-overlapping epitopes were again identified 
(143). In a similar fashion mAb which blocked ligand binding (0X34) did not lead to 
T cell activation whereas a combination of mAb to the remaining epitopes (0X54 
and 0X55) lead to marked proliferation of target T cells. Further observations were
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made regarding mAb-mediated T cell activation in this study, which are relevant to 
the current project. Firstly optimal CD2-mediated cellular activation appeared to 
require the presence of accessory cells, and this has been confirmed by other reports
(156). This function can be replaced with rabbit anti-mouse polyclonal antibody 
when CD2-transfected Jurkat cells are activated, suggesting that cross-linking of 
CD2 molecules may be important. Also, in the presence of cross-linking rabbit anti­
mouse antibody 0X34 mAb alone becomes mitogenic for Jurkat cells. Lastly CD2- 
mediated activation requires the presence of the TCR-CD3 complex, as no activation 
is seen in a TCR've Jurkat cell line (143).
Further studies however reported a TCR-independent ‘second’ pathway of T 
cell activation via the CD2 molecule (137, 155-160). There are clear theoretical 
objections to the presence of this pathway of T cell activation, since immune 
responses are specific and require the presence of structures with clonally distributed 
variable regions, whilst the CD2 molecule is entirely monomorphic within species. 
This objection can be overcome by ascribing CD2-mediated activation to in vitro 
artefact with no physiological counterpart. In support of this is evidence 
demonstrating the interdependence of the CD2 and TCR-CD3 pathways.
Experiments with human leukaemic T-cell lines expressing CD2 in the absence of 
CD3-TCR show the total dependence of CD2 on the presence of the TCR complex 
(161,162), although CD2 is able to function in the absence of TCR on NK cells 
(163). The close physical association between CD2 and TCR suggests that CD2- 
mediated signalling may be a consequence of the formation of TCR-CD2 aggregates. 
Furthermore CD2 appears to have an extensive role in regulating signals via TCR- 
CD3 as outlined in the next section.
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1.6.5.3 Costimulation mediated bv CP2
In addition to being a route for T cell activation itself, the CD2 molecule 
provides a means to influence signals transmitted via the TCR-CD3 complex. As 
outlined in the section above engagement of the TCR-CD3 complex by peptide- 
MHC or mAb exerting antigen-like effects is not sufficient to induce T cell growth 
and differentiation. A second costimulatory signal provided by one of a number of 
cell surface ligands is required. Evidence has accumulated that CD2 can provide such 
costimulatory signals (164). Firstly murine L cells transfected with CD58 added to 
anti-CD3 mAb or suboptimal concentrations of phytohaemagglutinin (PHA) induces 
proliferation of purified human T cells (165). Similarly the response of CD2+ T cell 
clones of known specificity to a B cell clone is greatly enhanced if that clone is 
transfected with CD58 (166). Interestingly the same effect was not seen when CD58 
was expressed on a third party cell, suggesting that a close proximity between the 
MHC-TCR conjugate and the CD2-CD58 pathway is needed, in contradistinction to 
the costimulatory signal provided by the CD28-B7 pathway where no spatial 
relationship is required between the first and second signals. In the reverse manner 
CD2-ve T cell clones of known specificity have been shown to have greatly 
increased proliferative responses after transfection with CD2 (167). Furthermore the 
cytoplasmic domain of CD2 is required for the integrity of this costimulatory signal, 
thus differentiating the adhesive and costimulatory functions of CD2. Attempts have 
been made at the molecular level to define the nature of this CD2-mediated 
costimulatory signal and experiments in CD2 transfected clones have shown 
enhanced CD3-mediated phosphorylation of the ZAP-70 family kinase p72syk after 
CD2 co-stimulation (168). The costimulatoiy effect of CD2-mediated signals is 
detectable at the level of induction of the IL2 gene, a process critical for T cell 
growth (168). CD2-mediated signals have also been shown to trigger lysis of CTL
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clones (169), which contrasts with the CD28/B7 pathway, which does not 
costimulate this activity (170). In a similar manner the activity of a rat NK-cell clone 
can be regulated with 0X34, demonstrating the involvement of CD2 in non-specific 
cytotoxicity (171).
1.6.5.4 ‘Negative signals’ and apoptosis mediated by CD2
In addition to providing a pathway to activate T cells CD2-mediated signals 
can also inhibit T cell responses. In a similar experiment to those outlined above a T 
cell hybridoma was shown to have greatly increased proliferation to antigen 
presenting B cells after transfection with CD2 cDNA. Addition of anti-CD2 mAb to 
the culture completely abrogated proliferation of the hybridoma to below that of the 
untransfected hybridoma and also abolished IL2 production (172). Further evidence 
that CD2 may provide negative signals came with the development of the LFA- 
3/IgGi fusion protein LFA-3TIP. This protein interacts with the ligand-binding site 
of CD2 and was shown to inhibit the response of T cells to CD2 independent 
antigens such as PHA, ConA and tetanus toxoid (173). These experiments 
demonstrated that a single mAb to the ligand-binding site of CD2 could transmit a 
‘negative signal’ to an activated T cell to prevent proliferation and IL2 production 
and these experiments were confirmed by other groups (143).
The nature of this negative signal has not been defined but experiments of a 
very similar nature later showed that CD2 might provide a pathway of apoptosis in 
activated T cells. During intrathymic T cell development elimination of autoreactive 
T cell clones occurs by apoptosis and in vilro thymocytes undergo apoptosis in 
response to ligation of surface CD2, CD3 or the Fas antigen (CD95) (174). 
Subsequent experiments showed that mature peripheral T cells can also undergo 
programmed cell death by apoptosis mediated through CD2 (175-177). In these 
experiments resting T cells were stimulated with a mitogenic pair of mAbs to CD2
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and introduction of a third mAb resulted in apoptotic cell death of the majority of 
cells (175,176). Studies later showed that a single anti-CD2 mAb could also promote 
apoptosis in cells activated by other means, such as 1L2 or anti-CD3 mAb (177). 
Initial experiments suggested that CD2 provides a distinct pathway of apoptosis 
separate from the Fas/Fas-L pathway. Particularly strong evidence came from 
experiments using T cells from patients with lymphoproliferative disease secondary 
to Fas gene mutations leading to the lack of cell surface expression of Fas molecules. 
These cells could still be induced to undergo apoptosis via the CD2 pathway (176). 
Later experiments however have suggested that targeting CD2 with mAb in activated 
cells leads to upregulation of CD95-L, and furthermore apoptosis in this system can 
be inhibited by anti-CD95 mAb, suggesting the two pathways are closely related 
(178). Finally, activated NK cells have also been shown to be susceptible to 
apoptosis mediated by a single anti-CD2 mAb, by an apparently Fas-independent 
pathway (179). This provides a possible role for CD2 in NK cells separate from its 
role in T cells, which appears to be dependent on the presence of the TCR.
1.6.5.5 CD2 and the regulation of cytokine production
As has been outlined above CD2 stimulation by mAb can either promote or 
inhibit T cell activation depending on the experimental circumstances. In a similar 
fashion the response of T cells in terms of cytokine production after CD2 stimulation 
has been investigated. In a series of experiments human T cells were stimulated via 
CD2, CD3, CD28, or by PFIA or staphylococcal enterotoxin. Significantly in view of 
findings in this thesis dissociation was noted between cellular proliferation and 
cytokine production. Whilst similar levels of proliferation were noted when cells 
were stimulated with any combination of mAb to CD2, CD3, CD28, or enterotoxin 
or PHA alone, the levels of measured cytokine production varied greatly (180). The
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most efficient system in terms of production of IL2, yEFN, IL4 and IL10 was 
stimulation via CD2 and CD28 simultaneously. CD2 stimulation alone caused 
similar levels of cytokine production to stimulation by the combination of anti-CD3 
plus anti-CD28 (except for IL2 production which is absolutely dependent on 
signalling via CD28), which however produced higher levels of cellular proliferation. 
Furthermore addition of anti-CD2 mAb to a similar culture abrogated cytokine 
production without affecting proliferation (181). These results suggest that in the 
same way that T cell activation can be regulated by second signals so cytokine 
production is subject to regulation by discrete cellular pathways, including CD2 
mediated signals.
CD2 mediated signals have also been shown to regulate the effect of the 
cytokine 1L12. IL12 is secreted by macrophages and plays a central role in the 
initiation of a Th] response by T cells (182). Most notably this involves the 
stimulation of yIFN production, cellular proliferation and the generation of cytolytic 
activity. Mab targeting the adhesion domain of CD2 or CD58 has been shown to 
inhibit lL12-mediated ylFN production by PHA-activated T cells (183). Conversely 
mitogenic pairs of anti-CD2 mAb costimulate EL 12 function to increase yEFN 
production and proliferation. These results have been interpreted as ascribing a role 
for the CD2-CD58 ligand pair in ensuring close proximity between T cells and 
macrophages for the maximal paracrine effect of IL12.
1.6.5.6 CD2 and the regulation of anergy
Another aspect of the ability of CD2-mediated signals to costimulate signalling 
via the TCR has been explored in the context of T cell anergy. As demonstrated 
above anergy can be induced in T cell clones by antigen presentation in the absence 
of costimulation via the B7 molecule. This anergic state can then be reversed by
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stimulation with antigen-presenting cells expressing clone-specific MHC and CD2 
(184). The conditions required for reversal of anergy in this system were 
investigated. Firstly blocking mAb to either MHC or CD58 on the APC prevented 
reversal of anergy, demonstrating both pathways are involved in the process.
Secondly a unique observation was made regarding CD2 epitopes. The T i l 3 epitope 
(CD2R) in man (but not the rat) is expressed on T cell activation (155). Following 
induction of anergy (an active process) the CD2R epitope is lost from the T cell 
clone. After incubation with IL2 for seven days the CD2R epitope is re-expressed, 
and its re-expression coincides with the cells susceptibility to anergy reversal through 
CD2-mediated signals. This model suggests a mechanism whereby the CD2 
molecule contributes to the anergic state by assuming a phenotype refractory to the 
transmission of positive costimulatory signals.
A caveat must be made regarding all the above observations on T cell function 
which are based largely on in vitro manipulation of the CD2 molecule with mAb. 
Despite the implication of CD2 involvement in many aspects of lymphocyte 
homeostasis CD2 gene knockout mice grow and develop quite normally and are able 
to generate normal immune responses (185). Qualifications can also be made 
regarding gene-knockout experiments however as such animals may adapt to the 
absence of the experimental molecule and therefore elaborate atypical immune 
responses.
1.7 Strategies to induce allograft tolerance: neonatal 
tolerance
The first demonstration of immunological tolerance to transplanted tissues was 
made by Medawar in 1953 (186) in which neonatal mice were made tolerant of cells
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of adult mice. This has subsequently been referred to as ‘classical’ immunological 
tolerance. Medawar injected a mix of allogeneic kidney, spleen and testis into the 
abdominal cavity of foetal and neonatal mice. When subsequently challenged with 
donor specific skin grafts these animals displayed varying degrees of prolonged graft 
survival. The concept of inducing tolerance in this way was prompted by the 
observation that skin grafts performed between cattle twins invariably survived, 
regardless of whether the twins were monozygotic (and therefore syngeneic) or 
dizygotic. This was interpreted in terms of mosaicism, which had previously been 
demonstrated for the erythrocytes of twin cattle by Owen (187). Medawar postulated 
that exposure of an immature immune system to antigen led to subsequent 
unresponsiveness to that antigen. This theory predicts that foetal or neonatal 
inoculation of cells leads to a state of chimerism where cells of both donor and host 
coexist, and the host becomes tolerant of all antigens expressed by the donor cells. 
This aspect is necessary to explain the observation that neonatal tolerance is not 
tissue specific. Thus inoculation of bone marrow cells influences the survival of such 
widely disparate organs as skin and kidney (188), an observation which was 
explicable after Medawars demonstration that ‘transplant antigens’ are expressed by 
both blood leukocytes and tissue parenchymal cells (189). In summarising his 
observations about neonatal tolerance Medawar made the following additional points 
(190).
1) The tolerant state is due to an alteration in the host, and not to graft 
adaptation or passive enhancement.
2) The tolerant state is specific to cells of the donor strain.
3) The tolerant state is systemic.
4) The tolerant state can be brought to an end by the infusion of specifically 
sensitised syngeneic cells and, more importantly, by naive syngeneic cells.
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This last observation suggests that tolerance is due to a central failure of the 
immune system, as otherwise the infused cells would come under the same 
influences which prevent rejection as the hosts own cells. Tolerance was noted to 
require persistence of the tolerising antigen, and if the chimeric state was lost 
tolerance also was lost. Medawar outlined two broad possible explanations for 
neonatal tolerance:
1) Cells preadapted to react upon encountering particular antigen are 
eliminated from the organism. Tolerance is therefore a property of the organism 
rather than of the cell.
2) ‘Antibody forming cells’ can respond to an antigen and undergo a change 
other than activation or cell death. This implies the existence of a ‘tolerant’ cell.
Support for the first hypothesis came with the elaboration of the theory of the 
clonal basis of the immune response (191), whereby clones of immunocompetent 
cells react to a single antigen only and self-reactive clones are eliminated when 
prenatal contact is made between the reacting cell and self-components.
The possibility of inducing specific tolerance by introducing foreign cellular 
antigens into the developing foetal or neonatal immune system and allowing 
elimination of the donor reactive clones clearly provided support for this model.
Later evidence supported the concept of the elimination of reactive clones in models 
of neonatal tolerance (192, 193).
1.8 Monoclonal antibodies in transplant tolerance
The development of monoclonal antibody technology allowed the production 
of large amounts of antibody of a single, predetermined specificity. Kohler and 
Milstein devised a technique of fusing an immortal murine myeloma cell line 
(usually a non-secreting variant) with spleen cells from an immunised mouse (194,
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195). A very high proportion of the resulting tetraploid clones (up to 10%) produced 
antibody with specificity for the original immunogen, perhaps because actively 
dividing cells are more prone to fusion. This technique therefore allowed production 
and perpetuation of a unique clone of antibody producing cells specific to the 
immunising antigen without the need to precisely define the antigen.
1.8.1 Antibody structure
Antibodies are symmetrical molecules consisting of two identical heavy chains 
(MW 50000-70000) and two light chains (MW 25000). Immunoglobulins are 
grouped into five classes: IgM, IgG, IgD, IgE and IgA. The class of immunoglobulin 
is determined by its heavy chain (Ch), the above classes having p, 8 , y, e and a  heavy 
chains respectively. IgM and IgD Ch are encoded by single genes whereas the 
remaining classes can be divided into subclasses (isotypes), each with its own 
constant region gene. Light chains exist in two forms, k  and X. In the mouse and rat 
there is a single CK gene and four Cx genes; despite the variability of X chains, 95% 
of Ig molecules bear k  light chains (196).
IgM exists as a pentamer or hexamer; its multimeric nature gives it greater 
avidity and facilitates complement activation. It is the oldest immunoglobulin 
phylogenetically and the first to appear in ontogeny and in an immune response. IgG 
exists as a monomer and is by far the commonest immunoglobulin in serum. There 
are four mouse, rat and human IgG subclasses: G l, G2a, G2b and G3 in the mouse, 
G l, G2a, G2b and G2c in the rat. The names of the IgG subclasses reflect the history 
of their discovery, which was broadly in order of decreasing serum concentration.
The name of an isotype does not therefore imply a structural or functional homology 
between species (197).
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1.8.2 The mechanism of immunosuppression by monoclonal
antibody in animal models of transplantation
Five potential mechanisms of monoclonal antibody-mediated 
immunosuppression have been implicated in animal models:
1) Cellular depletion
2) Transmission of negative signals
3) Ligand modulation
4) Blockade of intercellular adhesion
5) Blockade of costimulatory signals
Each mAb may act by more than one of these mechanisms in any particular 
model, for example transmission of a dominant negative signal to a cell may lead to 
cell death and cellular depletion, and ligand modulation may reduce intercellular 
adhesive forces. Each mechanism will be considered in turn.
1.8.2.1 Cellular depletion mediated by monoclonal antibody
Cellular depletion is an in vivo phenomenon whereby the proportion of target 
cells is reduced after administration of monoclonal antibody. There are three possible 
mechanisms by which mAb deplete cells in vivo: complement-dependent cytotoxicity 
(CDC), opsonisation of target cells (antibody-dependent cellular cytotoxicity - 
ADCC) and delivery of a negative signal leading to cell death (apoptosis).
1.8.2.1.1 Complement-mediated lvsis
Direct lysis of cells coated with antibody occurs by the classical pathway of 
complement activation and is reproducible in vitro. The first step is binding of a 
single C lq molecule to the CH2 domain of the Fc portion of immunoglobulin. This 
ultimately leads to the conversion of C3 to C3b and activation of the terminal lytic
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sequence leading to disruption of the cell membrane (198). IgM is a very potent 
activator of complement whereas IgG induced activation depends on isotype. In 
some systems both the mouse and rat IgGl do not activate complement whereas 
IgG2a and IgG2b are both complement activating (199). The rat mAb GK1.5 
(IgG2b) used in early experimental transplantation is lytic of mouse CD4 cells in 
vitro (200) and depletes CD4 T cells in vivo (201). However it was later noted that 
when chimeric antibodies of GK1.5 were generated with identical epitope specificity 
but differing isotype the ability to generate CDC in vitro does not correlate with in 
vivo depletion (202). In particular the IgGl isotype of GK1.5 is as effective at 
inducing depletion as the TgG2b isotype. This suggests that additional mechanisms to 
CDC are responsible for cellular depletion. In addition mAb may cause cellular 
depletion in mice with a congenital complement deficiency (203). The depletion 
mechanism of mAb appears to depend upon the presence of the Fc component as 
F(ab)2 fragments of GK1.5 prepared with pepsin do not cause cellular depletion 
(204). Furthermore other mAb of complement-fixing isotype in vitro do not cause 
cellular depletion in vivo (205). The bulk of evidence suggests that in vivo cellular 
depletion does not correlate with the ability of a mAb to mediate CDC. It has 
however been suggested that pairs of mAb targeting distinct epitopes on the CD4 
molecule may induce synergistic lysis by CDC which correlates with in vivo 
depletion (206).
1.8.2.1.2 Antibody-dependent cellular cytotoxicity
This process implies the enhanced killing of opsonised cells by killer cells 
expressing an Fc receptor. Monocytes, macrophages, T cells and Natural Killer cells 
can all participate in ADCC as they all express Fc receptors. ADCC is widely 
accepted as an in vitro correlate of such Fc-dependent effector mechanisms (199), 
although ADCC involves cell lysis and 51Cr-release assays do not provide a
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measurement of opsonisation and phagocytosis of labelled cells, a process which 
does not result in release of cell contents into culture supernatant. Little has been 
published on the ability of xenogeneic mAb to direct ADCC in the rat. A study using 
isotype switch variants of a murine anti-IL2 mAb showed that the IgGl isotype is 
more effective than both IgG2a and IgG2b (207). Experiments have demonstrated 
the ability of both murine (208) and rabbit (209) mAb but not horse antibody (209) to 
direct human ADCC and rat mAb is able to direct murine ADCC (202). In these 
experiments the ability to direct ADCC is very dependent on isotype. Using isotype 
switch variants of identical epitope specificity, Kipps et al showed that murine IgG2a 
is very effective at directing human ADCC using blood mononuclear cells as effector 
cells; IgG2b is less effective and IgGl is not effective at all (208). In rat ADCC the 
most effective murine isotype depends on the effector cell used. Splenocyte-mediated 
ADCC is most effectively enhanced by IgG3 isotype whereas peritoneal 
macrophage-mediated ADCC is most effectively enhanced by IgGl and IgG2a 
isotypes (2 0 2 ).
1.8.2.1.3 T cell homeostasis after T cell depletion
In adult humans the major mechanism of T cell regeneration is via expansion 
of the peripheral T cell pool. In experimental animals however this role is performed 
by thymic processes (2 1 0 )
1.8.2.2 Transmission of negative signals by monoclonal antibody
The ability of cell-surface ligands to deliver negative signals was initially 
described in functional terms in assays of T cell activation. To fulfil the criteria for 
delivery of a negative signal a surface antigen-antibody interaction must inhibit T 
cell activation mediated by a separate pathway in the absence of blockade of the first 
antigen with its natural ligand. Early experiments showed that the proliferation of T
1.40
cells activated by anti-CD3 antibody in the presence of la' (class II negative) 
accessory cells could be inhibited by the addition of anti-CD4 mAb (211). In a 
similar fashion Con A mediated activation of a T cell clone (lacking accessory cells) 
can be inhibited by anti-CD4 mAb (212). More compelling evidence that the CD4 
molecule is able to mediate signals distinct from its role as part of the TCR complex 
came with the production of a CD4+/CD8+ clone (a herpes-virus infected mutant). In 
this clone only CD8  is physically associated with the TCR complex (and therefore 
able to interact with MHC molecules) and activation signals mediated via the TCR 
complex can be inhibited by concomitant signalling via CD4 (213). The CD2 
molecule has also been shown to be capable of delivering regulatory signals during T 
cell activation. More recently with the advent of assays of DNA fragmentation the 
inhibition of T cell activation mediated by cell surface ligands has been interpreted in 
terms of the induction of apoptosis (214).
1.8.2.3 Ligand modulation induced by monoclonal antibody
Antigenic modulation is the down-regulation of a cell surface antigen 
expression induced by exposure to specific antibody and was initially described 
when it was noted that the susceptibility of a leukaemic cell line to specific anti-sera 
was reduced by prior exposure of the cell to antibody (215). Other features of this 
process were later elaborated. Firstly it was noted that the presence of monocytes is 
an absolute requirement (216). The process of modulation is energy dependent on the 
part of the cell expressing the antigen and does not occur at 4°C, but does not require 
energy expenditure on the part of the monocyte, as prior fixing of the monocytes 
with azide does not influence modulation (217). In addition surface-to-surface 
contact with monocytes is required (217). The Fc portion of the antibody is required 
for modulation as F(ab)2 fragments are ineffective (216, 217). It was later shown that 
secondary labelling with polyclonal antibody could substitute for monocytes in
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inducing modulation suggesting that cross-linking of antigen is the crucial step (218). 
Internalisation of the labelling antibody is not however required as antigen 
modulation can be stimulated by solid phase antibody (218). Significantly it has also 
been shown that antigen modulation by specific antibody can also decrease the 
expression of associated surface molecules. In this way anti-CD4 mAb has been 
shown to partially comodulate CD2, CD3 (218) and the T cell receptor (219). 
Antibody-induced modulation of CD2 in the mouse has been shown to be 
immunosuppressive (2 2 0 ), and particularly potent immunosuppression has been 
achieved with the modulating murine anti-rat CD4 mAb RIB 5/2 (221). Antigenic 
modulation is also the primary mechanism of action of the anti-CD4 mAb OKT4 
used in primate models of transplantation (2 2 2 ).
1.8.2.4 Blockade of intercellular adhesion
The two pathways of intercellular adhesion most extensively studied are the 
CD2-CD48/58 pathway and the LFA-1 (CD1 la)-ICAM-l (CD54) pathway. Both of 
these molecular pairs have been shown to mediate intercellular adhesion when 
biochemically purified (161), although the distinction between intercellular adhesion 
and signal transduction is not clear. The role of the CD2 pathway in T cell activation 
has been extensively discussed and in a similar manner to the bi-directional flow of 
signals in the CD2-CD48 pathway both LFA-1 expressed on T cells (223) and 
ICAM-1 on monocytes and endothelium (224) have been shown to mediate 
regulatory signals in immune responses in addition to intercellular adhesion. 
Interestingly mAb directed against ICAM-1 (on monocytes) is able to inhibit T cell 
proliferation mediated by anti-CD3 mAb, presumably via a regulatory effect on 
monocyte-derived cytokines (224). The potency of blockade of these two pathways 
on in vitro alloreactivity has been demonstrated (225) and recent studies have been 
performed showing a beneficial effect of anti-LFA-1 therapy in experimental bone
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marrow transplantation (226) and both anti-LFA-1 (227) and anti-ICAM-1 mAb 
(228) have been assessed in phase I trials in human renal transplantation.
1.8.2.5 Blockade of costimulatorv signals
T cell activation requires antigen-MHC recognition plus non-specific 
costimulatory signals (90), and the absence of these signals may lead to clonal 
anergy (98). Early demonstrations of this phenomenon used fixed anti-CD3 mAb in 
the absence of accessory molecules to induce anergy (94). A similar effect has been 
demonstrated by activating T cells whilst blockading costimulatory pathways with 
monoclonal antibody. Pathways successfully targeted in this way include CD2 (see 
below), CD28 (see below), gp39-CD40 (229) and LFA-1 (230).
1.9 Anti-CD4 monoclonal antibodies in animal models of 
transplantation
As the bulk of research efforts in the use of mAb in transplantation have 
focussed on the CD4 molecule the key developments in this field will be outlined 
here.
The efficacy of anti-CD4 mAb in influencing alloimmune responses was first 
realised when it was demonstrated that the murine anti-rat CD4 mAb W3/25 is able 
to abrogate the mixed lymphocyte reaction without killing participating cells (231). 
More extensive studies were performed with the rat anti-murine CD4 mAb GK1.5, 
which was shown to inhibit in vitro proliferation and class II directed cytolysis (200).
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1.9.1 General immunological effects of anti-CD4 monoclonal
antibody therapy
The earliest observation made on the effect of the in vivo use of anti-CD4 mAb 
was its ability to prevent humoral immunity. Initially anti-Thy-1 mAh was shown to 
prevent the generation of agglutinating serum to SRBC administered at the same 
time (39). It was later shown by ELISA that therapy with the depleting anti-CD4 
mAb GK1.5 prevented both the IgM and IgG response to various antigens 
administered intravenously including SRBC and KLH (232), and BSA (201). 
Antibody production stimulated by T-independent antigens (eg LPS) was unaffected. 
A crucial aspect of this suppression of humoral immunity was the observation that 
treated animals also failed to generate an antiglobulin response to the administered 
antibody. This finding was extended to show that both GK1.5 and 0X38 induce 
immunological tolerance to themselves, which correlates with their ability to induce 
cellular depletion, as low doses, which are insufficient to induce depletion, also allow 
the development of an anti-globulin response (233, 234). That cellular depletion is 
not the only mechanism involved in tolerance induction to protein antigens is shown 
by the fact that an antiglobulin response was generated against an anti-CD45 mAb 
administered at the same time as GK1.5 (233). Abrogation of the anti-globulin 
response is not however a prerequisite for an immunosuppressive effect as the 
depleting murine mAb BWH4 is unable to induce tolerance to itself whilst having a 
potent effect on allosensitisation (235). Benjamin looked carefully at the issue of 
anti-globulin response after mAb therapy and confirmed that certain anti-CD4 mAb 
are able to induce tolerance to their own isotypic and idiotypic determinants and can 
also induce tolerance to co-administered non-cell binding mAb. Other cell binding 
mAb however are very immunogenic and anti-CD4 therapy is unable to prevent the 
generation of an anti-idiotypic immune response (236). Anti-CD4 mAb also prevents
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the induction of a humoral response to alloantigens after the transplantation of both 
skin grafts (237) and vascularised cardiac allografts (234,238).
Later experiments showed that the ability of anti-CD4 mAb to block the 
generation of humoral immunity to a wide variety of antigens is not matched by a 
similar inhibition of cellular immunity. The mAh GK1.5 for example is able to 
inhibit both the primary and secondary CD4-driven induction of CD8 + cytotoxic T 
cells directed against viral antigens (239) but is unable to abrogate the production of 
specific CTL generated against alloantigens presented by skin (238) or cardiac 
allografts (237). The mechanism of antigen recognition differs in these two models in 
that viral antigens are presented in the context of self-class IT molecules whereas 
class I and class II transplant antigens are recognised directly by host T cells at a 
higher frequency, which may be a more potent stimulus. Other experimental 
evidence also exists showing that allolytic CD8  T cells can function in the absence of 
CD4-mediated help (240). The consistent observation however that anti-CD4 mAb is 
able to influence humoral immunity to a much greater degree than cellular immunity 
provided an early indication of a dichotomy amongst CD4 helper T cells and 
suggests that different helper cell populations are involved in the provision of help 
for humoral and cellular immunity.
1.9.2 Influence of anti-CD4 therapy on allograft survival
The potent effect of anti-CD4 mAh on humoral and cellular responses 
prompted their use in animal models of transplantation. Early work by Cobbold 
showed that anti-CD4 mAb is able to marginally prolong the survival of skin 
allografts, which is extended by the addition of anti-CD8  mAb (39). The first 
indications of the complexity of mAb therapy came with the demonstration that a 
mAb (W3/25) with potent in vilro effects (231) and immunosuppressive effect in
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EAE (205) does not influence allograft survival (241) and mAb with potent in vivo 
effects on humoral immunity (GK1.5) also did not influence skin allograft survival 
(237). However tolerance to vascularised cardiac allografts has been achieved with 
depleting anti-CD4 monotherapy in the mouse using GK1.5 (242) and the YTS 
family of mAbs (243) and in the rat using 0X38 (234). More stringent models of 
allograft rejection such as skin grafts or high responder rat strains have required the 
combination of anti-CD4 mAb therapy with other modalities such as Cyclosporine 
(244) or anti-CD3 mAb (245). Results with rodent models cannot easily be 
extrapolated to primates and humans however, where anti-CD4 mAb has a less 
marked immunosuppressive effect and in general promotes a host anti-globulin 
response (246, 247).
An important aspect of therapy with mAb is the timing of administration in 
relation to the exposure of the animal to antigen. This is important because CD4 T 
cells have differential roles in the sensitisation and effector phases of allograft 
rejection (235) and it is known that primed CD8  cells can function in the absence of 
CD4 derived help (40, 240). The inhibitory effect of anti-CD4 mAb is most potent if 
binding with CD4 occurs prior to activation via the CD3-TCR complex (248) and in 
vitro studies of T cell activation have confirmed that prior incubation with anti-CD4 
is necessary to inhibit stimulation via the TCR (143). Anti-CD4 mAb administered 
during the sensitisation phase in a system using skin graft priming is effective in 
abrogating accelerated graft rejection but has no effect when administered more than 
seven days after the priming event (249) when a mature B cell response has evolved 
which is no longer dependent on T cell help. This is in contrast to cyclosporine and 
anti-IL2 mAb both of which are effective when administered during the effector 
phase of an immune response (250). The crucial time point for ligation of CD4 with 
antibody is when host T cells encounter graft antigen. Experimental evidence
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suggests that sensitisation to an organ allograft occurs by the migration of graft 
leukocytes to host regional lymph nodes via lymphatics (92). Monoclonal antibody 
therapy administered at the time of solid organ transplantation therefore will label T 
cells prior to their encounter with graft APCs in regional lymph nodes. That early 
post-operative anti-CD4 mAb therapy is effective in preventing allostimulation has 
been demonstrated by Sayegh (251).
1.9.3 Depleting and non-depleting anti-CD4 antibody regimens
A common effect of anti-CD4 therapy is target cell depletion. Two mAbs used 
in early experiments, GK1.5 and 0X38, both cause cellular depletion and early 
publications attributed their immunosuppressive effect to target cell depletion (39, 
242). This belief was reinforced when it was shown that cellular depletion caused by 
0X38 correlated with administered dose and low doses failed to cause either cellular 
depletion or prolong graft survival (234), and antibody regimes using combinations 
of two different anti-CD4 mAbs produced profound cellular depletion and allowed 
permanent allograft survival in high-responder rat strain combinations (244). 
Furthermore using the GK1.5 family of isotype switch variants it was shown that the 
ability to cause cellular depletion coincided with the ability to influence immune 
responses, although the effect on allograft survival was not tested (202). That cellular 
depletion is not however the sole cause of the in vivo effect of anti-CD4 mAb was 
shown when it was demonstrated that:
1) Cellular depletion is not of itself sufficient to induce permanent 
allograft survival
2) Depletion is not necessary for some anti-CD4 mAbs to be effective. 
Numerous lines of evidence suggest that cellular depletion alone is not
sufficient explanation for the effect of anti-CD4 mAbs. The two murine anti-CD4
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mAbs W3/25 and BWH-4 cause a similar degree of cellular depletion but only 
BWH-4 is effective in prolonging allograft survival (235). Secondly the anti-CD4 
mAb pair of 0X35 and 0X38 causes profound depletion and is effective in inducing 
transplant tolerance, its effect however can be completely abrogated by pre-operative 
thymectomy without any effect on lymphocyte populations (244). Attempts to induce 
allograft tolerance without causing cellular depletion are obviously attractive, as they 
do not entail the prolonged non-specific immunosuppression of depleting protocols. 
As has been explained above the ability to cause cellular depletion rests partly in the 
Fc portion of the antibody molecule. Initial attempts to devise a non-depleting mAb 
therefore used F(ab)2 fragments of the depleting antibody GK1.5. This was shown to 
be effective in inhibiting humoral immunity without causing cellular depletion (204). 
Similarly the complement-fixing (IgG2b) murine antibodies YTS191.1 and YTA3.1 
have been used in combination in ‘sub-lytic’ doses to induce tolerance to human y- 
globulin without causing depletion (206). Following this work mAbs were devised 
which do not deplete T cells. An early example is the rat anti-mouse CD4 mAb KT6 . 
This (IgG2a) mAb competes for binding with the depleting antibody YTS191 
suggesting the significance of specific epitopes in influencing ligand function. KT6  
causes blockade of CD4 without modulation and has been shown to be successful in 
promoting allograft survival (252). Other non-depleting mAb have been devised 
which function by causing modulation of the CD4 molecule. The rat antibody 
YTS 177.9 modulates the CD4 molecule and allows tolerance induction to 
intravenously administered peptides and skin grafts differing at multiple minor 
transplant antigens (253). These regimes are in general not as effective at inducing 
transplant tolerance as depleting regimes and do not alone allow permanent survival 
of cardiac allografts. Prolonged CD4 blockade may be a more effective mechanism 
of immunosuppression than ligand modulation as modulation alone may allow
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internalisation of the mAb and re-expression of unlabelled CD4 (254). More potent 
immunosuppression has been obtained in the rat using the murine non-depleting 
mAb RJLB5/2. This antibody modulates the CD4 molecule and is able to prevent the 
induction of an anti-globulin response when given in high doses for prolonged 
periods. It has been demonstrated to allow transplant tolerance to rat skin grafts when 
used in high doses (255), to prevent host sensitisation by skin-grafting (249), and to 
induce tolerance to cardiac allografts when used in a single low dose in combination 
with an infusion of donor splenocytes (2 2 1 ).
1.9.4 Differential effects of anti-CD4 mAb on CD4 subsets
A notable effect of all depleting regimes of anti-CD4 mAb is the incomplete 
depletion of CD4 T cells. This is true of regimes in both rats (234) (256) and mice 
(39, 257, 258) where increasing the dose of mAb rarely depletes CD4 T cells beyond 
95%. Naive and memory cell populations appear to respond differently to anti-CD4 
mAb labelling in vivo. Weyand demonstrated that although the mAb GK1.5 is able to 
abolish primary anti-viral cytolytic responses secondary responses resulting from 
earlier priming remained intact, suggesting that memory cells reside within the 
undepleted CD4 population (239). Further in vitro evidence showed that activation of 
CD4 T cells via the TCR protected cells from the inhibitory effects of anti-CD4 mAb
(259) and in vivo studies showed that undepleted cells after therapy with GK1.5 
contained a high percentage of cells expressing the IL2-receptor activation marker
(260). More specifically CD4 cells of the Vp6  family, when stimulated by the 
superantigen Mls-1, are spared depletion by GK1.5 therapy when assessed by the 
Vp6 -specific antibody RR4-7 (260).
CD4 T cells can be further divided into Thi and TI12 subsets on the basis of 
function and cytokine production (60). Thi cells produce the signature cytokine ylFN
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and provide help for macrophage-dominant DTH-type responses whereas Th2 cells 
produce LL4, the dominant cytokine stimulating B cell activity. In a similar manner 
to naive and memory cells these two subsets have been shown to respond differently 
to anti-CD4 mAb. An analysis of cytokines produced in MLR experiments has 
shown that after the initial culture levels of IL4 are similar in W3/25 labelled and 
unlabelled cultures but after a period of rest followed by restimulation IL4 levels 
(detected by RT-PCR of mRNA) were greatly increased in cultures containing 
W3/25 and undetectable in unlabelled cultures (261). The authors interpreted these 
findings as suggesting that Thi cells require greater numbers of TCR-MHC 
interactions to be activated and are therefore more susceptible to anti-CD4 mAb- 
mediated blockade. Similarly CD4 T cells stimulated by anti-CD3 mAb show an 
inability to generate Thi cytokines when labelled with GK1.5 (262). Some transplant 
models have also been able to demonstrate a relative sparing of Th2 function after 
anti-CD4mAb therapy. The non-depleting mAb BWH-4 has been used in a model of 
accelerated graft rejection and has been shown to abrogate the production of IL2 but 
preserves IL4 elaboration at both the gene and protein level (263, 264), although 
immune deviation is incomplete as an explanation of transplant tolerance (see 
below).
1.9.5 Induction of non-classical tolerance by anti-CD4 mAb therapy 
in transplant models
In order to meet the criteria for donor-specific immunological tolerance it is 
necessary to demonstrate that animals with long surviving grafts will accept further 
grafts from the donor strain but reject grafts from a third-party strain. Many models 
of transplant tolerance induced by anti-CD4 mAb have met this criterion (221,234, 
265). However in contrast to ‘classical immunological tolerance’, where tolerant
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animals do not produce immunological responses to donor type cells (188), 
alloreactive lymphocytes are detectable in these animals (253,266) and typically 
react normally to donor-type cells in the MLR (234) (265). This has been termed 
‘split’ or ‘functional’ tolerance and has also been demonstrated in transplant 
protocols using organ culture (267) and donor-specific blood transfusion (266). This 
dissonance between in vitro and in vivo assays of tolerance has been described earlier 
when it was also noted that assays of proliferation in the MLR and CML failed to 
predict the development of neonatally induced tolerance (268). Fathman addressed 
the issue of cells from tolerant animals responding normally in the MLR and 
suggested that animals become tolerant to peptides presented during tolerance 
induction, which will include MHC molecules presenting tissue-specific peptides 
(269). As clonal deletion has been excluded as a mechanism of tolerance induction in 
these models the peripheral mechanisms of tolerance including anergy, suppression 
and immune-deviation have been explored, all of which have been implicated in 
different systems.
1.9.5.1 Anergy in anti-CD4 mAh transplant models
As alloreactive lymphocytes represent a small proportion of the entire T cell 
repertoire, precise (monoclonal) mechanisms have been devised to investigate anergy 
amongst the graft-reactive cells. If donor and host animals differ at the M is l a locus 
the fate and function of M is l a reactive Vp6 + T cell clones can be monitored with 
clonotypic antibodies. The first demonstration of clonal anergy using this method 
was in a bone marrow transplant model when the M is l a- reactive Vp6 + clone was 
shown to be anergic when stimulated by an anti-Vp6  mAb (270). In a similar fashion 
the Vp gene segments encoding reactivity with the class 11 antigen IE have been 
defined (V p5 ,11 and 17). In a pancreatic islet cell transplant model using the
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depleting mAb GK1.5 Alters and colleagues demonstrated that lymphocytes from B6  
mice (IE-) tolerant to IE+ islets showed greatly diminished proliferation to anti-Vpil 
mAb (256). Furthermore this anergic state could be reversed by the addition of IL2. 
Anergy of a similar type has been demonstrated in CD8  T cells after treatment with 
anti-CD3 mAb (271).
1.9.5.2 Immune suppression in anti-CD4 mAh transplant models
Much of the work on suppressor T cells has been done by Waldmann and 
colleagues. This group have used a model of murine allogeneic skin transplantation 
across a multiple minor antigen mismatch under cover of non-depleting anti-CD4 
and CD8  mAbs. An early indication that cells from tolerant hosts are able to 
influence naive cells came with the observation that infusion of naive cells is unable 
to break tolerance (‘dominant-tolerance’) (272). Adoptive transfer experiments also 
showed that tolerance in the T cell population is stable and long lasting, this would 
require either that the initial tolerised cells survive indefinitely or that new thymic 
emigrants come under the influence of tolerant cells and are themselves tolerised. To 
explore this last point further adoptive transfer experiments were performed of naive 
cells into tolerant animals whose T cells are transgenic for the human CD2 gene.
Two features suggested that the new cells had themselves become tolerant:
1) After a period of co-habitation in the tolerant host the host T cells 
were depleted with an anti-human CD2 mAb without affecting the 
tolerant state
2) Cells from the chimeric mouse could be infused into a second T cell 
depleted host and not break tolerance.
Waldmann termed this phenomenon ‘infectious tolerance’ (273). This would 
imply that naive T cells receive signals from tolerant T cells at close proximity at the
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site of antigen presentation. To test this hypothesis the same group sought evidence 
of ‘linked suppression’. They found that CBA (H-2k) mice tolerant to a minor- 
mismatched skin graft could then accept a third party graft transgenic for the class 1
h  Umolecule K and the tolerised minor antigens but would reject the K antigen when 
expressed on a separate graft. This was interpreted as meaning tolerant T cells 
recognising the tolerised minor antigens expressed on class II molecules then become 
tolerant to foreign class I molecules expressed on the same APC (274). Similar 
results were obtained by another group who showed that tolerance to APC-depleted 
(but not naive) hearts could be transferred by splenocytes from rats made tolerant 
with anti-CD4 mAb (275). Waldmann has suggested two possible mechanisms by 
which naive T cells in these models come under the influence of tolerant T cells 
(276). In a passive model tolerant anergic cells would accumulate at the site of 
antigen presentation resulting in diminished collaborative units. This would mean 
that new naive cells would encounter foreign antigen isolated from T cell help and 
would themselves become tolerant (the ‘civil-service’ model). In an active system 
tolerant T cells would influence naive cells by secreting tolerance-inducing 
cytokines.
1.9.5.3 Patterns of cytokine secretion in anti-CD4 mAh transplant models
Early indicators of diminished expression of cytokine receptors in tolerant 
cardiac allografts compared to acutely rejecting allografts came from an analysis of 
IL2-receptor expression (277). This was matched by a failure of cultured graft 
infiltrating cells to produce IL2 despite normal IL2 gene expression. Graft tolerance 
in this model could be abrogated by administration of exogenous IL2, suggesting a 
selective failure of IL2 translation. Following this publication many groups have 
explored the differential production of cytokines in tolerant and rejecting allografts. 
As has been outlined in section 1.9.4 CD4 T cells can be sub-divided into Thi and
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Th2 subsets which correlate broadly with cytokine secretion favouring help for cell- 
mediated or humoral immunity respectively. This dichotomy is most clearly seen in 
the response of both humans and mice to chronic parasitic infections (60). There is 
extensive evidence that during rejection of organ transplants all cytokines may be 
expressed within the graft, representing the redundancy of immune pathways in graft 
rejection (278). In keeping with this allografts can be rejected in IL2 knockout mice 
despite detectable IL4 expression in the graft (279) and ylFN knockout mice 
similarly reject allografts despite having diminished DTH responses (280).
Numerous transplant models have shown a preferential decrease of Thi-associated 
cytokines during the induction of adult tolerance including anti-CD4 mAb (281) and 
anti-TCR mAb (282) regimes and donor specific transfusion (DST) (283), however 
the association of upregulated Th2 cytokines with allograft tolerance is more 
problematic. In a model of transplant tolerance mediated by DST Josien noted a 
broad reduction of transcripts for both Thi and Th2 cytokines (284) and in a 
transplant model where rejection is known to be mediated by alloantibody Tweedle 
noted a preferential decrease in Th2 cytokine-gene transcripts in tolerant cardiac 
allografts (285). An interesting aspect of the Thi/Th2 dichotomy has been the 
observation by Waldmanns group that infectious tolerance by adoptive transfer in his 
model of tolerance to minor mismatched allografts can be abrogated by the addition 
of anti-EL4 mAb at the time of cell infusion. As tolerant lymphocytes in his model do 
not produce increased levels of IL4 Waldmann has surmised that the anti-IL4 
antibody neutralises IL4 produced by naive cells in the process of tolerance induction 
after contact with host lymphocytes. This would then allow these cells to develop 
Thi functions (286). Although the bulk of evidence suggests that differential Thi/Th2 
functions are detectable in transplant models it does not support a simple association 
of preferential Th2 utilisation leading to allograft tolerance.
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1.10 Anti-CD2 monoclonal antibodies in experimental 
transplantation
1.10.1 Anti-CD2 monoclonal antibody therapy in murine models of 
transplantation
Compared to the body of work published on the effect of anti-CD4 mAb 
relatively little work has been done on anti-CD2 mAb therapy. Early studies were 
performed in the mouse using the anti-CD2 mAb 12-15 (287). An interesting aspect 
of 12-15 mAb is the discordance between its in vitro and in vivo effects. Numerous 
experiments have demonstrated its inability to affect the MLR (288) (289), or the in 
vitro induction of allo-CTL (290). Despite the involvement of the CD2-CD48 
pathway in the augmentation of CTL lysis (discussed in Chapter 2), anti-CD2 mAb is 
not able to inhibit in vitro lysis by either allo-CTL or a CTL clone (154). Some 
workers have shown a slight inhibition of anti-CD3 mediated proliferation by the 
mAb 12-15 with associated reduction in IL2 and IL4 production (291) whilst others 
have been unable to demonstrate this effect (290). In vivo experiments however have 
shown the potency of anti-CD2 in various aspects of T cell immunity. In vivo 
priming for TNP-specific CTL (288) and allo-CTL (289) (292) is inhibited by 
concurrent administration of anti-CD2 mAb. Anti-CD2 is also able to delay the 
isotype switch from IgM to IgG after injection of the antigen oxazalone, although 
this effect is slight compared to the effect on CTL induction (293).
The in vivo effect of anti-CD2 mAb therapy in mice however does not extend 
to the induction of transplant tolerance; when used as monotherapy it is only able to 
prolong cardiac allograft survival (292). In this model mAb therapy (with the rat 
mAb 12-15) is most effective when administered preoperatively, and has no effect
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when administered four days after transplantation. This inability to influence an 
established rejection process and the effect on CTL induction rather than lysis 
suggests that anti-CD2 in this model affects the afferent limb of alloimmunity. A 
consistently detectable effect of anti-CD2 therapy in the mouse is down-modulation 
of the CD2 molecule, which occurs without comodulation of CD4, CD8  or CD3
(288). Further analysis using Fab and F(ab) 2 fragments demonstrates that the Fc 
component is crucial for both antigen modulation and the immunosuppressive effect
(289). In these models of murine anti-CD2 therapy there is no evidence of cellular 
depletion. Although anti-CD2 mAb is unable to influence the proliferation of 
lymphocytes stimulated in vitro with anti-CD3 mAb, when lymphocytes are taken 
from animals treated in vivo with anti-CD2 mAb, proliferation subsequently induced 
in vitro by anti-CD3 mAb is inhibited (294). This may be due to more efficient 
antigen modulation after in vivo administration of mAb (295). Furthermore inhibition 
of proliferation in these assays was accompanied by altered cytokine production; IL2 
and IL4 production was diminished whilst the production o f the immunosuppressive 
cytokine TGFp was increased (294). A contrary effect on IL4 production has been 
noted in the context of transferable suppression. CD2 mAb treated and immunised 
animals produce CD4 T cells which are able to inhibit the in vitro generation of CTL 
against the original immunogen (289). Culture supernatants in these assays show a 
consistent increase in IL4 levels compared to controls, suggesting that anti-CD2 
mAb therapy has favoured the development of a Th2 phenotype. This is in contrast to 
blockade of costimulation by the CD28-B7 pathway, where antibody therapy favours 
the development of a Thi phenotype (122), and demonstrates a qualitative difference 
between the mechanisms of these two costimulatory pathways.
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1.10.1.1 Combination monoclonal antibody therapy in the mouse
Whilst anti-CD2 mAb therapy alone is not able to induce allograft tolerance in 
the mouse it is more effective when combined with other therapies. The earliest work 
combined anti-CD2 with anti-CD3 mAb (296) to induce allograft tolerance. In this 
regime anti-CD2 was administered prior to anti-CD3 and prevented anti-CD3 
mediated cytokine release. Combination with anti-CD4 was ineffective. Further 
experiments in mice have shown that anti-CD2 is also able to synergise with FK506 
(297), anti-CD48 (290) and anti-CD28 (291) therapy to induce allograft tolerance. 
Experiments using anti-CD2 mAb therapy with human cell cultures have also shown 
that interference with more than one accessory T cell pathway is necessary to 
suppress proliferative responses (225). Taken together these results imply that 
numerous intercellular pathways are available to T cells for the provision of 
costimulatory signals and blockade of one pathway alone is insufficient to ‘isolate’ a 
T cell.
1.10.2 Anti-CD2 monoclonal antibody therapy in rat models of 
transplantation
Little work has been published using anti-CD2 mAb in the rat and a consistent 
picture of its effect is hard to obtain. An early work demonstrated the inability of 
0X34 to influence the MLR (298), which was later contradicted by two other groups 
showing a variable inhibition (299, 300). Both of these publications also 
demonstrated a minor inhibition of anti-TCR mediated T cell activation by anti-CD2 
mAb in the rat. Similarly conflicting evidence exists regarding the effect of anti-CD2 
mAb in allograft models. The mAbs 0X34 (IgG2a) and 0X54 (IgGl) were assessed 
by Hirahara using a vascularised cardiac allograft in a low responder (Lewis-DA) 
strain combination. 0X34 in this study was able to induce permanent allograft
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survival whereas 0X54 was only able to slightly prolong graft survival (299). Using 
0X34 in an identical strain combination Sido was only able to prolong allograft 
survival to a MST of 45 days (300). These groups also give conflicting 
interpretations of flow cytometry data. Hirahara showed a predominant depletion of 
CD4 T cells with some modulation of CD2 from remaining cells whilst Sido reported 
down-modulation of CD2 to less than 20% of naive levels without significant 
cellular depletion, in a similar manner to anti-CD2 therapy in the mouse (301).
1.10.3 Mechanisms of action of anti-CD2 mAb therapy in rodent 
studies
The small number of publications available does not describe a clear pattern for 
the efficacy of anti-CD2 mAb therapy at modulating immune responses in vivo in the 
rat and also suggests a different mechanism of anti-CD2 mAb therapy in rats and 
mice. However some indication of the mechanisms involved can be deduced. The 
synergy in action between anti-CD2 mAb and anti-CD48 mAb in the mouse (290) 
suggests that simple blockade of the CD2-CD48 ligand pair is an inadequate 
explanation. Further evidence in the rat has shown that the mAb 0X45 is very 
effective at modulating CD48 from the surface of rat LNC but does not prolong 
allograft survival or influence proliferative responses to various mitogens, again 
suggesting that interference with the CD2-CD48 pathway does not explain the 
potency of anti-CD2 mAb (301). A similar series of experiments performed in the 
mouse has shown that while modulating anti-CD48 mAb is unable to influence 
proliferative responses it does inhibit the in vitro generation of allo-CTL to a greater 
extent than anti-CD2 mAb, again suggesting a mechanism other than simple ligand- 
receptor blockade (302). Furthermore the ability of anti-CD2 mAbs binding domains 
other than the CD48-binding domain (eg 0X54 and 0X55) to influence immune
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responses suggests there is no absolute requirement for ligand-receptor blockade 
(303). A different interpretation of these findings is that there are further unidentified 
ligands for the CD2 molecule.
A consistent finding in murine studies is modulation of the CD2 antigen. This 
requires intact mAb (including the Fc portion) and epitope specificity appears less 
important than isotype (304). Down modulation of CD2 in this model is associated 
with upregulation of other adhesion molecules, which may contribute to an 
inappropriate activation environment where adhesion receptors are upregulated yet 
fail to engage their ligands. As described above the picture in rat models is less clear, 
with both cellular depletion and CD2 modulation being described. Using 0X34 
therapy in a model of adjuvant arthritis in Lewis strain rats however Hoffman also 
described selective CD4 T cell depletion associated with diminished disease severity 
(305). In a recent paper analysing the in vivo effect of the mAbs 0X34, 0X54 and 
0X55 Sido noted that in the high responder transplant combination DA to Lewis that 
modulating 0X34 and 0X55 were most effective in prolonging allograft survival and 
that graft rejection in animals treated by these two modalities coincided with 
clearance of mAb from the serum and re-expression of modulated CD2 molecules 
(303). A further observation was made in this paper regarding differential effects on 
B and T cell immunity. Sido demonstrated that despite inhibiting the generation of 
CTL to KLH, anti-CD2 mAb therapy was unable to prevent the generation of a 
humoral response to the same antigen (303), suggesting a minor role for CD2 in T 
cell help for humoral responses, in agreement with murine studies.
Little detail is available regarding the maintenance of transplant tolerance 
induced by anti-CD2 mAb therapy. Kreiger et al showed by in situ hybridisation that 
both Thi and Th2 cytokines are up regulated in rat cardiac allografts made tolerant 
with 0X34 therapy compared to isografts (306). In a murine model using an anti-
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CD2 mAb to obtain tolerance to pancreatic islet allografts Kapur noted a reduction in 
expression of both the CTL-associated cytokine granzyme B and 1L10 in tolerant 
grafts (307), arguing against immune deviation as a mechanism of allograft 
tolerance. Recent murine studies using a combination of anti-CD2 and anti-CD3 
mAb have demonstrated a role for IL4, as addition of anti-IL4 mAb to the treatment 
regime abrogates tolerance and this regime is ineffective in EL4 knockout animals 
(308).
No evidence is available in transplant models on the transmission of negative 
signals via CD2 as a mechanism of immune tolerance. This phenomenon has been 
demonstrated in polyclonal in vitro systems where T cell activation and cytokine 
secretion mediated by a CD2 mAb pair can be inhibited by a third anti-CD2 mAb 
(181).
1.10.4 Anti-CD2 mAb therapy in primate models
Following the efficacy of anti-CD2 mAb therapy in rodent models its use in 
both humans and baboons has been attempted. The construct LFA3TIP, which 
competitively inhibits the CD2-CD58 interaction, has been shown to prolong baboon 
cardiac allograft survival from ten to eighteen days (309). In a human series reported 
from Belgium forty patients were randomised to either Cyclosporine-based triple 
therapy alone or triple therapy plus the rat IgG2b anti-human CD2 mAb BTI-322. A 
reduction in acute rejection episodes at nine months was noted without any adverse 
side effects (310).
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1.11 Blockade of the CD28-B7 pathway in experimental
transplantation
Whilst the relationship of the CD2 pathway to the TCR complex is unclear and 
signalling by these two pathways does not fit neatly into the two signal paradigm 
devised by Bretscher and Cohn, the CD28-B7 pathway, in contrast, appears to be a 
more purely costimulatory pathway so that attempts to blockade CD28-B7 with 
CTLAffg have been performed with the hope of fulfilling Bretscher and Cohn’s 
predictions of clonal anergy.
1.11.1 Construction of CTLA J g
The human CTLAJg construct was originally elaborated by Linsley et al 
(116). cDNA coding for the extracellular domain of CTLA4 was extracted from total 
RNA of a human leukaemia cell line. This fragment was then ligated with cDNA 
coding for the hinge, CH2 and CH3 domains of human Ig Cyl and inserted into a 
mammalian expression vector, CDM8 , which was transfected into COS cells. The 
resulting supernatant contains a product which binds to B7 with 20-fold greater 
affinity than CD28Ig (116) and binds efficiently to human, rat and murine B7 (311).
1.11.2 Immunological effect of CTLAJg therapy
Compared to the extensive published literature on the effect of anti-CD2 in 
allo-immune responses there is comparatively little information regarding the use of 
CTLAdg. Early in vitro studies demonstrated that CTLAdg is able to inhibit the 
MLR (116, 312) but does not inhibit proliferation induced by the more potent 
mitogens Con A and immobilised anti-CD3 mAb (313). Analysis of cytokine 
production in these experiments showed that the production of both IL2 and IL4
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mirrored the degree of cellular proliferation, arguing against a differential subset 
effect. In comparing in vivo and in vitro effect Baliga noted that whilst CTLAftg is 
very effective at inhibiting the MLR when added directly to the culture, even high 
dose in vivo therapy fails to inhibit the proliferation of cells from treated animals 
(313). In a similar manner to some experiments with anti-CD2 mAb, CTLAJg is 
able to prevent the in vivo priming of hapten-induced (TNP) CTL induction and in 
vitro restimulation of primed CTL and also inhibits the afferent limb of contact 
sensitivity but does not prevent the more potent in vivo priming of allo-CTL in 
murine models (313). CTLAJg has no effect on lysis of established murine CTL 
when added to cultures. These results suggest there is a hierarchy of immunological 
stimuli with allo-immunisation the most difficult to circumvent and that in vivo 
responses have other pathways of costimulation in addition to the CD28-B7 system. 
Workers using the rat model however have shown inhibition of in vivo allo-CTL 
induction by CTLATg (314).
Other in vivo studies established that CTLAJg therapy in SRBC or KLH 
treated mice is able to inhibit the production of antibody-forming cells (127). 
Likewise CTLAftg inhibited the formation of alloantibody in a rat renal allograft 
model (314). This contrasts with anti-CD2 mAb, which has a more potent effect on T 
cell than B cell responses.
Unlike mAb therapy directed at T cell antigens these potent effects on T and B 
cell responses in rodents are achieved without major effects on T cell subsets and 
ligand expression. Analysis of the T cell antigens CD4, CD8 , CD2 and CD3 antigens 
showed no change after CTLAftg therapy (313), as did analysis of class IIMHC 
expression in splenocytes from treated animals (127).
1.11.3 CTLA J g  therapy in transplant models
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In rodent transplant models conflicting results have been reported on the 
efficacy of CTLAJg therapy. It is able to induce indefinite graft survival and donor 
specific tolerance after xenogeneic pancreatic islet grafting in the mouse (315), but is 
only able to prolong non-vascularised cardiac allograft survival (MST 35 days)
(313). Early reports suggested that CTLAdg is unable to produce tolerance to rat 
vascularised cardiac allografts (in the high responder Brown Norway to Lewis 
combination) (312) however later reports demonstrated tolerance to murine 
vascularised cardiac allografts (316) and rat renal allografts (317).
An important aspect of the regimes used in these experiments is the timing of 
the dose of CTLA4Ig. Some workers administered the construct (50|iig/mouse or 
0.5mg/rat given intravenously) at the time of transplantation (313, 316) whilst others 
have demonstrated an advantage in delaying administration until 48 hours post- 
operatively (314, 318). Delaying administration until days 4 and 5 (319) or day 7 
(313) has no effect on allograft survival demonstrating that CTLAJg is unable to 
reverse an established rejection process. As the half-life of CTlAftg in mice is 2.8 
days (127) the bulk of CTLA4g administered at day 0 would still be circulating after 
48 hours. There are two possible explanations for the enhanced effect of delayed 
therapy:
1) There is evidence that alloimmune responses are most effectively stimulated 
by dendritic cells, and Larsen has shown that the migration of dendritic cells to the 
spleen peaks two days after transplantation (320)
2) Differential expression of B7 molecules may influence the effect of 
C flA ftg  therapy as it is known that B7-1 expression is maximal 48 hours after 
stimulation of APC (121).
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The second explanation is the most likely, as it is specific to CTLAdg whereas 
an advantage in delaying treatment has not been noted with other 
immunosuppressive modalities. In keeping with this finding is the observation that 
perfusion of the donor heart with CTLA^g prior to transplant does not affect 
allograft survival, suggesting that CTLA4 ligands are not available prior to induction 
of an immune response (316).
A notable effect of CTLAJg therapy is its ability to synergise with other 
modalities to induce transplant tolerance in more stringent experimental models. In 
high responder Lewis rats CTLAftg therapy alone is unable to induce permanent 
allograft survival. Permanent survival of cardiac allografts in these animals however 
can be obtained by combining CTLAdg with either anti-CD4 mAb (321) or donor- 
specific blood transfusion (318), and of renal allografts by combining CTLA4g 
therapy with low dose Cyclosporine A (322). Tolerance to highly immunogenic 
secondary skin grafts in mice can be obtained by combining CTLAJg with donor- 
specific transfusion (323) and to small bowel allografts in Lewis rats by combining 
CTLAftg with anti-CD4 mAb (324). Combining CTLA4lg with depleting regimes of 
anti-CD4 and anti-CD8  mAb has also proved successful in prolonging survival of 
cardiac xenografts (325). In view of the redundancy of costimulatory pathways in T 
cell activation an attractive therapeutic strategy is to combine CTLAJg with 
blockade of other accessory T cell molecules. In this way CTLA4g has been shown 
to combine with blockade of the LFA-1 pathway to induce long-term acceptance of 
pancreatic islet allografts (326) and with anti-CD2 mAb to induce tolerance to non- 
vascularised murine cardiac allografts (291). A particularly potent effect has been 
obtained by combining CTLAJg with blockade of the CD40-gp39 pathway, which is 
an important costimulatory pathway in the development of B cell responses. This
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regime has been shown to induce long-term survival of allogeneic skin grafts in mice 
(327).
An interesting use of CTLA4g has been the transfection of myoblasts with 
cDNA coding for CTLAJg. When allogeneic myoblasts are transfected in this way 
and transplanted into live animals a small proportion develop stable secretion of low- 
dose CTLAdg. This has been shown to extend survival of pancreatic islet allografts 
(MST 32 days) without other treatment (328).
Recently mAb targeting the CD28 molecule has been used in experimental 
transplantation in an attempt to overcome the dual blockade by CTLA4lg of the 
CD28 and CTLA4 molecules. By allowing signalling via the CTLA4 molecule it was 
hoped that the negative regulatory function of this molecule could be retained whilst 
inhibiting the costimulatory function of CD28. Using the modulating mAb JJ319 in 
the DA to Lewis cardiac allograft model Dengler et al noted a very similar 
prolongation of allograft survival to that induced by CTLAftg alone (329). This 
group also noted a conflict between the in vivo and in vilro effect of JJ319. This mAb 
was shown to costimulate T cell activation in both the MLR and mitogen-mediated 
activation when added directly to culture plates whereas lymphocytes taken from a 
JJ319 treated animal showed reduced proliferative responses in identical 
experiments. This finding may be explained by more efficient CD28 modulation 
after in vivo therapy preventing transmission of a positive signal.
1.11.4 Mechanism of tolerance induction by CTLALe therapy
There are few publications exploring tolerance mechanisms induced by 
CTLAJg so a consensus view is difficult to obtain. In a similar manner to other 
regimes tolerance in these models can be assessed under the general headings of 
deletion, anergy and suppression.
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1.11.4.1 Deletion
In the models where CTTAftg produces allograft tolerance it does so by a non- 
classical mechanism. There is no published data demonstrating deletion of 
alloreactive cells in tolerant animals whereas there is data demonstrating functioning 
alloreactive cells in these models in terms of proliferation (318) and cytokine 
production (317).
1.11.4.2 Anergy
In view of the predictions of Bretscher and Cohn’s two-signal model of T cell 
activation and the demonstrations of clonal anergy in in vitro systems this is an 
attractive explanation for immune tolerance in transplant models. Unfortunately in 
the transplant setting anergy has not been formally demonstrated. In the early 
experiments of Linsley et al showing inhibition of antibody responses to SRBC even 
high dose CTLA4g therapy did not induce tolerance as most animals displayed 
enhanced responses when retested after 25 days (127). Similarly CTLA^g therapy in 
models of solid organ transplantation displays evidence of activation of alloreactive 
cells. Numerous groups have demonstrated a reduction in the MLR at early time 
points after transplantation (when cultures may be contaminated by residual 
CTLAftg), which have not been reproduced in animals with long surviving grafts 
(314, 318). Analysis of effector cell function in animals made tolerant to allografts 
with CTLAftg has also shown that despite survival of the graft donor specific CTL 
are produced with similar titrations to rejecting controls (291). This is a significant 
observation as studies performed early after transplantation have shown the ability of 
CTLAftg to prevent the induction of allo-CTL (see above). This anomaly suggests 
that:
1) CTL are produced with slower kinetics in tolerant animals
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2) CTL produced under these circumstances are unable to effect tissue 
damage in vivo.
This demonstration of effector cells in tolerant animals suggests that tolerance 
in these models is maintained by immune regulation within the allograft.
1.11.4.3 Suppression
Histological examination of tolerant allografts in CTLAJg treated animals has 
shown that despite preservation of graft function and architecture a cellular infiltrate, 
predominantly of mononuclear cells, still occurs (314). Sayegh and co-workers have 
sought evidence for immune-deviation in the pattern of cytokine secretion by these 
cells. Immunohistology of grafts from treated mice shows diminished staining for 
yEFN with increased staining for IL4 compared to rejecting controls. The difficulty in 
extrapolating results from in vitro systems is demonstrated by the fact that, in 
contrast to the above result, T cell hybridomas only produce LL4 after costimulation 
via CD28 (122). Analysis of immunoglobulin isotypes provides further evidence for 
differential subset activation in CTLA^g treated animals, as cardiac allografts show 
increased staining for the Th2-associated IgGl isotype (317). Support for the TI12 
dominance in CTLAJg treated animals comes from experiments in the EAE model, 
where a similar phenomenon has been demonstrated by immunohistology in the 
nervous system of treated rats (330). Diminished elaboration of Thi cytokines in the 
allograft could reflect either failed expansion of the Thi subset or diminished 
secretion of Thi cytokines by reactive T cells. To answer this question a more 
precise definition of the mechanisms underlying CTLA^g induced tolerance in a 
monoclonal system has been devised using pigeon cytochrome c as a nominal 
antigen and the fate of Ag reactive Vp3 and V al 1 T cells followed with specific
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mAb. Using this technique Judge et al have shown that both mechanisms may be 
involved, as expansion of reactive cells is reduced by approximately 50% (excluding 
deletion as a mechanism) with diminished cytokine secretion by the remaining cells 
(331). Despite the evidence of Th2 dominance in some transplant models treated with 
CTLA^g, adoptive transfer of cells from tolerant animals fails to influence allograft 
survival in naive recipients (312), arguing against a potent suppressive effect.
Contrary to the predictions of Bretscher and Cohn’s ‘two signal’ model 
therefore there is no clear evidence for anergy in models of transplant tolerance 
induced by CTLAftg and immune regulation appears to be a more likely mechanism. 
In a similar manner to other regimes evidence for different mechanisms can be 
discerned, which may depend on the model under study.
1.12 High and low responder rat strains in transplant 
models
The distinction between high and low responder rat strains was originally made 
in experiments of allograft survival induced by donor specific transfusion and 
passive enhancement by transfer of immune serum. It was noted that both techniques 
were able to induce permanent allograft survival in DA strain rats but not in Lewis 
rats (332). Experiments using numerous other regimes have confirmed that rat strains 
differ in their ease of tolerance induction. Rats of R Tla haplotype (DA and ACI) are 
consistently the easiest in which to induce tolerance and have been used in mAb 
models of transplant tolerance including anti-CD4 (234) and anti-CD2 (299) mAb. 
High responder rat strains include Lewis (RT11) and PVG-RT1U These strains have 
historically been very resistant to tolerance induction, and have usually required 
multiple treatment modalities. Tolerance to DA kidney allografts has been obtained
in these animals by using a combination of Cyclosporine A with either anti-CD4 or 
anti-TCR mAb (245) whereas the more immunogenic lung allograft is not tolerised 
in Lewis rats by a combination of Cyclosporine A and CTLAdg (333). Attempts by 
conventional mechanisms (DST or anti-CD4 mAb therapy) to induce tolerance to 
cardiac and skin allografts in Lewis rats were unsuccessful. Success was achieved by 
either combining potent immunosuppressive regimes or with myeloablation. Frede et 
al achieved allograft tolerance in the cardiac model in Lewis rats by combining 
donor-specific transfusion with Cyclosporine A and Rapamycin (334) whilst Zeng et 
al used a toxic regime of total lymphoid irradiation, anti-thymocyte globulin and 
donor blood transfusion (335). Simpler regimes to induce tolerance have been 
devised which involve combining CTLAJg with other modalities. Firstly Lin et al 
noted in the Brown Norway to Lewis combination that donor blood transfusion 
combined with CTLAdg two days post operatively is successful in the majority of 
recipients (318), whilst Fathman’s group successfully obtained allograft tolerance in 
Lewis rats to both hearts (321) and small bowel (324) by combining CTLAftg with 
anti-CD4 mAb. Most of these regimes are inconsistent in their effect, inducing 
tolerance in only a minority of recipients. A similar effect can be achieved in Lewis 
rats by a prolonged ( 6  week) regime of post-operative anti-CD4 mAb, which again 
produces tolerance in a minority of recipients (336). In the high-responder strain 
combination of DA (RTla) to Lou (RT1°) skin graft tolerance has been achieved in a 
minority of recipients by combining a prolonged post-operative regime of two anti- 
CD4 mAb (0X35 and 0X38) with Cyclosporine A, (although other reports suggest 
that class I Ac is the low responder phenotype to Aa-see below).
Three areas of research have been performed to distinguish the immunological 
responses of high and low responder strain rats to account for the difference in 
allograft survival.
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1) llano et al noted that 0X35 (anti-CD4 mAb) is able to induce cardiac 
allograft tolerance in DA rats when used per-operatively whereas high dose, 
prolonged therapy is required in high responder Wistar Furth (RT1U) rats (337). No 
differences were detectable in alloreactivity of tolerant animals; in particular 
unseparated cells from both strains reacted normally in MLR and reconstituted 
rejection in irradiated hosts. However when cells from naive animals were divided 
into CD4 and CD8  subsets a differential activity of the CD8  subset was noted. CD8  
cells from DA strain rats were unable to respond independently in the MLR to 
foreign cells and were unable to reconstitute rejection in irradiated hosts, whereas 
CD8  cells from Wistar Furth rats were able to perform both functions without CD4 T 
cell help, suggesting that CD8  T cells from high responder strain rats are able to 
generate their own helper activity.
2) A number of groups have worked with PVG congenic animals in which 
response to the class I Aa is genetically controlled, PVG-RT10 being a low responder 
phenotype and PVG-RT1U the high responder phenotype. Using R1 (AaBcCcD°) and 
R8  (AaBuCuDu) recombinants, Butcher et al analysed their respective responses to 
class I (Aa) disparate grafts (low responders fail to reject these grafts). This group 
demonstrated that the low responder phenotype fails to generate alloantibody and 
CTL to the Aa antigen (338). Using the same strain combinations Stepkowski et al 
found by limiting dilution analysis that the deficit in the low responder animals is at 
the level of helper-T cell precursors, the frequency of cytotoxic-T cell precursors 
being equal in the two strains (339).
3) Another group have analysed the response of high and low responder strain 
rats to mAb therapy. Yin et al noted that the anti-CD4 mAb 0X38 induces cardiac 
allograft tolerance in the Lewis to DA combination but not the reverse (336). On 
analysing the kinetics of lymphocyte depletion induced by 0X38 in the two strains it
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was noted that allograft tolerance correlated with more profound and prolonged CD4 
T cell depletion in DA strain rats. In DA strain rats a preoperative dose of 4x5mg/kg 
0X38 induced over 90% depletion of CD4 T cells with return to 50% of pre- 
treatment levels 14 weeks post operatively, in contrast in Lewis rats the same dose of 
0X38 induced only 80% depletion with return to 50% of pre-treatment levels after 
one week. The difference in allograft survival therefore may reflect more prolonged 
mAb-induced immunosuppression in the low responder strain.
The work of Butcher et al with congenic PVG rat strains suggests that the 
potent response of high responder rats is genetically controlled at the level of both 
the responder and stimulus. However the work of Yin et al and other observations 
made in this thesis suggests that the high responder status of Lewis rats is a more 
generalised phenomenon which also applies to non-MHC antigens.
1.13 Aims of this project
Extensive knowledge of the effect of anti-CD4 mAb therapy in rodent models 
of solid organ transplantation has been obtained by many different laboratories and it 
has largely been by using the CD4 antigen as a target molecule that attempts have 
been made to obtain transplant tolerance with mAb. These experiments have met 
with success in rodent models which has not been reproduced in higher animals. 
Partly for this reason research efforts have recently turned away from mAb to smaller 
molecules as induction therapy in experimental and clinical transplantation. 
Numerous other surface antigens are involved in T cell activation beside CD4, and 
the effect of targeting these ligands with mAb has not been explored to the same 
degree. The CD2 molecule has a complex relationship with the T cell receptor and 
multiple functions in T cell homeostasis and provides a promising target for 
immunotherapy. The effect of targeting CD2 with mAb has been explored in murine
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models largely by the group of JS Bromberg in Charlestown, Carolina, USA. This 
group have reported that anti-CD2 mAb therapy in the mouse has an 
immunosuppressive effect dependent on CD2 modulation without causing significant 
cellular depletion (292, 304). This effect is not however potent enough to allow 
permanent allograft survival in mice without the addition of anti-CD3 mAb, with 
which anti-CD2 mAb has a special relationship in murine systems. Consequently 
these experiments do not allow an analysis of the effect of targeting the CD2 
molecule alone, so that results are difficult to interpret at the cellular and molecular 
level. The rat therefore would seem to be a more promising model with which to 
explore therapy targetting this molecule, as the group of Hirahara in Tokyo has 
shown its ability to induce permanent allograft survival in low responder strain rats 
(299).
This project aimed therefore to use two different anti-CD2 mAb, 0X34 and 
0X55, in rat cardiac allograft experiments. Firstly cardiac allografts were performed 
in low responder DA rats using induction therapy with various doses of 0X34 and 
0X55. These experiments investigated the requirements for ligand saturation, 
modulation and cellular depletion to induce permanent allograft survival in these 
animals. This optimal dose of 0X34 was then combined with other therapies in the 
high responder Lewis strain, and again the effect on CD2 expression and cell 
populations was investigated. In these experiments the response of the treated rats to 
the injected mAb was also assessed in terms of the generation of an anti-globulin 
response and the clearance of antibody.
Having established the potency of anti-CD2 mAb in allograft models a series 
of experiments were performed to reproduce these effects in vitro, to explore the 
mechanism of action of the mAb. These included examining the ability of anti-CD2 
mAb to act as a mitogen, and its effect on the allogeneic MLR and mitogen-induced
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cytokine release. Throughout these experiments the effect of anti-CD2 mAb was 
compared directly with that of anti-CD4 mAb and CTLA4g in similar assays.
Lastly having established models of allograft tolerance in both DA and Lewis 
strain rats the immunological mechanisms maintaining tolerance were investigated. 
Investigations included an assessment of the donor-specific effector mechanisms in 
tolerant animals, histology of the tolerised grafts and measurement of the response of 
cells from tolerant animals to donor antigen.
The data regarding the use of anti-CD2 mAb in rat models is compared to 
previous work in the mouse and rat, to obtain a consensus view on the potential of 
CD2 as a target molecule in the transplant setting.
2 Materials and Methods
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2.1 Media used with lymphocyte preparations
2.1.1 Wash medium:
Hanks Buffered Salt Solution (HBSS) (GibcoBRL Life Technologies, Paisley, 
UK) supplemented with 2% heat-inactivated (HI) Foetal Calf Serum (FCS) (Sigma 
Biosciences, Poole, Dorset, UK), 100 U/ml Penicillin, lOOpg/ml Streptomycin and 
lOmM Hepes solution (all Gibco BRL), was used in all preparative procedures for 
cells, unless otherwise stated.
2.1.2 Culture medium:
RPMI 1640 (Gibco BRL) supplemented with 2mM L-glutamine (Gibco BRL), 
100 U/ml Penicillin, lOOpg/ml Streptomycin, and 5xl0*5 2-Mercaptoethanol (FCS) 
(Fischer Scientific, Loughborough, UK) was used as a culture medium for cells, 
supplemented with HI normal syngeneic rat serum or FCS as stated.
2.2 Maintenance of hvbridomas
Hybridoma cells producing 0X34 (IgG2a mouse monoclonal directed at the 
ligand-binding epitope of domain 1 of the CD2 molecule (133,150,152,340)), 
0X55 (IgGl mouse monoclonal which binds non-competitively with 0X34 to an 
epitope on domain 1 of CD2 not involved in the CD2-CD48 interaction (133)), 
0X38 (IgG2a mouse monoclonal directed at the CD4 molecule (340)), and R73 
(IgGl mouse monoclonal directed at a constant determinant of the a/(3 TCR (341))
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were obtained from the European Collection of Animal Cell Cultures (Salisbury, 
UK). Cells were cultured in complete RPMI + 10% FCS in 5% CO2 at 37°C.
The 112-dependent CTLL cell-line and the Natural-Killer cell-sensitive 
lymphoid Y3 cell line were also obtained from European Collection of Animal Cell 
Cultures (Salisbury, UK) and cultured as above.
2.2.1 Monoclonal antibodies used in in vitro and in vivo experiments
Agent Isotype Target Molecule
0X34 Murine IgG2a CD2
0X55 Murine IgGl CD2
0X38 Murine IgG2a CD4
R73 Murine IgGl aBTCR
CTlAdg Human IgGl B7
ESH8 Murine IgG2a Human factor VIII
0X1 Murine IgGl CD45
Table 2.1 Reagents used in transplant experiments
2.2.2 Preparation of monoclonal antibodies.
Hybridoma cells were washed in serum-free medium and resuspended at 
2xl06/ml before injecting 0.5 ml into pristane primed BALB/c mice to produce 
ascites. Ascites was purified with a protein A column and quantified by radial 
immuno-diffusion assay using Nanorid RID plates (The Binding Site, Birmingham, 
UK) according to the manufacturers instructions. Purified mAb was then diluted in 
PBS to a working concentration of 5 or lOmg/ml. The control mouse IgG2a antibody 
ESH8  (anti-human factor VIII) was obtained from the Scottish Antibody Production 
Unit, Lanarkshire, Scotland. The construct CTLA4lg was a gift of Dr. Linsley, BMS 
Seattle (116).
2.2.3 Characterisation of monoclonal antibody
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After production by the techniques described in materials and methods, the titre of 
monoclonal antibodies was characterised by flow cytometry using serial tenfold 
dilutions of mAb wash medium incubated with lymph node cells (LNCs) as targets. 
The construct CTLAdg, which does not bind resting LNCs, was characterised using 
ConA blasts (which express the activation antigen B7) as a target cell.
2.3 Experimental animals
Adult Lewis (LEW, RT11), DA (RTla) and PVG (RT1°) were obtained from 
Olac (Bicester, Oxon, UK). Donor and recipient pairs were mismatched at both 
major and minor histocompatibility loci.
2.3.1 Heterotopic heart transplantation.
Procedures were performed under halothane anaesthesia. The donor rat was 
heparinised (200u) before exsanguination by division of the abdominal vessels. The 
donor heart was exposed and the pulmonary artery and aorta were divided and all 
other vessels ligated. The donor heart was drained of blood and stored at 4°C before 
transplanting to the abdominal vessels of the recipient rat in the manner described by 
Ono and Lindsey (342). Survival of cardiac allografts was assessed by alternate day 
palpation and rejection defined as cessation of beating.
For confirmation of transplant tolerance identical second grafts or third party 
cardiac allografts were harvested in the same manner and anastomosed to the carotid 
artery and internal jugular vein.
2.4 Preparation of cell suspensions
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Lymph node cells were prepared by harvesting lymph nodes from the rat 
cervical and mesenteric lymphatic plexuses into wash medium using sterile 
techniques. Lymph nodes were compressed through a wire mesh sieve to disrupt the 
node and release free cells. Cell suspensions were then decanted and washed three 
times in wash medium to remove debris before resuspending at the working 
concentration.
Splenocytes were prepared by harvesting a rat spleen using sterile techniques 
into wash medium. The spleen was then disrupted in wash medium with sterile 
plastic forceps to release free cells. Red blood cells within the cell suspension were 
lysed by adding 5mls of sterile water to the resuspended cell pellet followed 
immediately by 5mls of 2N saline. Cells were washed three times in wash medium 
and debris discarded.
Peripheral blood lymphocytes were prepared either by harvesting blood from 
an anaesthetised rat by direct cardiac puncture into a syringe containing 0.5mls 
1 : 1 0 0 0  heparin or by the expression of small quantities of blood from the rat tail after 
transection of tail tip of an anaesthetised rat. Whole blood was then diluted 1:1 with 
PBS before layering onto 5mls 75% Percoll with 25% balanced salt solution 
containing 1% Hepes. Tubes were centrifuged at 2000 revs/min for 20 minutes. 
Lymphocytes were harvested by aspiration from the plasma: Percoll interface. Red 
blood cells were then lysed by hypotonic shock and cells washed and resuspended as 
described above.
Peritoneal macrophages were prepared by injecting 20 mis of culture medium 
into the peritoneal cavity of a freshly killed rat. The abdomen was then opened and 
medium aspirated. Cells were isolated by centrifugation at 4°C and identified by flow 
cytometric methods with the macrophage-specific antibody EDI.
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2.4.1 Preparation of purified CD4 T cells
LNCs were prepared from two naive rats, washed and suspended in 1ml wash 
medium as described above. This cell suspension was then incubated for 30 minutes 
on ice with pure 0X8 and 0X12 antibody (50pl of lOmg/ml) to saturate CD8  and B 
cells. Cells were then washed three times, counted and resuspended at 108/ml. Goat 
anti-mouse IgG-coated magnetic beads (Biomag, Advanced Magnetics Inc., UK) 
were then prepared (lm i per 103 cells) by washing three times in HBSS. Biomag 
beads were then added to the cell suspension and incubated for 2 0  minutes on ice 
with periodic shaking. Bound cells were then separated by magnetic traction, 
retained and resuspended in 2 mis wash medium (to dislodge trapped cells). After 
repeated separation of cells supernatants containing CD4 cells were pooled together 
and re-incubated with Magnabeads and the process repeated. Purified CD4 cells were 
then washed, counted and analysed by flow cytometry to assay degree of purity.
2.4.2 Preparation of Concanavalin A transformed lymphoblasts 
(Con A blasts)
Splenocytes were prepared as above and resuspended in culture medium at 2.5 
x 106/ml. 10 mis of cells were then placed into 50ml culture flasks with 50pl ConA 
at 1 mg/ml. Cells were then incubated in 5% C02 at 37°C for 72 hours before using 
as target cells.
2.5 Assay of antibody-induced cellular activation
Lymph node cells were prepared and harvested as above. Monoclonal 
antibodies (either R73 or 0X34) were used to induce lymphocyte activation either 
fixed to a plate surface or in solution. Ninety-six flat-bottomed well plates (Life
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Technologies) were coated with 50jul/well polyclonal rabbit anti-mouse serum at 
10jng/ml and incubated at 37°C for 2 hours in a sterile environment. Plates were then 
washed three times with PBS before adding 30pl/well R73/OX34 at 5pg/ml in PBS. 
Parallel plates were set up containing the same antibodies in solution at 20jag/ml. 
Wells containing PBS only were used as controls. Plates were then incubated for a 
further two hours before further washing. Unbound binding sites were then saturated 
by overnight ‘blocking’ with 1% mouse serum at lOOpl/well at 4°C. Plates were 
again washed before adding 2xl05 purified CD4 T cells in 200pl culture medium per 
well. Plates were incubated at 37°C for 24 hours before adding tritiated thymidine 
(1 pCi/well) in serum-free medium and further culture for eighteen hours. Cells were 
harvested and thymidine incorporation measured by quantitation of p emission.
For determination of the influence of second antibodies on proliferation by 
anti-TCR mAb LNCs were incubated with a concentration range of antibody in 
culture medium for 2 0  minutes on ice and washed to remove excess antibody prior to 
adding to wells.
2.6 The mixed lymphocyte reaction (MLR)
Spleen cells were used as stimulators in one-way MLRs. Prior to adding to U- 
bottomed 96-well plates (Life Technologies) splenocytes were resuspended at 
2xl06/ml in culture medium and subjected to irradiation (2000 rads). Responder cells 
were allogeneic lymph node cell suspensions at 4x106 per ml in culture medium. 
Control wells were cultured without stimulator cells (negative control) or with 
responders only containing ConA (5pg/ml) (positive control). lOOpl of each cell 
suspension were co-cultured in 5% CO2 at 37°C for three, four or five days before 
pulsing for 18 hours with tritiated thymidine (1 jnCi/well). Early experiments revealed
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that cellular proliferation in these reactions increased over the period three to five 
days. However the thymidine incorpoartion after three days was sufficient to allow 
discrimination between experimental conditions so this time point was used in the 
majority of experiments to save on incubation time. Cellular incorporation of 
thymidine was measured by quantitation of p emission. Identical cultures were set up 
and cell culture supernatants retained for evaluation of cytokine concentration.
For evaluation of the effect of monoclonal antibody on proliferation induced by 
the MLR reagents were added at stated concentrations to responding lymphocytes for 
30 minutes on ice and washed to remove excess antibody prior to adding to wells 
containing stimulator cell populations.
2.7 IL2 assay.
DL2 concentration in culture supernatants was assayed using the IL2 dependent 
murine cell line CTLL. 5x10 CTLL cells were plated in lOOpl culture medium with 
lOOpl serial dilutions of MLR culture supernatant or IL2 standards. Plates were 
cultured for 24 hours before pulsing with tritiated thymidine (lpCi/well) and 
incorporation measured as above. Values for IL2, expressed as units/ml, were 
derived from a standard curve of human recombinant EL2 (Glaxo Laboratories, 
Geneva, Switzerland). Specificity of the assay was confirmed by the ability of anti- 
1L2 and the inability of anti-IL4mAbs to block CTLL proliferation.
2.8 vIFN assay
ylFN concentration in culture supernatants was assayed using an ELISA 
system. Ninety-six well flat bottom plates (Immulon 4, Dynatech, Billingshurst, UK.) 
were coated with lOOpl of a 1:1000 dilution of rabbit anti-mouse ylFN serum in
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0.1M NaHCCb (cross reactive with rat ylFN, a gift of Dr John Tite, Wellcome 
Research Laboratories, Beckenham, UK) overnight at 4°C. All subsequent 
incubations were at 37°C in 5% CO2 alternating with extensive washing using 
PBS/0.05% Tween 20. Plates were ‘blocked’ with 200jal/well 10% FCS prior to the 
addition of MLR culture supernatants or recombinant rat ylFN standards (Life 
Technologies) followed by lOOpl/well biotin conjugated mouse monoclonal anti-rat 
ylFN, DB1, (a gift of Dr P van der Meide, BPRC, Rijswijk, The Netherlands) for one 
hour. 1:100 dilution extravidin peroxidase (Sigma Chemical Co Ltd, Poole UK) was 
then added at lOOpl/well followed by lOOpl/well TMB peroxidase substrate 
(Dynatech Laboratories) for 30 minutes at room temperature. The reaction was 
stopped by the addition of 0.2M H2SO4 and optical density read at 450nm with a 
Dynatech MR 5000-plate reader. Values for ylFN were derived by comparison with a 
standard curve constructed from serial dilutions of ylFN standards.
2.9 Preparation of target cells for cytotoxicity assays.
Strain specific ConA blasts were prepared as above. Blasts were washed to 
remove FCS and then resuspended at 2.5 xl07/ml in serum-free culture medium. 
Blasts were then incubated with 5 MBq 51Cr for 1 hour with periodic shaking in a 
water-bath at 37°C. Target cells were then washed five times in wash medium to 
remove free isotope before suspending at 1 0 6/ml in culture medium.
2.10 In vitro generation of cytotoxic T lymphocytes (CTLs)
Specific CTL were generated in a ‘bulk’ MLR. In order to ascertain the 
optimum responder: stimulator ratio for CTL generation LNCs were suspended at 2,
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4 and 8xl06/ml and were incubated in equal volumes with irradiated DA splenocytes 
at 106/ml in 20mls complete RPM1 medium in 5% CO2 at 37°C for 5 days.
2,11 CTL-mediated cytotoxicity assay
To assess the activity of generated CTLs serial dilutions of effector cells from 
the bulk MLR culture (starting ratio 200:1) were then incubated with 104 target cells 
(51Cr-labelled strain-specific ConA blasts) in 200pl complete medium in 96 well V- 
bottomed plates (Bibby Sterilin, Stone, Staffordshire) for 6  hours before harvesting 
lOOpl supernatant, y emission from released 51Cr was measured using a 1282 
Compugamma (LKB Wallac). Maximum release from lysed cells was measured 
following the addition of lOOpl Triton X and spontaneous release measured in wells 
containing labelled targets only. Percentage cytotoxicity is expressed as lOOx 
(experimental-spontaneous cpm/maximum-spontaneous cpm). These experiments 
revealed that maximal CTL generation occurred with a responder: stimulator ratio of 
2:1 in the bulk MLR, which was used in all subsequent experiments (figure 2.1).
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Figure 2.1 In vitro generation of allo-CTL.
Specific cytotoxicity of Lewis allo-CTL generated in bulk MLR 
with DA strain stimulators at effector: stimulator ratios of 8 ,4  
and 2
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2.11.1 NK cell-mediated cytotoxicity assay
A ‘bulk MLR’ was used as a source of effector cells as above. The assay was 
performed as described for CTL above, but using 51Cr-labelled NK-sensitive Y3 
targets cells.
2.12 Flow cytometric analysis of lymphocyte antigen
expression after in vivo monoclonal antibody therapy
The monoclonal antibody under study was injected at the required dose into the 
dorsal vein of the penis at stated time points. Lymphocyte populations were then 
harvested as above at different time points after administration. Cells were washed 
and suspended at 107/ml in PBS/0.2% FCS. For assessment of ligand expression by 
two-colour analysis IOOjliI cells were incubated for 30 minutes on ice with either 
10pl mAb directly conjugated to fluorochrome, or with a lOpl purified primary 
antibody followed by 2 0 jal polyclonal rabbit anti-mouse antibody bound to 
fluorochrome. Cells were washed repeatedly between incubations in PBS and prior 
to FACS analysis (Coulter EPICS). Initial control experiments were performed to 
assess non-specific binding of the isotype-matched control antibody (IgG2a) ESH 8  
to murine lymphocytes and maximal binding by the pan-specific murine anti-CD45 
antibody 0X1 (Figure 2.2).
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Figure 2.2 Positive and negative controls in flow cytometry 
experiments.
Flow cytometry experiments were performed according to the 
method in the text using a) the irrelevant murine antibody ESH 8  
and b) the lymphocyte pan-specific antibody 0 X 1 followed by 
rabbit anti-mouse FITC.
2.13 Flow cytometric analysis of elimination of circulating 
antibody after intravenous administration
The presence of circulating antibody in treated rats was determined by a non- 
quantitative flow cytometric method. Monoclonal antibody treated rats were 
tail-bled into heparin-containing eppendorf tubes at set time points after 
administration of antibody. Samples were centrifuged at low speed and serum 
extracted and diluted 1:1 with PBS. lOOpl dilute serum was then incubated on 
ice with lOOpl strain-specific LNCs at 10 /ml for 30 minutes. After three 
washes antibody binding to lymphocytes was detected by further incubation 
with FITC-conjugated rabbit anti-mouse antibody and FACS analysis. Figure 
2.3 shows control experiments where naive rat serum or 20 pi 1:1000 0X34 
were used in the first incubation.
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Figure 2.3 Positive and negative controls in flow cytometric 
detection of circulating mAb in rat serum.
Lewis LNCs were incubated with a) naive Lewis serum or b)
20jnl 1:1000 0X34 before secondary labelling with FITC- 
conjugated rabbit anti-mouse antibody.
2.14 Flow cytometric detections of circulating antiglobulin 
response after intravenous administration of 
monoclonal antibody
The anti-globulin response of mAb treated rats was detected by a non- 
quantitative flow cytometric method. Serum from mAb-treated rats was prepared as 
above. Fresh LNCs (lOOpl containing 106 cells in PBS) were incubated with 10pl 
0X34 or 0X38 at 5mg/ml on ice for 30 minutes followed by washing. These anti­
body labelled cells were then used as targets and incubated with lOOpl dilute (1:1) 
serum from rats treated as above. Cells were washed and the presence of anti-mouse 
Ig was determined by tertiary labelling with 20pl FITC-labelled mouse anti-rat IgM 
and IgG antibody. Figure 2.4 shows control experiments demonstrating a) labelling 
of target cells with appropriate 0X34 or 0X38 target antibody, b) control
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experiments where OX34-labelled Lewis LNCs are incubated with naive rat serum 
before tertiary labelling with FITC-conjugated mouse anti-rat IgG and IgM, c) 
control experiments where OX38-labelled Lewis LNCs are incubated with naive rat 
serum before tertiary labelling with FITC-conjugated mouse anti-rat IgG and IgM. 
These experiments show that approximately 20% of OX34-labelled LNCs are 
labelled with mouse anti-rat IgM after incubation with naive rat serum, this probably 
represents labelling of IgM-expressing B cells.
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Figure 2.4 Flow cytometric detection of circulating 
antiglobulin response.
Control experiments showing a) labelling of target cells with 
0X34 and 0X38, b) background labelling of OX34-labelled 
targets with anti-IgG and anti-IgM, c) background labelling of 
0X3 8 -label led targets with anti-IgG and anti-IgM
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2.15 Determination of total circulating leukocyte number
This method was used to obtain the absolute numbers of circulating 
lymphocytes after administration of antibody, whereas flow cytometry was used to 
assess relative proportions of lymphocyte subsets. Rats were tail-bled into heparin- 
containing eppendorf tubes; blood was then diluted 1:20 with Turck’s solution (2% 
acetic acid in water plus 5-6 grains of gentian violet per 100 mis). The sample was 
then shaken gently for one minute to lyse red cells. Leukocytes stain deep violet 
black and can be counted on a haemocytometer slide.
2.16 Antibody-mediated, complement-dependent 
cytotoxicity assay
The ability of 0X34 and 0X38 to lyse lymphocytes by complement-mediated 
mechanisms was assessed by an in vitro 5 Chromium release assay. DA strain 
splenocyte ConA blasts were prepared and incubated w ith 5 Chromium and used as 
target cells as described above. 50pl of target cells at 106/ml were then incubated 
with 50pl of serial tripling dilutions of serum or antibody (initial concentration 
20(ng/ml) in 96 V well plates at room temperature for 30 minutes. After washing, 
lOOpl of fresh DA serum was added as a source of complement. Cells were 
incubated for 2 hours at 37°C before harvesting lOOpl of supernatant for y counting 
and estimation of cytotoxicity using the formula:
% specific 51Cr release = experimental-spontaneous xlOO
maximum-spontaneous
Heat inactivated (56°C for 30 minutes) normal Lewis rat serum was used to
determine spontaneous release; maximum release was determined by detergent lysis
of target cells.
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2.17 Monoclonal antibody-mediated antibody-dependent 
cellular cytotoxicity
This process depends upon recognition of antibody coating rat lymphocytes by 
Fc receptors on phagocytic cells. FACS analysis revealed that the NK-sensitive rat 
lymphoma cell line Y3 is labelled by both 0X34 and 0X38. To assess the ability of 
phagocytic cells to recognise mouse mAb a standard cytotoxicity assay was 
performed using antibody-labelled Y3 cells as targets. Y3 cells were labelled with 
51Cr as described above and resuspended in a minimal volume of culture medium. 
500jul of cells were then incubated on ice for 30 minutes with 20jul 0X34 or 0X55 
(5mg/ml). In the absence of a suitable assay for macrophage function the ability of 
NK cells (which express an identical FcyRl 11) to participate in ADCC was assessed. 
Effector cells were obtained from Lewis LNCs after 5 days of culture in a ‘bulk’ 
MLR with DA splenocytes as described above. Effector cells were suspended 
initially at 2xl06/ml and antibody-coated Y3 cells at 104/ml. Serial dilutions of lOOpl 
effector cells (starting 200:1) were then incubated with lOOpl target cells in V- 
bottomed plates and 51Cr release measured as described.
2.18 Statistical analysis
2.18.1 Parametric data
Results of thymidine incorporation assays, chromium release assays and 
ELISA plates were analysed by Students t test using integral software with Microsoft 
Excel (Microsoft Corp).
2.18.2 Non-parametric data
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Survival data from transplant experiments is displayed graphically using 
Kaplan-Meyer survival curves. Comparison between curves was performed by the 
logrank test. Calculations were performed manually with the aid of a pocket 
calculator according to the formula laid out in Introduction to Medical Statistics, 
(Bland, M).
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3 Effect of monoclonal antibody therapy on survival
of cardiac allografts in high and low responder 
strain rats.
3.1 Study objective:
1) To establish the effect of pre- and post- operative therapy with the anti- 
CD2 mAb 0X34 and 0X55 on cardiac allograft survival in the Lewis 
to DA transplant model.
2) To establish the minimal dose of 0X34 required to induce permanent 
allograft survival in DA strain rats and to compare this with therapy 
with anti-CD4, anti-TCR and CTLAdg.
3) To assess the effect of therapy with anti-CD4, anti-CD2, and CTLA4lg 
on cardiac allograft survival in high responder Lewis rats.
4) To assess the effect of combination therapy with anti-CD2 plus either 
anti-TCR, anti-CD4 or CTLA4g on cardiac allograft survival in the 
high responder rat strains Lewis and PVG.
5) To establish the optimum dose of combination therapy with anti-CD2 
plus either anti-CD4 or CTLATg that prolongs cardiac allograft 
survival in Lewis strain rats.
3.2 Study design:
Cardiac allografts were performed between reciprocal pairs of DA and Lewis 
strain rats and from DA to PVG rats. Monoclonal antibodies were administered to
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rats either pre- or post- transplantation at the stated doses. Survival of cardiac 
allografts induced by each regime was recorded and compared graphically. Figures 
on graphs represent doses of mAb and figures in brackets represent dosing schedule 
relative to time of transplantation.
3.3 Survival of cardiac allografts in untreated animals
In order to establish the kinetics of unmodified cardiac allograft rejection grafts 
were performed in naive animals. Unmodified high and low responder rat strains 
were shown to reject cardiac allografts in a similar time span (6 - 8  days). Control 
experiments were performed only at the beginning of the project and control curves 
appearing in subsequent survival graphs refer to this experiment.
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Figure 3.1 Survival of cardiac allografts in untreated control 
rats
Graph shows post-operative survival of reciprocal cardiac 
allografts in unmodified DA and Lewis rats.
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3.4 Experiments to assess the ability of monoclonal antibody 
therapy to prolong allograft survival in low responder 
rats.
3.4.1 Effect of 0X 34 and 0X 55 therapy on survival of Lewis 
allografts in DA strain rats
Firstly mAb to CD2 was used in transplant experiments in the Lewis to DA 
model. Antibody was administered intravenously prior to transplantation. Increasing 
doses of 0X34 were used to find an optimum dose that consistently induces 
prolonged allograft survival. 0X34 administered at 5mg/kg intravenously on two 
occasions preoperatively induced permanent allograft survival in 80% of recipients 
(figure 3.2). Increasing the dose of 0X34 did not increase the survival rate as a small 
percentage of rats always rejected their allografts (figure 3.3). In a similar manner 
0X55 was administered preoperatively and was noted to be less effective on a dose- 
for-dose basis (figure 3.3).
We then asked if 0X34 therapy is as effective when administered post- 
operatively, after the induction of an immune response. A similar dose to one that 
induced long-term allograft survival when administered pre-operatively was much 
less successful when administered two days later (figure 3.4).
% 
gr
af
t 
su
rv
iv
al
 
% 
gr
af
t 
su
rv
iv
al
3.92
100
80
i :
60
40
20
— ■—  Unmodified Lew-DA (n=5)
 0X34 2.5mg/kg (day 0) n=7
  0X34 5mg/kg (day 0) n=7
 0X34 5,5mg/kg (days -1,0) n=12
20 40 60 80
days
100
Figure 3.2 Effect on graft survival in DA rats of pre­
operative 0X34 therapy
Survival o f  Lewis cardiac allografts in DA strain rats treated 
pre-operatively with increasing doses o f  0 X 3 4  (0 X 3 4  
2x5m g/kg v unm odified p<0.01, logrank test).
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0X34 10,5,5mg/kg (-2,-1,0) 
n=7
0X34 10,5mg/kg (-1,0) n=5 
0X34 5,5mg/kg (-1,0) n=12 
0X55 10,10mg/kg (-1,0) n=6
20 40 60
days
80 100
Figure 3.3 Effect on graft survival in DA rats of pre­
operative 0X55 or high dose 0X34 therapy
Survival o f  Lewis cardiac allografts in DA strain rats treated 
pre-operatively w ith high dose 0 X 3 4  (l0 -20m g/kg) or 0X 5 5  
(20m g/kg) therapy (0 X 3 4  [all doses] v 0X 5 5  p<0.05, logrank 
test). Figures in brackets refer to treatm ent day relative to day o f  
transplant.
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Figure 3.4 Effect on graft survival in DA rats of post­
operative 0X34 therapy
Survival o f  cardiac allografts in DA rats treated with 0 X 3 4  
(lO m g/kg) pre- or post-operatively (pre- v post-operative 
therapy, p<0.05 logrank test). Figures in brackets refer to 
treatm ent day relative to day o f  transplant.
3.4.2 Anti-CD2, anti-CD4, anti-TCR and CTLAJg therapy all 
induce long-term allograft survival in DA rats
The effect o f  CTLAftg, anti-TC R  and anti-CD4 mAb therapy on allograft 
survival in DA strain rats was then assessed in com parison to anti-CD2 mAb therapy. 
0 X 3 8  was adm inistered at a dose o f  10,2,2,2 m g/kg (the optim um  dose in this strain 
com bination (343)) on consecutive days prior to transplant and 0.5 m g/rat CTLA ftg 
was adm inistered day 2 post-operatively. All m odalities induced sim ilar prolongation 
o f  allograft survival (figure 3.5).
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Figure 3.5 0X34, 0X38 and CTLA4lg induce permanent 
graft survival in DA rats
Survival o f  Lewis cardiac allografts in DA strain rats treated 
w ith 0 X 3 4 , 0 X 3 8  or CTLA4Ig m onotherapy. Figures in 
brackets refer to treatm ent day relative to day o f  transplant.
3.5 E xperim ents to assess the ability  o f  targeting accessory  
m olecules to prolong a llograft survival in high  
responder rats.
In a sim ilar m anner to above the reagents under study were adm inistered to 
high responder Lewis rats grafted with DA strain hearts to assess their influence in 
this m ore rigorous m odel o f  allograft rejection. 0 X 3 4  and 0 X 3 8  were adm inistered 
over consecutive days pre-operatively w hilst C T L A Jg  was adm inistered two days 
post-operatively. All reagents tested produced some prolongation o f  graft survival 
although none were able to induce perm anent engraftm ent. 0 X 3 4  2x5m g/kg, 
M ST=20 days; 0 X 3 8  10+3x2mg/kg, M S T -1 8  days and CTLA4Ig 2m g/kg, M ST=19 
days (figure 3.6).
3.95
100
80
60
40
20
0
l v .;_
■DA-Lew (unmodified) n=4 
0X34 5,5mg/kg (-1,0) n=6 
0X38 10,2,2,2mg/kg (-3,-2,-1,0) n=5
 CTLA4lg 2mg/kg (2) n=4
L
10 20 30 40
days
50 60 70
Figure 3.6 0X34, 0X38 and CTLA4Ig fail to induce 
permanent allograft survival in Lewis rats
Survival o f  DA allografts in Lewis rats treated with 0 X 3 4 ,
0 X 3 8  or CTLA4 lg m onotherapy at doses which induce 
perm anent graft survival in DA rats. Figures in brackets refer to 
treatm ent day relative to day o f  transplant.
3.5.1 Combination therapy in the prolongation of allograft survival 
in high responder strain rats.
Each o f  the m odalities tested produced a sim ilar profile o f  survival curve in 
Lewis rats, w ith no grafts achieving perm anent allograft survival. C om binations o f  
m Ab were therefore tested in an attem pt to induce allograft tolerance in high- 
responder rats.
3.5.1.1 Anti-CD2 plus anti-TCR monoclonal antibody therapy in Lewis and 
PVG strain rats
As can be seen from the above experim ents anti-TCR, CD2 and CD4 m Ab and 
CTLA4Ig therapy induced long-term  allograft survival in the m ajority o f  DA strain 
rats but had less im pact in Lewis rats. In view  o f  the published m urine studies 
com bining anti-CD3 with anti-CD2 mAb therapy this com bination was then assessed 
in the DA to Lewis cardiac allograft model. Even high doses o f  both m odalities 
induced an M ST o f  only 19 days; identical to the M ST induced by ‘standard dose’
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(2x5m g/kg) 0 X 3 4  m onotherapy and failed to induce perm anent engraftm ent in any 
recipient (figure 3.7).
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0.5mg/kg (0,1) n=4 
0X34 10,10,5mg/kg (-1,0,6)+R73 
0.5mg/kg (0,1) n=10
re 60 -  0X34 5,5mg/kg (-1,0) n=6>
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Figure 3.7 Combination therapy with 0X34 and R73 in 
Lewis rats
Survival o f  DA allografts in Lewis rats treated with com bination 
therapy with 0 X 3 4  and R73. Figures in brackets refer to 
treatm ent day relative to day o f  transplant. Control anim als 
treated with 0 X 3 4  m onotherapy (experim ent perform ed jo intly  
with J Casey).
W e then asked if  the failure o f  this m Ab com bination to im prove allograft 
survival was an effect peculiar to the DA to Lewis strain pair. W e therefore assessed 
the effect o f  the same m Ab strategy in the DA to PVG (RT-1°) strain com bination. 
Increasing doses o f  each m Ab were adm inistered and R73 was adm inistered both 
pre- and post-operatively. Even by using 0 X 3 4  at tw ice the ‘standard dose’ 
(2x l0m g/kg) and R73 (2x2m g/kg) the M ST was only m arginally prolonged (14 
days) with no allograft surviving beyond 20 days (figure 3.8).
3.5.1.2 Anti-CD2 plus anti-CD4 monoclonal antibody therapy in Lewis strain 
rats
In view  o f  the failure o f  anti-TCR mAb to com bine with anti-CD2 mAb 
therapy to prolong allograft survival in high responder strain rats it was then decided
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to combine anti-CD2 therapy with anti-CD4 therapy. When standard doses of 0X34 
(2x5mg/kg) and 0X38 (10,2,2,2 mg/kg) were administered preoperatively to Lewis 
rats receiving DA allografts median survival is prolonged to 49 days with 50% of 
treated rats going on to permanent allograft survival. Increasing the dose of both 
reagents substantially (0X34 3x5mg/kg plus 0X38 3x10 mg/kg pre-operatively) 
produced a modest increase in allograft survival (MST 100 days) with 8  of 15 rats 
permanently accepting their allografts (figure 3.9).
3.5.1.3 Anti-CD2 monoclonal antibody plus CTLAJg therapy in Lewis strain 
rats
In a similar manner anti-CD2  mAb therapy was then combined with CTLA^g 
therapy in the high responder DA to Lewis combination. Standard doses of each 
modality (0X34 2x5mg/kg pre-operatively plus CTLA4g 2 mg/kg post-operatively) 
extended median allograft survival to 49 days with 5 of 11 rats permanently 
accepting their allografts. Increasing doses of both modalities were then assessed for 
their effect on the proportion of rats permanently accepting their allografts. Firstly a 
second dose of CTLAJg was administered at the time of transplantation in addition 
to the post-operative dose at day 2. This regime did not improve allograft survival, 
inducing a median survival of 46 days with 2 of 8  animals permanently accepting 
their allografts. The dose of 0X34 was then doubled to 2xl0mg/kg given pre­
operatively along with a standard post-operative dose (2mg/kg) of CTLAJg. Using 
this regime median survival was extended to over 100 days with 4 of 6  animals 
permanently accepting their allografts (figure 3.10).
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0.3mg/kg (1,2) n=4
 0X34 10,10mg/kg (-1,0)
R73 2mg/kg (0,1) n=5
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0 5 10 15 20
days
Figure 3.8 Combination therapy with 0X34 and R73 in PVG 
rats
Survival o f  DA allografts in PVG rats treated with com bination 
therapy with 0 X 3 4  and R73. Figures in brackets refer to 
treatm ent day relative to day o f  transplant (experim ent 
perform ed jo in tly  with J Casey).
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Figure 3.9 Combination therapy with 0X34 and 0X38 in 
Lewis rats
Survival o f  DA cardiac allografts in Lewis rats treated with 
com bination 0 X 3 4  and 0 X 3 8  m onoclonal antibody therapy. 
Control rats treated w ith 0 X 3 4  m onotherapy (0 X 3 4  5,5m g/kg v 
0 X 3 4  5,5m g/kg + 0 X 3 8  10,2,2,2m g/kg p<0.05, logrank test). 
Figures in brackets refer to treatm ent day relative to day o f 
transplant.
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Figure 3.10 Combination therapy with 0X34 and CTLAJg 
in Lewis rats
Survival o f  DA cardiac allografts in Lewis rats treated with 
com bination therapy with 0 X 3 4  CTLA4Ig. Control anim als 
treated with 0 X 3 4  m onotherapy (0 X 3 4  5,5 m g/kg v 0 X 3 4  
5,5m g/kg + CTLA4Ig 2m g/kg p<0.05, logrank test). Figures in 
brackets refer to treatm ent day relative to day o f  transplant.
3-6 C onclusions and d iscussion  o f results
3.6.1 Monoclonal antibody therapy in low responder DA rats.
Initial control experim ents revealed that naive Lewis and DA strain rats reject 
reciprocal allografts in a sim ilar tim e span, with no heart graft surviving beyond 8 
days.
Survival studies revealed that 0 X 3 4  is able to induce perm anent allograft 
survival o f  Lewis allografts in DA strain rats at an optim um  dose o f  2x5 m g/kg given 
pre-operatively (10 o f  12 rats perm anently accepted their allografts). This is a low er 
dose than that used by ITirahara (3x7m g/kg) although this regim e was adm inistered 
via the peritoneal route (299). Low er doses o f  0 X 3 4  (2.5m g/kg and 5 m g/kg) 
induced only m inim al prolongation o f  allograft survival suggesting that a threshold 
level o f  im m unosuppression is required to prevent acute rejection. Later studies
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revealed that these doses of mAb induced similar initial levels of cellular depletion 
(see Chapter 5), suggesting this is not the only mechanism involved in their 
immunosuppressive effect. Higher doses of 0X34 produced very similar survival 
curves, in that a consistent proportion of allografts (10-20%) was rejected, even 
when 2x10 mg/kg was administered. Furthermore these rejections always occurred 
within the time span of unmodified acute allograft rejection (7-11 days). Late graft 
failure did not occur with these regimes (graft failure within the first 72 hours in 
naive animals are regarded as technical failures and excluded from analysis in these 
experiments). These findings are consistent with the hypothesis that acute rejection 
in these animals is an all-or-nothing response, and a threshold level of 
immunosuppression is required to prevent the response. A possible explanation for 
the consistent proportion of rats able to reject allografts despite 0X34 therapy is 
failure of the injection technique, although this is unlikely as the procedure was 
performed on anaesthetised rats.
Post-operative doses of 0X34 are less effective at inducing allograft survival 
with only 3 of 12 grafts being permanently accepted after this regime. Other workers 
using anti-CD2 mAb in the rat (299) and mouse (292, 344) models have noted 
similar findings (although Hirahara was able to induce permanent graft survival in 
DA rats using a regime of 7mg/kg consecutively for 8 days post-operatively (299)). 
This however contrasts with the well-described benefits of administering CTLAJg 
post-operatively (318). As discussed in the introduction there are two possible 
explanations for the beneficial effect of post-operative therapy with CTLAJg: either 
the upregulation of B7-2 (121) or the migration of allo-APC (320) to regional lymph 
nodes, both of which processes reach maximal levels 48 hours after transplantation. 
The observation that anti-CD2 mAb is most effective when given at the time of 
transplantation suggests that the process of allosensitisation begins immediately after
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revascularisation, so that the theory of sensitisation begining after migration of allo- 
APC to the spleen is not supported by evidence presented here. (The unusual 
observation therefore that CTLA4g is most effective when administered post- 
transplantation is most likely explained by the upregulation of B7-2). The spread of 
graft failures after post-operative therapy with 0X34 (days 11-26) contrasts with the 
all-or-nothing response of pre-operative therapy, and suggests that 0X34 has limited 
success at reversing an established immune response. This is in keeping with in vitro 
findings described later showing that 0X34 is effective during the inductive phase of 
an immune response, but has little effect on established effector mechanisms.
Pre-operative therapy with 0X55 is less effective than 0X34 at inducing 
permanent allograft survival, even when used at higher doses. Of the group of six 
treated rats four grafts were rejected. Three of these occurred under 10 days, and one 
graft was rejected at day 20, the only late graft failure noted in DA rats after pre- 
operative therapy. The use of 0X55 in transplant experiments has only been reported 
in a single publication previously, where it was noted to have minimal effect on graft 
survival in high responder Lewis rats (303).
Also reported is the effect of therapy with 0X38 and CTLAJg in the low 
responder Lewis to DA combination. The use of these therapies in rat transplant 
experiments is well recorded (234, 314, 345). The pattern of survival curves obtained 
with these modalities conforms to that of 0X34, in that a small percentage of 
allografts is rejected in the first twelve days post-transplant.
3.6.2 Monoclonal antibody therapy in high responder Lewis and 
PVG rats
Therapy with 0X 34,0X 38 and CTLAJg at doses that are able to produce 
permanent allograft survival in DA rats is only able to prolong allograft survival in
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Lewis rats. The survival curves obtained for the three modes of therapy in Lewis rats 
differ to those obtained in DA rats but are very similar to each other, in that there is a 
gradual attrition of all allografts during the period 10-60 days. This is an interesting 
observation as data discussed in this thesis suggests that these three modalities have 
different mechanisms of action, yet produce very similar effects at the level of 
allograft survival in the two rat strains examined. The large number of late graft 
failures seen in Lewis rats differs from the all-or-nothing response seen with DA 
strain animals. This may be interpreted as an inability of DA strain rats to mount an 
immune response to allografts after exposure to graft antigen during a period of 
immunosuppression by a variety of modalities, whereas the same modalities in Lewis 
rats are able to prevent acute allograft rejection for the duration of their effect, but 
the rats retain the ability to mount an immune response once the effect of the 
administered therapy has declined. Further evidence of the importance of the 
duration of immunosuppression is presented in Chapter 5.
As described in the introduction murine studies have shown a beneficial effect 
of combining anti-CD2 mAb with anti-TCR mAb (296) (anti-CD2 mAb alone is 
ineffective in producing permanent allograft survival in mice). The same tactic was 
therefore tried in high responder rats. No survival advantage was noted with this 
combination in either Lewis or PVG strain rats, even with high dose therapy, 
demonstrating that synergy between monoclonal antibody therapies targeting distinct 
cell surface ligands is not readily transferred between species.
In contrast a combination of ‘standard’ doses of 0X34 (2x5mg/kg) and 0X38 
(10,2,2,2mg/kg) has a marked effect on allograft survival in Lewis rats, inducing a 
MST of 49 days with 50% of allografts achieving permanent engraftment. The 
relationship between these two therapies may be additive, whereby the effect of the 
two therapies combined (at doses X+Y) is equal to the effect of a dose 2X or 2Y of
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single therapy, or synergistic, whereby the effect of doses X+Y exceeds the effect of 
either 2X or 2Y. In order to establish precisely the nature of the relationship between 
the effect of 0X34 and 0X38 it would be necessary to perform experiments using 
both 0X34 and 0X38 alone at doses of 2x5mg/kg + 10,2,2,2mg/kg (=26mg/kg).
This experiment has not been performed so we are unable to say unequivocally that 
the effect between these two therapies is synergistic rather than additive. There is 
indirect evidence however that the combined effect is synergistic:
1) High dose 0X34 therapy (20mg/kg) used in combination with R73 
confers no survival benefit in Lewis rats.
2) High dose 0X38 therapy (30mg/kg) has a minimal survival advantage 
over standard dose when used in combination with 0X34 in Lewis rats.
3) High dose 0X34 therapy (20mg/kg) has only a small survival 
advantage over standard dose when used in combination with CTLAdg 
in Lewis rats.
4) In Chapter 5 the interaction between 0X34 and 0X38 or CTLAJg is 
seen to produce more profound T cell depletion than seen when 0X34 
is used alone. Evidence is also presented in DA rats that T cell 
depletion caused by 0X34 is not dose dependent, so that the extra 
depletion caused by a combination of reagents must be due to a 
functional interaction.
5) A further functional interaction is seen between 0X34 and CTLA4g 
which leads to abrogation of the anti-globulin response to 0X34 and 
prolonged cellular depletion.
In a similar manner to the combined effect of 0X34 and 0X38 a survival 
advantage is noted by combining 0X34 with CTLAJg therapy in Lewis rats. 
Furthermore the trend is one of prolonged survival with increasing dose of 0X34 in
that CTLAdg 2mg/kg +0X34 2x5mg/kg induces a MST of 49 days and CTLAJg 
2mg/kg + 0X34 2xl0mg/kg induces a MST of >100 days (although the proportion 
of permanently engrafted animals is not greatly increased and the dose effect does 
not reach statistical significance). Again this argues against a simple additive 
immunosuppressive effect of combining the two therapies. Chapter 5 describes a 
mechanism of synergy whereby CTLAJg therapy induces prolonged survival of 
0X34 mAb within Lewis rats, and increasing the initial dose of 0X34 would 
therefore allow a higher dose of 0X34 to remain circulating during the period when 
Lewis rats treated with 0X34 alone are able to eliminate 0X34 and mount a 
rejection response (day 12-60). This prolonged circulation of 0X34 may be crucial in 
allowing the development of transplant tolerance in Lewis rats.
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4 The comparative effect of anti-CD2 monoclonal 
antibody on in vitro lymphocyte functions
4.1 Study objective
Data from transplant experiments showed anti-CD2 mAb to be very effective 
at prolonging allograft survival in rat models, particularly when used in combination 
with other modalities. The biological effects of anti-CD4 mAb and CTLAJg have 
been discussed in the introduction in terms of the selective inhibition of signal 1 and 
signal 2 pathways. In this section inhibitory effects on lymphocyte function are 
demonstrated for these two modalities which can be interpreted as a consequence of 
blockade of these two pathways. Experiments are demonstrated which show that the 
effects of anti-CD2 mAb cannot readily be fit into the same two-signal paradigm. In 
order to elucidate its mechanism of action a series of experiments were performed 
examining the effect of anti-CD2 mAb on in vitro T cell functions and these effects 
were compared to those of anti-CD4 mAb and the chimeric protein CTLAJg. This 
series of experiments aimed therefore to dissect the steps of allostimulation using in 
vitro assays and to examine the influence of anti-CD2 mAb at each stage using 
models of:
1) Direct antibody-mediated T cell activation
2) Alloantigen driven cellular proliferation
3) Alloantigen driven cytokine elaboration
4) Generation of allospeciflc CTL
5) Amplification and function of Natural Killer cell activity
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Secondly experiments were performed to explore the ability of anti-CD2 mAb 
to cause lysis of T cells in vitro. These include a) an assessment of the ability of anti- 
CD2 mAb to cause complement-mediated cytolysis (CDC) and b) an assessment of 
the ability of anti-CD2 mAb to promote antibody-dependent cellular cytotoxicity 
(ADCC).
4.2 Study design
1) The mitogenic ability of anti-CD2 and anti-TCR mAb was examined using 
plate-bound mAb and mAb in solution as described in materials and methods to 
stimulate purified CD4 T cells. Cells were cultured for 24 hours prior to the addition 
of 3H-Thymidine.
2) In order to investigate the influence of mAb on cellular proliferation induced 
by allogeneic cells standard MLR plates were set up as described in materials and 
methods using reciprocal DA and Lewis strain cell populations. ESH8, CTLAflg, 
anti-CD2, anti-CD4 and anti-TCR mAb at a range of doses were incubated with 
responder cells prior to adding to stimulator cells. Control wells contained responder 
and stimulator cells (medium only), responder cells without stimulator cells and 
responder cells plus ConA. Plates were cultured for three days unless stated in the 
text.
3) In order to investigate the influence of mAb on cellular proliferation induced 
by anti-TCR mAb, anti-TCR plates were prepared as described in materials and 
methods. Responder cells were pre-incubated with mAb preparartions at doses stated 
in the text on ice to allow labelling without ligand modulation. Cells were washed 
prior to adding to mAb-lined wells. Proliferation was measured by thymidine 
incorporation in the standard manner.
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4) Culture supernatants were retained from the above experiments to assess the 
influence of the reagents tested on elaboration of the cytokines IL2 and ylFN.
5) To assess the influence of mAb on the in vitro generation of allo-CTL ‘bulk’ 
MLR cultures were established as described in materials and methods, using DA 
strain splenocytes as stimulator cells and Lewis LNCs as responders. A responder: 
stimulator ratio of 2:1 was used to generate specific CTL. Anti-CD2 and anti-CD4 
mAb were added at 20jag/ml at the beginning of these cultures to assess inhibition of 
CTL generation. 51Cr labelled DA splenocytes were used as target cells in subsequent 
cytotoxicity assays.
6) To assess the effect of monoclonal antibody on the lytic activity of allo-CTL 
induced in the ‘bulk’ MLR parallel, unmodified cultures were set up to produce CTL. 
Cell cultures were then washed and incubated with 20pg mAb prior to mixing with 
target cells as described in materials and methods.
7) To assess the effect of monoclonal antibody on NK cell function ‘bulk’
MLR cultures were set up to produce NK cells (non-specific cytotoxicity of cell 
cultures is greater after a period of allostimulation presumably due to the generation 
of LAK cells). Monoclonal antibody was added to cultures to assess influence on NK 
cell generation. NK effectors generated in unmodified cultures were incubated with 
mAb prior to mixing with Y3 target cells as described in materials and methods.
8) The ability of 0X34 and 0X38 to lyse lymphocytes by complement- 
mediated pathways was assessed by an in vitro5 Chromium release assay using 
labelled DA strain ConA blasts as target cells. Serum from either a naive Lewis rat or 
one undergoing acute allograft rejection of a DA strain heart was heat- inactivated 
and used as controls (the acute phase serum therefore provided a source of cytotoxic 
antibody for use as a positive control). Target cells were incubated with serial
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tripling dilutions of control serum or monoclonal antibody (initial concentration 
20pg/ml) and an equal volume of fresh DA serum used as a source of complement.
9) In the absence of a suitable assay for macrophage function the ability of 
0X34 (IgG2a) and 0X55 (IgGl) to promote ADCC by NK cells (which also express 
FcyRl 11) was assessed. Effector cells were obtained from Lewis LNCs after 5 days 
of culture in a ‘bulk’ MLR with DA splenocytes. Effector cells were then incubated 
at different dilutions with Y3 blast cells labelled with either 0X34 (IgG2a), 0X55 
(IgG 1) or unlabelled.
4.3 Analysis of the effect of monoclonal antibody on assays 
of T cell function: T cell activation
The ability of anti-CD2 mAb to activate T cells directly and to influence 
proliferation of T cells activated by other means was examined.
4.3.1 Anti-CD2 monoclonal antibody as a mitogen
Firstly experiments were performed to explore the abilty of 0X34 to induce T 
cell activation. The CD2 molecule is known to provide a pathway for T cell 
activation in experimental systems, usually when a combination of monoclonal 
antibodies is used. T cell activation was measured in a series of six experiments 
where purified Lewis strain CD4 T cells were incubated for 24 hours in flat bottom 
wells containing either plate-bound or soluble 0X34 or the anti-TCR mAb R73 and 
proliferation measured 18 hours later as described in materials and methods. Table
4.1 shows that R73 is mitogenic both in solution and when immobilised on the well 
surface. 0X34 is not mitogenic for T cells under the same circumstances.
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Medium Soluble
0X34
Immobilised
0X34
Soluble
R73
Immobilised
R73
cpm (mean) 1946 3583 1594 12141 1133908
SD 312 822 253 2671 5891
p value <0.01 <0.05 <0.001 <1x10 ;
Table 4.1 Direct mitogenic effect of 0X34 compared to R73
Mean thymidine incorporation by Lewis strain CD4 T cells 
stimulated by soluble and plate-bound monoclonal antibody 
(20pg/ml) (mean of six experiments, analysis by unmatched t 
test) (experiments performed with Dr Hilary Marshall).
4.3.2 Effect of anti-CD2 monoclonal antibody on the mixed 
lymphocyte reaction
In vitro assays of alloreactivity were performed to establish if the effect of anti- 
CD2 mAb on transplant survival in different rat strains is reproducible in in vitro 
systems. Mixed lymphocyte reactions were performed and the effect of blockade of 
cellular ligands examined. Lewis and DA strain LNCs were used as responders and 
irradiated DA and Lewis strain splenocytes as stimulators. Firstly the reagents under 
study were assessed in a one way-MLR for their effect on allogeneic stimulation 
induced in Lewis LNCs by DA splenocytes. Antibodies were used at the saturating 
concentration of 20pg/ml as determined by flow cytometry, and were added to cells 
when co-culture commenced (figure 4.1).
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Figure 4.1 Effect of 0X34 compared to 0X38 and CTLA^g 
on proliferation in MLR experiments
M ean thym idine incorporation by Lewis strain LNCs (one 
experim ent) stim ulated by DA splenocytes on addition o f  
m onoclonal antibody (20 pg/m l) at beginning o f  culture. Control 
wells contain m ixed lym phocytes alone and responder cells 
alone (6 wells per reagent; m edium  v 0 X 3 4  p<0.001, 
unm atched t test).
This single experim ent showed a m arked ability o f  anti-CD4 mAb and 
CTLA4lg to inhibit the M LR but also show ed a lesser inhibition by anti-CD2 m Ab in 
this strain com bination and at this dose. Experim ents were then perform ed with 
reciprocal strain com binations and dose ranges o f  0 X 3 4 , 0 X 5 5  and CTLAijIg to 
explore this effect further.
Firstly, using DA and Lewis splenocytes and LNCs, M LRs were perform ed 
with the addition o f  0 X 3 4  in decreasing doses from  lOpg/ml. Figure 4.2 shows the 
m ean o f  three experim ents using DA LNCs as responders and o f  six experim ents 
using Lewis LNCs as responders (proliferation m easured at day 3 in all experim ents), 
confirm ing the inability o f  0 X 3 4  to influence the MLR.
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Figure 4.2 Dose effect of 0X34 in MLR experiments
M ean thym idine incorporation by DA LNCs (three experim ents) 
and Lewis LNCs (six experim ents) stim ulated by reciprocal 
strain splenocytes on addition o f  0 X 3 4  (pg/m l) at beginning o f  
culture. Control wells contain responder cells plus ConA, m ixed 
lym phocytes alone or responder cells alone (m edium  v 0 X 3 4  
lOpg/ml n/s in both series).
Secondly parallel plates were set up to assess the ability o f  0 X 5 5  to influence 
the proliferation o f  Lewis LNCs stim ulated by irradiated DA splenocytes. Figure 4.3 
shows the m ean results o f  a four experim ents with proliferation m easured at day 
three.
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Figure 4.3 Dose effect of 0X55 in MLR experiments
M ean thym idine incorporation by Lewis LNCs stim ulated by 
DA splenocytes on addition o f  0X 5 5  (jug/ml) at beginning o f  
culture. Control wells contain responder cells plus ConA, m ixed 
lym phocytes alone or responder cells alone (m ean o f  four 
experim ents, m edium  v O X 55  lOpg/ml n/s).
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4.3.3 Effect o f C T L A Jg on the mixed lymphocyte reaction
CTLA4Ig therapy has been shown to have differential effects on allograft 
survival in high and low  responder strain rats, and initial experim ents dem onstrated 
its ability to influence the M LR using Lewis strain responder cells. Further 
experim ents were therefore perform ed to confirm  the ability o f  C T L A ^g to inhibit T 
cell activation in this system  and to explore any strain specific effect o f  this 
inhibition. C T L A ^g at a range o f  doses (pg/m l) was added at the beginning o f  
culture using the sam e lym phocyte preparations as above from  DA (three 
experim ents) and Lewis (four experim ents) rats and the proliferation obtained under 
these conditions expressed as the proliferation index (thym idine incorporation
*
expressed as percentage o f  that obtained in unm odified reaction). Figure 4.4 
dem onstrates that addition o f  C T L A Jg  to an MLR inhibited proliferation o f  
lym phocytes from both high and low responder strain rats equally.
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Figure 4.4 Dose effect of CTLA4Ig in MLR experiments 
using DA and Lewis strain responders
M ean relative proliferation o f  DA LNCs (three experim ents) and 
Lewis LNCs (four experim ents) on incubation w ith reciprocal 
strain splenocytes w ith addition o f  C T L A ^g (pg/m l) at 
beginning o f  culture (experim ent perform ed with D r I N ew m an)
Both 0 X 3 8  and CTLA4Ig therefore have dem onstrable effects on lym phocyte 
function in in vitro m odels o f  alloreactivity that parallel their in vivo effect. In view
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of their potent effect on allograft survival the absence of effect of 0X34 and 0X55 is 
surprising. Lymphocyte proliferation in the mixed lymphocyte reaction is 
functionally analogous to stimulation by alloantigens in vivo in that both TCR 
mediated signals and costimulatory signals are required. To further examine the 
effect of mAb in terms of this signal 1/signal 2 paradigm the effect of the reagents 
under study on T cell activation mediated by antibody to the T cell receptor were 
then assessed.
4.3.4 Analysis of the effect of monoclonal antibody on assays of T cell 
function: anti-TCR antibody mediated activation
In these experiments Lewis strain LNCs (2 x 105/well) were preincubated with 
the reagent under study (10pg/ml) on ice for 30 minutes prior to adding to flat- 
bottomed wells coated with anti-TCR antibody as described in materials and 
methods. Cells were cultured for 24 hours initially, and then for a further 18 hours 
after the addition of thymidine. Figure 4.5 shows the mean results from three 
experiments. Of the reagents tested only 0X38 is able to partially suppress 
lymphocyte proliferation in this model.
Further experiments were then performed using a dose range of 0X34 and 
figure 4.6 shows the mean of three experiments confirming the inability of this mAb 
to influence T cell activation in this system. These data provide further evidence that 
although CD2 is associated with the TCR complex anti-CD2 mAb does not influence 
TCR mediated signalling.
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Medium 0X38 0X34 CTLA4lg 0X55
Figure 4.5 0X34 and CTLA Jg are unable to inhibit T cell 
activation via TCR
Thym idine incorporation by Lewis LNCs pre-incubated with 
m Ab (pg/m l) and stim ulated via the T cell receptor with fixed 
R73 m Ab for 24 hours (m ean o f  three experim ents; m edium  v 
0 X 3 8  p<0.05, unm atched t test).
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Figure 4.6 Dose effect of 0X34 in anti-TCR mAb mediated 
proliferation experiments
Thym idine incorporation by LNCs pre-incubated w ith 0X 3 4  
(pg/m l) and stim ulated via the T cell receptor w ith fixed R73 
m Ab for 24 hours (m ean o f  three experim ents).
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4.4 Analysis of the effect of monoclonal antibody on assays
of T cell function: cytokine production
The above experiments used the incorporation of 3H Thymidine as an indicator 
of cellular proliferation, and show that 0X34 is neither able to stimulate T cell 
activation itself nor suppress T cell activation caused by other means. However in 
addition to proliferation, T cell activation leads to the production of cytokines and 
the generation of effector functions. I therefore wished to explore the production of 
cytokines by lymphocytes stimulated by the above methods, to confirm that 
continued cellular proliferation in the presence of anti-CD2 mAb was accompanied 
by normal cytokine production. The key cytokines involved in the generation of cell- 
mediated immunity are IL2 and ylFN. Supernatants from the above experiments were 
preserved and the production of these cytokines assayed.
4.4.1 Influence of monoclonal antibody on IL2 production in MLR 
supernatants
IL2 was measured using the IL2-dependent CTLL cell line. 5x10 CTLL cells 
were cultured in 200pl complete medium containing serial dilutions of supernatant 
from the mixed lymphocyte reactions and anti-TCR reactions outlined above. Cells 
were cultured for 24 hours before the addition of 3H Thymidine as described in 
materials and methods. Incorporation was compared to a standard curve obtained 
using human IL2. Figure 4.7 shows the mean results from three experiments where 
IL2 was measured in MLR supernatants after the addition of medium alone, 0X38, 
0X34, 0X55 or ESH8 (lOpg/kg) or a culture in the absence of stimulators. The IL2 
concentration in supernatants of responder cells stimulated by ConA alone (control 
well in MLR experiments) is excluded from this analysis as levels greater than
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lOOOu/ml are obtained. This graph dem onstrates that IL2 production broadly m irrors 
cellu lar proliferation, and that in addition to its inability to influence proliferation in 
the M LR anti-CD2 mAb has m inim al influence on IL2 production.
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Figure 4.7 Effect of mAb on LL2 production by lymphocytes 
in the MLR
Estim ation o f  IL2 concentration in M LR supernatant after 
addition o f  mAb ( lOpg/ml) at beginning o f  culture. Control 
wells contained m ixed lymphocytes in m edium  or responder 
cells alone (m ean o f  four experim ents, m edium  v 0 X 3 8  p<0.05, 
unm atched t test).
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Figure 4.8 Effect of dose range of anti-CD2 mAb on IL2 
production by lymphocytes in the MLR
Estim ation o f  IL2 concentration in M LR supernatant after 
addition o f  dose range o f  0 X 3 4  (mean o f  three experim ents) or 
0X 5 5  (m ean o f  two experim ents) mAb (pg/m l) at beginning o f  
culture. Control wells contained m ixed lym phocytes in m edium  
alone.
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The influence of anti-CD2 mAb on IL2 elaboration was further demonstrated 
by the addition of a dose range of mAb to MLR experiments as above. The 1L2 
concentration in supernatants of these experiments is shown in figure 4.8.
4.4.2 Influence of monoclonal antibody on ylFN production in MLR 
supernatants
In a similar manner supernatants from the above experiments were assayed for 
their yIFN content. The data shown are obtained from reactions where antibody was 
added at lOpg/ml to the culture. Not all supernatants were retained for analysis so the 
data are incomplete. lOOpl culture supernatants were assayed by an ELISA system 
using polyclonal anti-ylFN as described in materials and methods and compared to a 
standard curve obtained using stock ylFN of known concentration. Table 4.2 
suggests that ylFN production mirrors closely cellular proliferation, in that both 
0X38 and CTLA^g are able to inhibit its production by alloantigen stimulated 
lymphocytes, whereas anti-CD2 mAb appears to have little effect.
Added
reagent
Experiment
1
Experiment
2
Experiment
3
Experiment
4
Mean
medium 46.6 31.2 101.7 59.8
0X38 14.1 14.1
0X55 73.4 87.4 80.4
0X34 35.5 70.3 88.3 85.9 70.0
CTLA Jg 9.8
responders
alone
17.2 13.3 15.2
Table 4.2 Influence of 0X 34 ,0X 55 ,0X 38  and CTLA4Ig on 
ylFN production in the MLR
lOOpl culture supernatants were preserved from experiments 
described in Section 4.4.1 and ylFN concentration measured by 
an ELISA system compared to ylFN standard solution (U/ml).
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4.4.3 Cytokine production by anti-TCR stimulated lymphocytes
Cytokine production in M LR supernatants m easured above appears to m irror 
very closely the degree o f  lym phocyte proliferation, and is not inhibited by anti-CD2 
mAb. In the same way IL2 and ylFN production by cells stim ulated with anti-TCR 
antibody was assessed. Supernatants were retained from three o f  the experim ents 
where Lewis LNCs were stim ulated by im m obilised anti-TCR antibody after 
incubating with reagents under study at 10pg/ml. JL2 and ylFN in these supernatants 
was assayed by the same m ethods as above. Despite achieving high levels o f 
proliferation, supernatants o f  T cells activated by anti-TCR mAb contained very low 
levels o f  1L2 (<2u/m l) so that com parisons betw een groups are not accurate using 
this CTLL assay and results are not shown. Figure 4.9 shows that in a sim ilar m anner 
to above ylFN production how ever follow ed closely the degree o f  cellu lar 
proliferation, and o f  the reagents tested anti-CD4 mAb produced the greatest 
inhibition o f  ylFN elaboration.
80
Medium 0X34 0X55 0X38 CTLA4lg
Figure 4.9 Influence of 0X34, 0X55, 0X38 and CTLA4Ig on 
ylFN production by anti-TCR stimulated lymphocytes
Estim ation o f  ylFN concentration in supernatant o f  anti-TCR 
stim ulated Lewis LNCs (m ean o f  three experim ents) 
preincubated with m Ab (lO pg/m l). Cells cultured for 24 hours, 
control wells contained cells and m edium  only (m edium  v 0 X 3 8  
p<0.05, unm atched t test).
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To further investigate the influence o f  anti-CD2 m Ab on elaboration o f  ylFN 
by anti-TC R  stim ulated LNCs supernatants were taken from a series o f  TCR plates 
w here responder cells had been incubated with a dose range o f  0 X 3 4  prior to 
incubation. Figure 4.10 confirm s that 0 X 3 4  has m inim al influence on ylFN 
production in this system.
Medium 0X34 10 0X 341 0X34 0.1 0X34 0.01
Figure 4.10 Influence of dose range of 0X34 on ylFN 
production by anti-TCR stimulated lymphocytes
Estim ation o f  ylFN concentration in supernatant o f  anti-TCR 
stim ulated Lewis LNCs (m ean o f  three experim ents) pre- 
incubated w ith dose range o f  0 X 3 4  m Ab (pg/m l). Cells cultured 
for 24 hours, control wells contain cells and m edium  only.
4.5 A nalysis o f  the effect o f  m onoclonal antibody on assays  
o f  T cell function: lym phocyte effector functions
Results dem onstrated above show  that antibody to the CD2 m olecule has little 
detectable effect on lym phocyte proliferation in the m odels described and has 
m inim al influence on the elaboration o f  the signature Thi cytokines IL2 and ylFN by 
activated lymphocytes. These results do not accord w ith the potent in vivo effect o f 
anti-CD2 mAb. I next w ished to explore the possibility that activated CD4 T cells 
w hich are labelled with anti-CD 2 m Ab and able to secrete Thi cytokines norm ally
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are still unable to provide help for the generation o f  antigen-specific cell m ediated 
immunity. To this end a system  o f  in vitro generation o f  cytotoxic T lym phocytes 
(CTL) that could be m anipulated w ith different reagents was devised. Lewis strain 
LNCs w ere cultured in 20 m is com plete m edium  with irradiated DA splenocytes for 
five days in a ‘bu lk ’ MLR. Earlier experim ents had shown this to be an effective 
m ethod o f  generating allo-CTL (figure 2.1). The influence o f  mAb on this system 
was assessed by adding antibody to the culture m edium  at 10 pg/m l at the beginning 
o f  the culture. The cytotoxicity o f  the generated effectors was then m easured in a 
standard MChrom ium -release assay using DA strain ConA blasts as target cells at 
decreasing effector: target ratios. This experim ent was repeated three tim es using 
both anti-CD4 and anti-CD2 m Ah in the bulk culture m edium . 0 X 3 8  effectively 
abolished the generation o f  CTL in this system and 0 X 3 4  also consistently 
d im inished the potency o f  CTL generation. A typical result is shown in figure 4.11.
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Figure 4.11 Effect of 0X34 on the in vitro induction of CTL
Specific cytotoxicicty o f  Lewis CTL generated in ‘bu lk ’ MLR 
with DA splenocytes on addition o f  mAb (lO pg/m l) at 
beginning o f  culture.
This result suggests one o f  two broad alternative explanations; either that anti- 
CD2 mAb prevents CD4 T cells providing help for the generation o f  CTL or that 
anti-CD2 m Ab inhibits the activity o f  CTL generated in this system  (as 0 X 3 4  is free
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in solution during the M LR culture any CTL generated will be labelled with 
antibody). To explore the latter possibility as an explanation for the failure to 
generate specific cytotoxicity in this system  a parallel experim ent was designed in 
w hich CTLs were generated in an unm odified bulk M LR and then incubated with 
antibody briefly before addition to DA strain targets in the ?1Chrom ium -release 
assay. This experim ent was repeated three tim es and on each occasion neither anti- 
CD4 m Ab nor anti-CD2 mAb were able to influence the activity o f  CTL generated in 
an unm odified MLR. Figure 4.12 shows a typical result.
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Figure 4.12 Effect of 0X34 on the lytic capacity of allo-CTL
Specific cytotoxicity o f  Lewis CTL generated in ‘bu lk ’ MLR 
with DA splenocytes com pared to sim ilar effectors labelled with 
m Ab (lO pg/m l) prior to addition to DA targets.
O f the above experim ents only the generation o f  CTL in the M LR is affected by 
0X 3 4 . This suggests that 0 X 3 4  m ay exert its inhibitory effect on cell-m ediated 
im m unity in vitro at a stage betw een the recognition o f  alloantigen by CD4 T cells 
(and subsequent activation and cytokine release) and the provision o f  cognate signals 
to CD8 cells. This m echanism  is discussed further at the end o f  the chapter.
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4.6 A nalysis o f  the effect o f  m onoclonal antibody on assays  
o f  N atural K iller cell functions
The data presented above dem onstrate that m Ab to the CD2 m olecule has 
effects on T lym phocytes which are less easily dem onstrated than those o f  anti-CD 4 
mAb and CTLA ^g. The CD2 m olecule is also how ever expressed on NK  cells in 
addition to T lym phocytes in the rat. W e therefore then assessed the effect o f  anti- 
CD2 m Ab on non-specific cytotoxicity. The sam e ‘bulk ' M LR as above was used as 
a source o f  NK cells and the influence o f  mAb during the period o f  alloactivation 
was assessed by incubation w ith NK sensitive Y3 cells (figure 4.13).
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Figure 4.13 Effect of 0X34 on the in vitro amplification of 
NK activity
Cytotoxicity against Y3 target cells o f  effector cells generated in 
‘bu lk ’ M LR on addition o f  m Ab (20jug/ml) at beginning o f  five- 
day culture.
0 X 3 4  has an apparent inhibitory effect on the am plification o f  NK activity in 
the M LR, but not to the sam e degree as 0X 38 . This experim ent was repeated with 
identical results. W e then assessed the effect o f  mAb on the lytic activity o f  effector 
cells generated in an unm odified M LR against Y3 targets. After five days o f  culture 
cells were w ashed and aliquots incubated briefly with 0 X 3 4  before addition to 
' “Chrom ium  labelled Y3 cells in a standard NK cell assay as described in m aterials
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and m ethods (figure 4.14). In contrast to its inhibitory effect on the generation o f  NK 
activity, 0 X 3 4  had no inhibitory effect on the lytic activity o f  activated NK cells.
The apparent increase in cytotoxicity by O X 34-labelled NK cells may be due to 
soluble 0 X 3 4  acting as an opsonin on Y3 cells. This experim ent was repeated with 
sim ilar results.
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Figure 4.14 Effect of 0X34 on the lytic capacity of NK cells
Cytotoxicity against Y3 target cells o f  effectors generated in a 
bulk M LR at responder: stim ulator ratios o f  2 and 4. Effector 
cells are unm odified or labelled with 0 X 3 4  and washed prior to 
adding to target cells.
4.7 A nalysis o f  the ab ility  o f  m onoclonal antibody to lvse T  
cells by com plem ent fixation
Figure 4.15 shows high levels o f  cytotoxic antibody in the serum  taken from a 
rat undergoing acute rejection o f  a DA allograft, dem onstrating that this system  is 
capable o f  m easuring CDC. Both 0 X 3 4  and 0 X 3 8  are unable to lyse blast cells in 
this system.
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4.8 A nalysis o f  the ability o f  m onoclonal antibody to lyse T  
cells by prom oting A P C C
Figure 4.15 shows that m ouse mAb does not activate rat com plem ent. Evidence 
was sought for the participation o f  0 X 3 4  and 0 X 5 5  in antibody-dependent cellular 
cytotoxicity (ADCC), another Fc dependent function. As can be seen from figure 
4.16 both antibodies are very effective opsonm s o f  DA blast cells in this system.
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Figure 4.15 Assessment of the ability of mouse mAb to fix 
rat complement in vitro
A ssessm ent o f  in vitro com plem ent-m ediated cytotoxicity o f  DA 
blast cells by 0 X 3 4  and 0 X 3 8  m Ab (starting concentration 20 
jug/ml) com pared to D A -sensitised and naive rat serum.
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Figure 4.16 Assessment of the ability of mouse mAb to 
promote ADCC by NK cells in vitro
Lysis o f  Y3 target cells by M LR effector cells. Targets were 
labelled with m Ab and washed prior to incubation with effector 
cells.
4.9 C onclusions and d iscussion  o f  results
4.9.1 Direct mitogenic effect of monoclonal antibody
Anti-TCR m Ab is noted to be m itogenic for T cells both w hen fixed to the well 
surface and w hen in solution. The potent effects o f  anti-TCR in this context have 
been well described previously and are widely used as a research tool (346). In 
contrast 0 X 3 4  does not appear to be m itogenic for T cells either w hen in solution or 
when im m obilised on the plate surface.
4.9.2 Influence of monoclonal antibody on mixed lymphocyte 
reactions
Figure 4.1 concurs with previous reports that both anti-CD4 mAb and 
C T L A 4g are able to inhibit cellu lar proliferation in the M LR (116, 231). 
A lloactivation in this system is analogous to the transplant m odel, in that signal 1
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(via the TCR) and signal 2 (via costimulatory molecules) are required. The effects of 
anti-CD4 and CTLAdg on this system can be interpreted in terms of the blockade of 
these two signals. In the first MLR experiment there was also a small degree of 
inhibition by 0X34. Subsequent assays however reported in figure 4.2 show over a 
series of experiments using different responder and stimulator cell types and a dose 
range of reagents that neither 0X34 nor 0X55 had a net effect on cellular 
proliferation in this system. This suggests that either CD2-mediated functions are not 
influenced by anti-CD2 mAb labelling or that they are not crucial in cellular 
activation induced by allostimulation. Experiments reported in section 5.6.7 reveal 
that the CD2 ligand is profoundly modulated in cell cultures containing either 0X34 
or 0X55, establishing that normal expression of the CD2 molecule is not necessary 
for allostimulation in this system. Also notable is the clear dose-response relationship 
of CTLA4g in these experiments, suggesting that costimulatory signals can provide 
a quantitative regulation of T cell activation, rather than a simple ‘on-off signal. 
Furthermore despite the variable proliferative responses obtained by DA and Lewis 
strain responder cells (cells from Lewis strain rats tend to produce higher levels of 
thymidine incorporation on stimulation with DA strain cells than the reverse 
situation), the relative inhibition of this response by CTLA^g is similar in both rat 
strains.
The lack of effect of anti-CD2 mAb in MLR experiments is surprising in view 
of the potent effect of such reagents in transplant models. Anti-CD4 mAb and 
CTLA4g have potent effects on both systems, which are consistent with their 
postulated effects on signal 1 and signal 2 in T cell activation. The presence of 
normal lymphocyte activation by allogeneic cellular methods despite labelling with 
anti-CD2 mAb (and the modulation of the CD2 molecule shown in Chapter 5)
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suggests that these reagents exert their biological effect by mechanisms other than 
interference with T cell activation signals.
4.9.3 Influence of monoclonal antibody on anti-TCR mediated T cell 
activation
Stimulation of T cells by anti-TCR mAb has a very potent mitogenic effect that 
overcomes the need for costimulatory signals (346,347) and allows exploration of 
the influence of reagents on T cells stimulated purely via the T cell receptor (signal 
1). It is notable in these experiments that higher levels of thymidine incorporation are 
obtained after 24 hours than are obtained after three days of culture in the MLR. In 
these experiments 0X38 mAb is partially able to inhibit T cell activation, whilst 
CTLA4g, 0X34 and 0X55 have no effect. This is consistent with the theory that 
anti-CD4 mAb interferes with signalling via the TCR whilst CTLAJg blockades 
costimulatory pathways, and therefore does not influence this system. The inability 
of anti-CD2 mAb to inhibit the proliferation of T cells activated in this way provides 
further evidence that although CD2 is physically associated with the T cell receptor 
and signalling via the two pathways is closely linked, the biological effects of anti- 
CD2 mAb noted in transplant experiments can not be explained by interference with 
TCR-mediated signalling.
4.9.4 Influence of monoclonal antibody on mitogen-induced cytokine 
elaboration
In proliferation experiments reported above (both MLRs and anti-TCR 
mediated) the degree of cytokine (IL2 and ylFN) elaboration by activated cells is 
broadly in keeping with the degree of 3H incorporation. The exception to this is the 
very low level of IL2 noted in the supernatant of LNCs stimulated by anti-TCR mAb
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(<2 u/ml), despite very high levels of thymidine incorporation. A possible 
explanation for this finding is that the high level of cellular proliferation results in 
consumption of 1L2. However it has also been noted in these experiments that LNCs 
stimulated purely by ConA achieve similarly high levels of thymidine incorporation 
but also produce high concentrations of IL2 in culture supernatants (>1000u/ml). 
There is not therefore a direct correlation between cellular activation and IL2 
concentration in culture supernatant. Previously published work has shown 
measureable IL2 production in culture supernatants of CD4 T cells activated by mAb 
to the CD3 molecule if the cells are also labelled with anti-IL2R antibody (347). In 
these experiments there was also no direct correlation between TL2 production and 
thymidine incorporation. Other work using anti-CD4 mAb in mitogen assays using 
both anti-TCR mAb (262) and the allogeneic MLR (261) has shown a differential 
effect on cytokine production, causing a reduction in yIFN production whilst sparing 
IL2. For this reason we assessed the effect of anti-CD2 mAb on mitogen-induced 
production of 1L2 and ylFN in addition to its effect on proliferation, to exclude the 
possibility that anti-CD2 mAb exerts its effect by selective inhibition of Thj cytokine 
elaboration. In contrast to the widely disparate levels of IL2 production detectable 
after anti-TCR mAb and ConA mediated T cell activation, the levels of ylFN 
produced in anti-TCR reactions and the levels of both cytokines produced in MLR 
cultures appears to follow closely the degree of cellular proliferation and inhibition 
by mAb. Anti-CD4 mAb therefore inhibits IL2 production in the MLR to a similar 
degree as it is able to inhibit proliferation, and both anti-CD4 mAb and CTLAdg are 
able to inhibit ylFN production in the same way. (The effect of CTLAJg on IL2 
production in the MLR was not assessed). In contrast only anti-CD4 mAb is able to 
inhibit ylFN production by anti-TCR stimulated T cells. This is in keeping with 
earlier reports demonstrating the direct activation of T cells in this system without
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the requirement for costimulatory signals (211, 347). It is easier to draw conclusions 
from these experiments on the effect of anti-CD2 mAb on 1L2 production in mitogen 
assays rather than yIFN. For example the data demonstrated show an absence of 
effect on IL2 production using a wide dose range of 0X34 used in MLR assays. The 
data for ylFN is however less easy to interpret. The number of assessments of ylFN 
in MLR supernatants is small so a consistent picture has not been obtained, although 
ylFN levels are much higher than in supernatants of MLRs with added anti-CD4 
mAb and CTLA4g. In contrast dose-effect curves have been obtained for the effect 
of 0X34 mAb on ylFN by anti-TCR stimulated T cells giving a consistent result. 
Whilst ylFN concentration is lower in all wells containing 0X34, the inhibition at 
each concentration does not reach statistical significance at any particular dose. It is 
possible therefore that 0X34 mAb does have a small effect on ylFN production in 
this system. However in keeping with the readily demonstrated inhibition of Thi 
cytokines in the models in which 0X38 and CTLA^g have an effect, the absence of 
inhibition of proliferation by 0X34 is matched by a similar inability to prevent Thi 
cytokine release.
4.9.5 Influence of monoclonal antibody on CTL generation and 
function
Investigations so far reveal a paradoxical combination of profound in vivo 
immunosuppression by anti-CD2 mAb therapy and relative silence in in vitro assays. 
We therefore explored a further step in the alloactivation of T cells to explore the 
possibility that anti-CD2 mAb may influence the provision of cellular help by means 
other than inhibition of the elaboration of Thi cytokines, which has been readily 
demonstrated for both anti-CD4 mAb and CTLAdg. Initial experiments described in 
materials and methods have shown the ‘bulk’ MLR to be an effective means of
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generating specific CTL without the requirement for exogenous IL2. On repeating 
these experiments with mAb added to the culture it was noted that anti-CD4 mAb is 
able to abolish the generation of CTL in this system and that anti-CD2 mAb has a 
similar, although less marked effect. Murine studies have also shown that anti-CD2 
mAb can inhibit the in vitro induction of CTL (225, 290), although these experiments 
did not analyse the stages of this process in terms of proliferation and cytokine 
production. Furthermore neither mAb has any effect on the cytotoxic potential of 
CTL after they have been generated in an unmodified MLR. This is expected for 
anti-CD4 mAb, as CTL rarely express the CD4 molecule. CTL (predominantly 
CD8+) are labelled with anti-CD2 mAb but previous publications have also 
demonstrated the inability of 0X34 to inhibit CTL lysis (154). These findings for 
anti-CD2 mAb are contradictory. We have shown that anti-CD2 mAb labelling of 
CD4 T cells does not prevent activation and cytokine release at the level of allo- 
MHC recognition, and anti-CD2 mAb labelling of mature CTL does not prevent 
interaction with allo-MHC bearing target cells. The mechanism of the effect of anti- 
CD2 mAb in this in vitro system must therefore be either:
1) by interfering with the recognition of allo-MHC by CTL precursors
2) by inhibiting the provision of CD4-derived helper signals other than 
IL2 and ylFN to CTLp and prevention of CTL induction.
An isolated effect on CTLp may be because either a) CTLp are inherently 
more sensitive to an effect of anti-CD2 mAb (for example susceptibility to mAb 
induced cell death) or b) the low frequency of CTLp may lead to a dose-related 
exaggeration of anti-CD2 mAb mediated effects.
Regardless of the mechanism involved in the inhibition of induction of allo- 
CTL by 0X34, this finding is the only in vitro counterpart noted to the effects in 
intact animals. Due to the profound depletion of T cells in 0X34 treated animals it is
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not possible to compare meaningfully the influence of 0X34 on the generation of 
allo-CTL during the induction phase of graft tolerance in an intact animal with CTL 
induction during unmodified acute rejection.
4.9.6 Influence of monoclonal antibody on NK cell function in in 
vitro assays
The ‘bulk’ MLR used to generate CTL was also used as a source of NK 
effectors as these cells show greater NK activity than naive cells (possibly a result of 
cytokines in the culture medium producing LAK cells). In a similar manner to the 
inhibition of generation of specific cytotoxicity in this system, anti-CD4 mAb is able 
to reduce the non-specific cytotoxicity of MLR effector cells, presumably by 
reducing the availability of cytokines in the culture medium. It was also noted 
however that 0X34 is able to reduce the generation of NK activity, although to a 
lesser degree than 0X38. This is difficult to explain in similar terms as we have 
demonstrated that 0X34 has minimal effect on the elaboration of DL2 and ylFN in the 
MLR. However 0X34 may interfere with intercellular signals other than IL2 and 
ylFN. This would concur with the earlier demonstration of the inhibition of CTL 
generation, which also cannot be explained by inhibition of IL2 and ylFN production. 
Another possibility is that 0X34 labelling of CD2-bearing NK cells during the 
period of alloactivation and cytokine release leads to accelerated NK cell death. This 
has been demonstrated with human NK cells, where cross-linked anti-CD2 mAb are 
able to activate resting NK cells but induce apoptosis in IL2-primed NK cells (179).
In agreement with murine studies prior labelling with anti-CD2 mAb does not 
inhibit the lytic activity of non-specific effector cells (154). In the three sets of 
experiments performed, incubating MLR effector cells with 0X34 prior to adding to
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Y3 targets slightly increased the levels of NK activity. There are two possible 
explanations for this:
1) 0X34 acts as stimulus to a CD2-mediated pathway of NK cell 
activation (this phenomenon has also been noted in vitro experiments 
where the mAb is cross-linked by secondary antibody (169, 171))
2) Residual mAb in the washed OX34-labelled effector cells bound to NK 
targets (Y3 cells are also labelled by 0X34) and acted as an opsonin to 
increase ADCC (see below).
The observed effects of 0X34 on NK cell function however cannot explain the 
potent in vivo effects of 0X34 on graft rejection, as this process occurs largely 
independently of NK cells.
4.9.7 Mechanisms of monoclonal antibody-mediated cellular lysis
Studies outlined in Chapter 5 reveal that 0X34 mAb causes profound T cell 
depletion when administered to rats intravenously. As discussed at length in the 
introduction there are three possible mechanisms by which monoclonal antibodies 
may cause cellular depletion in animal systems:
1) by direct complement-mediated cytolysis (CDC)
2) by promoting antibody-dependent cellular cytotoxicity (ADCC) and 
opsonisation by cells expressing the Fc receptor
3) By delivery of a ‘negative signal5 to the target cell resulting in cell death. 
Evidence is presented in Section 5 showing that 0X34 therapy preferentially
and more rapidly depletes the CD4 than CD8 subset, suggesting that the CD4 T cell 
is uniquely sensitive to 0X34 binding and favours the participation of the ‘negative 
signal5 hypothesis for the mechanism of action of 0X34. However cellular assays are 
also demonstrated in this section to assess the ability of mAb to participate in the first 
two mechanisms described above.
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Figure 4.15 demonstrates clearly that neither 0X34 nor 0X38 have an intrinsic 
ability to lyse cells by complement fixation. This is an expected result, as evidence 
discussed in the introduction shows that mAb are inconsistent in their ability to fix 
foreign complement, and the evidence of the preferential depletion of CD4 cells 
makes a non-specific system such as CDC unlikely. For the mAb which have been 
shown to be capable of fixing complement this ability has been reproducible in 
experiments such as the one performed here (202,206). The ability to fix 
complement is dependent on the Fc portion of the mAb and is also isotype 
dependent. In rats IgGl is thought not to fix complement, (0X55 (IgGl) was not 
tested in this system) whilst TgG2a is a complement fixing isotype (202).
Another possible mechanism for cellular depletion is by non-specific killing of 
antibody-coated lymphocytes by cells expressing Fc receptors. This process may 
promote either cell lysis, as both NK cells and some T cells have been shown to be 
capable of ADCC (348) or opsonisation of target cells by monocytes and 
macrophages. As discussed ADCC has been assessed in this project by the ability of 
MLR effector cells to participate in this process. The experiment described in figure 
4.16 shows low levels of non-specific cytotoxicity for unmodified MLR effector 
cells against Y3 target cells. There is however a marked increase in cytotoxicity after 
incubation with both 0X55 (IgGl) and 0X34 (IgG2a). Furthermore the level of 
cytotoxicity diminishes only slightly with decrease of the effector: target ratio. This 
indicates that maximal lysis of target cells is obtained at the minimal effector: target 
ratio, indicating the efficiency of ADCC promoted by 0X34 and 0X55 mAb in this 
system. Similar results have been demonstrated for ADCC by mouse macrophages 
directed by the rat anti-CD4 mAb GK1.5 (202). Fc receptors of rat NK cells 
therefore are capable of interacting with mouse Ig, despite the inability of mouse Ig
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to fix rat complement. This is explained by the different loci on the Fc portion of an 
lgG molecule which are responsible for these two functions.
The very potent ability of mouse lgG2a to promote ADCC in this way can be 
incorporated into a possible mechanism for in vivo cellular depletion. It is possible 
that intravenous injection of 0X34 leads to labelling of lymphocytes with mouse 
mAb, which promotes an interaction with host macrophages. This theory would not 
however explain the selective effects of 0X34 mAb described in the next section.
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5 The comparative in vivo effects of anti-CD2
monoclonal antibody therapy
5.1 Study objective
Section 1 established that anti-CD2 mAb has a potent effect on allograft 
survival and Section 2 demonstrated unpredicted effects on in vitro immune 
responses, which suggest a different mechanism of action to both anti-CD4 mAb and 
CTLAftg therapy. In this section I therefore performed a further series of 
experiments to investigate the effect of anti-CD2 mAb on lymphocyte populations in 
vivo and again compared these effects to those induced by anti-CD4 mAb and 
CTLA4lg under the same conditions. Firstly experiments were performed on 
lymphocytes extracted from various rat lymphoid organs to determine the tissue 
distribution of CD2 and B7 in naive animals. I also explored the expression of B7 in 
rats undergoing acute allograft rejection and compared this to that of animals with 
long surviving allografts. The remainder of this section is divided into investigations 
of the pharmacokinetics and pharmacodynamics of anti-CD2 mAb therapy.
5.1.1 Pharmacokinetics of anti-CD2 mAb therapy.
This entails investigation of the extent of distribution of anti-CD2 mAb into 
lymphoid compartments after parenteral administration and the mechanism and 
kinetics of elimination of the foreign immunoglobulin by the rat host. The time 
course of mAb elimination is compared to the duration of immunosuppression and 
allograft survival in transplanted rats. The kinetics of elimination of 0X34 and 0X38 
at therapeutic doses is compared in DA and Lewis rats.
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5.1.2 Pharmacodynamics of anti-CD2 mAb therapy.
This entails investigation of the effect of administration of anti-CD2 mAb on 
lymphocyte population and antigen expression. The predominant effects noted after 
anti-CD2 mAb therapy in the rat are lymphocyte depletion and antigen modulation. 
These two effects are studied in detail and comparison is made between the effects in 
high and low responder strain rats. In addition the depleting and modulating effects 
of the different modalities under study are compared in an attempt to correlate 
prolongation of allograft survival with a measurable immunological effect.
5.2 Study design
1) To establish the extent and magnitude of CD2 and B7 expression 
lymphocytes were prepared from naive peripheral blood, lymph nodes, spleen, 
thymus and peritoneal lavage in the manner described in materials and methods. 
Lymphocytes were incubated with relevant fluorescein-conjugated test mAbs prior to 
FACS analysis. To demonstrate B7 expression PBLs were prepared from a naive rat, 
a rat acutely rejecting a cardiac allograft and also from Lewis rats with long 
surviving DA allografts after OX34-based therapy. These lymphocyte preparations 
were labelled with CTLAJg prior to secondary labelling and FACS analysis.
To investigate the tissue distribution of anti-CD2 mAb and CTLA4g after 
parenteral therapy DA strain rats were injected with 0X34 at various doses and 
CTLAJg at 2.5mg/kg. Lymphocytes were then prepared from peripheral blood, 
lymph nodes, spleen and thymus and labelling with 0X34 and CTLAJg was 
assessed by FACS analysis.
2) The kinetics of elimination of 0X34 was investigated in Lewis and DA 
strain rats and compared to that of 0X38. Monoclonal antibody was administered to
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both rat strains at the dose used to induce cardiac allograft survival in the Lewis to 
DA model (0X34 2x5mg/kg, 0X38 10,2,2,2mg/kg on consecutive days). The 
presence of residual mAb was assessed at days seven, fourteen and twenty-one on 
PBLs and in serum by flow cytometry. Rats were tail-bled into heparin-containing 
eppendorf tubes and samples were centrifuged at low speed and serum extracted and 
diluted 1:1 with PBS. lOOpl dilute serum was then incubated on ice with lOOjul naive 
strain-specific LNCs at 107/ml for 30 minutes. After three washes antibody binding 
to lymphocytes was detected by further incubation with FITC-conjugated rabbit anti­
mouse antibody and FACS analysis.
The generation of an anti-globulin response to the mouse immunoglobulin was 
assessed by a flow cytometric method. Serum from mAb-treated animals was 
prepared as above. Fresh LNCs (lOOpl containing 106 cells in PBS) were incubated 
with lOpl 0X34 or 0X38 at 5mg/ml on ice for 30 minutes followed by washing. 
These antibody-labelled cells were then used as targets and incubated with lOOpl 
dilute (1:1) serum from rats treated as above. Cells were washed and the presence of 
anti-mouse Ig was determined by tertiary labelling with 20pl FITC-labelled mouse 
anti-rat IgM and IgG antibody. The influence of co-administered CTLAftg on the 
generation of an anti-globulin response and mAb elimination was demonstrated by 
similar techniques.
3) To explore the pharmacodynamics of 0X34 mAb therapy a cohort of DA 
rats was injected with 2x5mg/kg 0X34. At each set time interval post injection six 
rats were sacrificed and PBLs and LNCs prepared for FACS analysis. The frequency 
of B cells and CD4 and CD8 T cells was then measured from each compartment. In a 
similar manner the effect of 0X55 mAb on lymphocyte populations was measured 
24 hours after intravenous administration of the therapeutic dose (2xl0mg/kg) for 
comparison of the depleting effects of the two mAb in view of the lesser ability of
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0X55 to influence graft survival. The effect of 0X34 mAb therapy on NK cell 
numbers is not directly measurable due to the absence of a specific NK cell marker 
for the rat. Therefore the NK cell frequency is estimated by calculating the non-B 
non-T cell population in a large number of rats at various time points after 0X34 
mAb therapy (this population also contains a small number of monocytes and y5T 
cells). In addition the effect of 0X34 therapy on NK cell function was measured by 
assessing the non-specific cytotoxicity of lymphocyte preparations from 0X34 
treated and naive rats. A comparison was also made of the depleting effect of 0X34 
(2x5mg/kg) and 0X38 (10,2,2,2mg/kg) in DA and Lewis rats (n=3). In this 
experiment relative depletion measured by flow cytometry is correlated to absolute 
reduction in circulating leukocyte numbers measured by microscopy.
4) The depleting effect of mAb combinations was assessed in a similar manner 
in Lewis rats. Reagents were administered at the optimum dose used to induce 
prolonged allograft survival and lymphocytes were prepared from peripheral blood at 
set time points for estimation of lymphocyte frequencies.
5) The saturation of CD2 ligands with 0X34 mAb after intravenous 
administration of low and high dose 0X34 was assessed by harvesting undepleted 
LNCs and PBLs 24 hours after 0X34 therapy. The extent of 0X34 labelling of cells 
was then determined by secondary labelling with FITC conjugated rabbit anti-mouse 
antibody (20jnl in 100 pi of cells). The presence of unsaturated 0X34 binding sites 
was then assessed by the addition of a further 10 pi 0X34 (5mg/ml) to lOOpl of cells 
on ice in vitro. After washing these cells were again incubated with 20pl FITC 
conjugated rabbit anti-mouse antibody. The mean channel fluorescence of bound 
0X34 of in vivo and in vitro treated samples were then compared by FACS analysis.
6) The modulating effect of anti-CD2 mAb therapy was measured by both in 
vitro and in vivo methods. PBLs were prepared from DA rats treated with 0X34 and
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0X55 and levels of CD2 expression measured by flow cytometry. The modulating 
effect of 0X34 was also compared directly to that of 0X38 in Lewis rats treated with 
both mAb. To assess the modulating effect of 0X34 in the absence of cellular 
depletion purified CD4 T cells were prepared and incubated with 0X34 in vitro. 5 
mis of CD4 T cell suspension were incubated at 4xl06/ml in culture medium for 18 
hours in 5% CO2 at 37°C with mAb (0X34 or 0X38) at 20pg/ml. After incubation 
cells were washed to remove excess antibody and resuspended on ice. Labelling of 
residual molecules with 0X34 and 0X38 was then detected using FITC-conjugated 
rabbit anti-mouse antibody and compared to the labelling of naive lymphocytes after 
incubation on ice for 30 minutes with the same concentration of mAb as above.
5.3 Distribution of the CD2 molecule
To establish the distribution of the CD2 molecule amongst lymphoid cells in 
the rat cells were prepared from lymph nodes, peripheral blood, spleen and thymus of 
a naive rat as described in materials and methods and incubated with 0X34 followed 
by fluorescein-conjugated rabbit anti-mouse antibody. This shows that CD2 is 
expressed at varying levels on cells from lymph nodes, spleen and circulating blood 
lymphocytes. In addition CD2 is expressed at a lower level on virtually all 
thymocytes (figure 5.1). Assessment of differential expression shows that CD2 is 
expressed on all T lymphocytes expressing the ap  TCR but not on B lymphocytes 
(figures 5.2, 5.3). There is also an apTCR- subset which is labelled by 0X34 on in 
vitro culture, which contains y5T cells and NK cells (figure 5.2). This subset is most 
notable amongst splenocytes where it forms 10% of the cell population. Amongst T 
cells CD2 is expressed equally on CD4 and CD8 cells (in figure 5.4 mean channel 
fluoresence of 0X34 labelling of CD4 cells=2.6, and of CD8 cells=2.4). Analysis of 
labelling with 0X34 by peritoneal macrophages (ED1+) shows labeling of both ED-
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1 and 0X34 at a very low level, which may represent non-specific labelling by Fc 
receptors (figure 5.5).
5.4 Distribution of the B7 molecule
The construct CTLAJg binds to the B7 molecule, which is expressed on APCs 
and activated B cells. B7 is expressed at a low level in the resting state and is 
upregulated on activation of both cell types. To demonstrate binding of CTLAJg to 
B7 in the resting and activated state PBLs were prepared from both a naive rat and a 
Lewis rat 50 days post transplant which was undergoing acute allograft rejection 
after failed therapy with 0X34 and CTLAJg. Cells were incubated with CTLAftg 
(20pl 1:100) and labelling measured with FITC-conjugated sheep anti-human 
antibody. As can be seen in figure 5.6 resting lymphocytes express B7 at a low level 
on a small minority of non-T cells. Both the number of cells and the intensity of B7 
labelling is upregulated in LNCs taken from an animal undergoing acute allograft 
rejection, but is still largely restricted to the non-T cell subset, (figure 5.6). B7 
expression (determined by CTLAJg labelling) was also determined in Lewis rats 
with healthy allografts at 21,40 and 150 days post-transplant after therapy with 
0X34 and CTLAdg. Interestingly these animals show a profile of CTLA^g labelling 
similar to naive rats (figure 5.7). A similar finding is noted in tolerant Lewis rats with 
DA allografts after therapy with 0X34 and 0X38.
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Figure 5.1 Distribution of the CD2 molecule on lymphoid 
cell subsets
Cells were prepared from lymphoid organs of a naive rat using 
the standard method. Cells were incubated with 0X34, washed 
and secondarily labelled with FITC rabbit anti-mouse Ig.
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Figure 5.2 Distribution of CD2 on T cells
Cells were prepared from lymphoid organs in the standard 
manner and incubated with FITC-conjugated 0X34 followed by 
PE-conjugated R73.
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Figure 5.3 CD2 is not expressed by B cells
Cells were prepared from lymphoid organs in the standard 
manner and incubated with 0X34 followed by PE-conjugated 
rabbit anti-mouse Ig and finally FITC-conjugated 0X12.
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Figure 5.4 CD2 expression on T cell subsets
Lymph node cells were incubated with FITC-conjugated 0X34 
followed by either a) W3/25-PE or b) OX8-PE.
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Figure 5.5 Labelling with 0X34 by peritoneal macrophages
A suspension o f  peritoneal cells was divided into two aliqouts 
and incubated with e ither a) FITC conjugated ED-1 or b) FITC 
conjugated 0X 34 .
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Figure 5.6 B7 expression on non-T cells from a rat rejecting 
an allograft
LNCs were taken from a naive rat 24 hours after administration 
of CTLATg (2.5mg/kh) and a transplanted Lewis rat rejecting a 
DA allograft after therapy with 0X34 and CTLAftg. Cells from 
the transplanted rat were incubated with CTLAftg and all cells 
secondarily labelled with FITC-conjugated rabbit anti-human 
antibody and finally R73-PE.
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Figure 5.7 B7 expression on non-T cells in tolerant Lewis 
rats
LNCs w ere taken from Lewis rats with long-surviving DA 
allografts after therapy w ith e ither a) 0 X 3 4  and 0 X 3 8  or b) 
0 X 3 4  and CTLA4Ig. Cells were incubated with CTLA^Ig 
follow ed by FITC -conjugated rabbit anti-hum an antibody and 
finally R73-PE.
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5.5 Pharmacokinetics of monoclonal antibody therapy
5.5.1 Distribution of 0X 34 after intravenous administration
To establish the extent of 0X34 labelling of lymphoid cells in vivo after 
intravenous injection, 10 mg/kg 0X34 was administered to a DA rat 24 hrs prior to 
harvesting LNCs, PBLs, splenocytes and thymocytes. The extent of 0X34 labelling 
of cells was then determined by secondary labelling with FITC conjugated rabbit 
anti-mouse antibody. Cells were then incubated with further 0X34 in vitro to detect 
unlabelled binding sites. 0X34 binding sites on LNCs, PBLs and splenocytes were 
all saturated after intravenous injection at this dose (figure 5.8) whereas thymocytes 
were labelled at a lower level. This suggests the presence of a blood-thymus barrier 
to the passage of 0X34, as in vitro incubation with further antibody substantially 
increased labelling. Therapy with lower doses of 0X34 (2.5mg/kg and 5mg/kg) fails 
to saturate all 0X34 binding sites on LNCs (figure 5.9).
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Figure 5.8 Saturation of binding sites on LNCs and 
thymocytes after 0X34 therapy
LNCs (top) and thym ocytes (bottom ) were prepared from a DA 
rat 24 hours after intravenous injection o f  0 X 3 4  ( lOmg/kg). 
Cells were incubated with rabbit anti-m ouse FITC (solid line) or 
0 X 3 4  follow ed by rabbit anti-m ouse FITC (dotted line).
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Figure 5.9 Saturation of binding sites on LNCs after low 
dose 0X34 therapy
DA rats w ere injected intravenously with 0 X 3 4  2.5m g/kg (top) 
or 5m g/kg (bottom ). Cells were incubated with rabbit an ti­
m ouse FITC (solid line) or 0 X 3 4  follow ed by rabbit anti-m ouse 
FITC (dotted line).
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5.5.2 Elimination of 0X 34 and 0X 38 by DA and Lewis strain rats 
after intravenous injection
We then asked if the difference in survival rates recorded between DA and 
Lewis strain rats may be associated with a more prolonged duration of action of 
either monoclonal antibody in DA compared to Lewis rats. We therefore wished to 
assess the kinetics of elimination of monoclonal antibody from the serum of treated 
rats and the generation of an antibody response to the foreign mouse protein. Lewis 
and DA rats (3 per group) were each injected intravenously with 0X34 (lOmg/kg) or 
0X38 (16mg/kg). PBLs were harvested at days 7,14 and 21 and tested for mAb 
labelling with FITC conjugated rabbit anti-mouse antibody. Serum was taken at 
similar time points and the presence of residual circulating mAb determined by 
incubating serum (diluted 1:1 in PBS) with fresh Lewis LNCs and using rabbit anti­
mouse FITC as a secondary label. In a similar manner the presence of an anti­
globulin response was assessed by a non-quantitative flow cytometric method. Fresh 
LNCs were labelled with 0X34 or 0X38, these cells were then incubated with serum 
from rats treated as above and the presence of anti-mouse Ig determined by tertiary 
labelling with FITC-conjugated mouse anti-rat IgG and IgM, as described in 
materials and methods. The results are summarised in Table 5.1. Examples are also 
given showing that DA strain rats do not generate anti-globulins when treated with 
either 0X34 or 0X38 (Figure 5.10), Lewis rats however generate IgG anti-globulins 
against 0X38 at day 14 (two of three rats) (Figure 5.11) and against 0X34 by day 21 
(three of three rats) (Figure 5.12).
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n=3 per group Day 7
Cell-bound
mAb
Circulating
mAb
Anti-Ig
response
DA 0X34 + + -
0X38 + - -
Lewis 0X34 + + -
0X38 - - -
n=3 per group Day 14
Cell-bound
mAb
Circulating
mAb
Anti-Ig
response
DA 0X34 + + -
0X38 + - -
Lewis 0X34 + - -
0X38 - - +
n=3 per group Day 21
Cell-bound
mAb
Circulating
mAb
Anti-Ig
response
DA 0X34 + - -
0X38 - - -
Lewis 0X34 - - +
0X38 - - +
Table 5.1 Elimination of 0X34 and 0X38 by DA and Lewis 
rats
Correlation between duration of cell-bound and circulating 
0X34 and 0X38 mAb with the generation of an anti-globulin 
response in Lewis and DA rats.
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Figure 5.10 Failure of DA strain rats to produce IgG 
antiglobulins against either 0X34 or 0X38 fourteen days 
after administration.
Serum from DA strain rats treated  with 0 X 3 4  (1-3) or 0 X 3 8  (4- 
6) was incubated w ith specific target cells before tertiary 
labelling with m ouse anti-rat IgG (see m aterials and m ethods for 
experim ental details and controls).
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Figure 5.11 Lewis strain rats produce IgG antiglobulins 
against 0X38 but not 0X34 fourteen days after 
administration.
Serum  from Lewis strain rats treated  w ith 0 X 3 4  (1-3) or 0 X 3 8  
(4-6) was incubated w ith specific target cells before tertiary 
labelling with m ouse anti-rat IgG (see m aterials and m ethods for 
experim ental details and controls).
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Figure 5.12 Lewis strain rats but not DA strain rats produce 
IgG antiglobulins against 0X34 twenty-one days after 
administration.
Serum from DA (1-3) and Lewis (4-6) strain rats treated with 
0X34 was incubated with specific target cells before tertiary 
labelling with mouse anti-rat IgG (see materials and methods for 
experimental details and controls).
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5.5.3 Distribution of CTLAJg after intravenous injection
In a naive animal labelling of a small minority of non-T cells from peripheral 
blood and lymph nodes is detectable 24 hours after intravenous injection of 
CTLAJg. Figure 5.6 shows a FACS analysis of LNCs taken from a rat 24 hours after 
administration of 2.5mg/kg CTLAJg intravenously. CTLAJg is detected with FITC- 
conjugated sheep anti-human antibody.
5.5.4 Elimination of 0X 34 by Lewis strain rats after intravenous 
injection in combination with CTLAJg
As has been demonstrated this combination of treatment modalities is effective 
in prolonging allograft survival in the high responder DA-Lewis strain combination. 
When used as monotherapy in Lewis strain rats 0X34 is eliminated from the 
circulation by day 14 and from the cell surface by day 21, and this elimination is 
associated with the development of an anti-OX34 IgG response. The CD28.B7 
pathway has been shown to provide costimulation in the development of B cell 
responses so we therefore explored the possibility that CTLAJg may influence the 
development of anti-OX34 immunoglobulin in this model and the subsequent 
elimination of monoclonal antibody.
Firstly three untransplanted Lewis rats were treated with 0X34 at the same 
dose as above (2x5mg/kg) followed by CTLAJg (2.5mg/kg) two days later. Rats 
were tail-bled at set time points and serum and cells were harvested and assayed for 
residual mouse monoclonal antibody and anti-OX34 immunoglobulin by tertiary 
labelling with mouse anti-rat immunoglobulin (IgM and IgG) as shown in Table 5.2.
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Lewis rats, n=3 I ►ay 14,21 and 21'
Cell-bound
mAb
Circulating
mAb
Anti-Ig
response
0X34 (2x5mg/kg) + 
CTLAJg (2.5mg/kg)
+ + -
Table 5.2 Effect of CTLAJg on elimination of 0X34 in 
Lewis rats
Persistence of circulating and cell-bound 0X34 mAb and failure 
of anti-OX34 response in Lewis rats treated with CTLAJg.
This experiment confirms that persistence of 0X34 in Lewis rats is extended 
when 0X34 is administered in conjunction with CTLAJg.
Secondly we explored the correlation between the generation of an anti­
globulin response, the elimination of monoclonal antibody, the persistence of cellular 
depletion and ligand modulation, and allograft survival in high responder Lewis rats. 
Six Lewis rats receiving DA heart transplants were treated intravenously with 0X34 
(2x10 mg/kg given pre-operatively) and CTLAJg (2.5mg/kg given 2 days post- 
operatively). Animals were tail-bled at days 21, 40 and 65 and serum separated. The 
presence of residual monoclonal antibody was determined by incubating with fresh 
LNCs and anti-OX34 antibody was detected using 0X34 labelled LNCs as target 
cells as described previously. Lymphocyte sub-population profiles were assessed by 
flow cytometry (see Section 5.6.1). Of this particular cohort of six transplanted rats 
one allograft was rejected at day 13 whilst the others went on to permanent allograft 
survival.
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Day 21 41) 65
G raft surviving Yes n=5 No n=l Yes n=5 No n=l Yes n=5 No n=l
a lg  response - + - + - +
Circulating antibody + - + - - -
Cellular depletion + - + - - -
Table 5.3 Abrogation of anti-globulin response by CTLA Jg 
and graft survival
Allograft survival following 0X34 and CTLAJg therapy in 
Lewis rats is associated with abrogation of the anti-globulin 
response, leading to persistence of 0X34 mAb and continued 
cellular depletion.
In this experiment the generation of an anti-globulin response in one of six rats 
correlates with elimination of mouse monoclonal antibody, the recovery of the T cell 
population and allograft rejection. This suggests that CTLAJg prevents the 
generation of an antiglobulin response to mouse protein allowing prolonged 
antibody-mediated cellular depletion, which is associated with allograft survival. The 
failure of CTLAJg to prevent an antiglobulin response in one of six rats may suggest 
that a threshold dose of CTLAJg is required or may represent a failure of 
experimental technique. The remaining five rats appear to eliminate mouse 
monoclonal antibody at a slower pace by mechanisms that do not involve 
antiglobulin.
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5.6 P harm acodynam ics o f  0 X 3 4  m onoclonal antibody  
therapy
5.6.1 Effect on lymphocyte populations of intravenous 0X34 therapy 
in DA rats.
To determ ine the effect o f  0 X 3 4  therapy on lym phocyte populations 0 X 3 4  
was adm inistered intravenously at 5m g/kg on two consecutive days to a cohort o f 
untransplanted DA rats. A t each predeterm ined tim e point post-injection six rats 
were sacrificed and PBLs and LNCs harvested for analysis.
5.6.1.1 Estimation of T cell frequency.
Firstly cells were incubated with FITC-conjugated R73 (anti-TC R) to establish 
the frequency o f  T cells in the lym phocyte population (figure 5.13).
100
80
+ 60nN.Q£
5s 40 
20 
0
i X
□  LNC
□  PBL
[ X X
Day
X
12
X
21 120
Figure 5.13 T cell depletion by 0X34
Frequency o f  T cells in DA LNCs and PBLs follow ing therapy 
with 0 X 3 4  (2x5m g/kg) (n=6).
0 X 3 4  treatm ent caused depletion o f  T cells from lymph nodes and peripheral 
blood. R73+ T cells form approxim ately 70%  o f  LNCs and PBLs in a naive animal.
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This figure declined progressively over the first 7 days after injection to reach a 
m inim al level o f  24%  in both populations. Some recovery was seen by day 21 and 
even at day 120 levels o f  R73 expression had not returned to norm al (66%  and 54% 
respectively).
5.6.1.2 Estimation of CD4:CD8 ratio
In a sim ilar m anner relative depletion o f  specific CD4 and CD8 subsets was 
assessed using fluorochrom e conjugated W 3/25 and 0 X 8  respectively. The 
frequency o f  CD8 T cells rem ained broadly constant throughout the period o f  the 
study (13-16% ) despite 0 X 3 4  therapy. The ratio o f  CD4 to CD8 cells was then 
established for each tim e point and is illustrated in figure 5.14.
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Figure 5.14 Preferential depletion of CD4 T cells by 0X34
CD4:CD8 ratio in LNCs and PBLs o f  DA rats (n=6) treated with 
0 X 3 4  (2x5mg/kg).
In an unm odified anim al the ratio o f  CD4 to CD8 T cells is approxim ately 
3.5:1. 0 X 3 4  therapy preferentially depletes the CD4 subset so that the CD4 
frequency falls from 54%  o f  both LNCs and PBLs to a m inim um  o f  14% and 5% 
respectively at day 12 (CD4: CDS ratio 0.9 and 0.4 respectively). The depletion o f  
CD4 cells appears to be less m arked am ongst LNCs than PBLs and recovered more
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fully over time. Again how ever by day 120 recovery o f  the CD4 population was still 
not com plete (CD4 frequency 47%  and 38%  respectively).
5.6.1.3 Estimation of B cell frequency after 0X34 therapy
Analysis with the B cell m arker 0 X 1 2  shows that the decreasing frequency o f 
T cells is m atched by an apparent relative expansion o f  the B cell subset. PBLs were 
prepared from the cohort o f  DA rats treated with 0 X 3 4  (2x5m g/kg) used in the 
above experim ents and stained for B cells at various tim e points. Figure 5.15 shows 
the reciprocal relationship o f  B and T cell populations after 0 X 3 4  therapy, and also 
shows that the non-B, non-T cell (R73-/O X12-) population rem ains unchanged 
despite 0 X 3 4  therapy.
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Figure 5.15 Relative preponderance of B cells after 0X34 
therapy
Percentages o f  T, B and unlabelled cells am ongst PBLs after 
adm inistration o f  0 X 3 4  (2x5m g/kg) to DA rats (n=6).
5.6.1.4 Influence of dose of 0X34 on cellular depletion
Doses o f  0 X 3 4  lower than 2x5m g/kg fail to prevent acute allograft rejection in 
DA strain rats. W e therefore investigated if  this difference in survival is associated 
with a lesser degree o f  cellu lar depletion by lower doses o f  mAb. Tw o DA rats were
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treated with 0 X 3 4  2.5 m g/kg and four rats with 5mg/kg. A fter 24 hours PBLs were 
taken and lym phocyte subset frequencies determ ined in the standard m anner. Figure 
5.16 shows the lymphocyte proportions in com parison to the data shown above for 
naive DA rats and DA rats treated  w ith 0 X 3 4  2x5m g/kg. The degree o f  depletion o f  
lym phocyte subsets is broadly sim ilar in anim als treated with each dose.
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□  CD8T cells
Naive 0X34 2.5 0X34 1x5 0X34 2x5
Figure 5.16 Effect of dose of 0X34 on lymphocyte depletion
Relative lym phocyte frequencies in peripheral blood o f  naive 
DA strain rats (n=6) and DA rats 24 hours after adm inistration 
o f  0 X 3 4  2.5m g/kg (n=3), 0 X 3 4  5m g/kg (n=4) and 0 X 3 4  
2x5m g/kg (n=6).
5.6.1.5 Estimation of NK cell frequency after 0X34 therapy
The lack o f  a specific NK cell m arker in the rat prevents precise delineation o f  
the effect o f  anti-CD2 therapy on NK cell num bers. The cell population which is 
both R73-ve and 0X 12-ve  contains the NK cell and y5 T cell fractions. This 
population appears to rem ain constant in size (approxim ately 10%) despite 0 X 3 4  
therapy in DA rats (Figure 5.15). N atural k iller cells in the rat express the CD2 
m olecule and w ould therefore be expected to be labelled by 0 X 3 4  mAb after 
intravenous adm inistration. H ow ever when 0 X 3 4  labelling o f  non-depleted cells is 
m easured at various tim e points after intravenous 0 X 3 4  therapy in a large num ber
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(24) of DA rats it is notable that the proportion of cells labelled with 0X34 coincides 
very closely in size with the remaining R73+ T cell fraction (Table 5.4).
n=24 R73+ RaM+
LNC (SD) 32.52 (10.22) 32.37(11.38)
PBL (SD) 30.87(13.54) 30.52(11.27)
Table 5.4 Estimation of labeling with 0X34 and R73 on 
residual cells after 0X34 therapy
Mean percentage (SD) of DA PBLs labelled with either R73 or 
rabbit anti-mouse antibody at a range of time points following 
administration 0X34 (n=24).
5.6.1.6 Estimation of NK cell function after 0X34 therapy.
Despite the greatly depleted T cell numbers assay of non-specific cellular 
cytotoxicity in a DA strain rat after intravenous administration of 0X34 shows very 
little effect, suggesting that NK cells have not been significantly depleted by 0X34. 
This is in keeping with the apparent inability of 0X34 to label NK cells. To estimate 
NK cell function splenocytes were prepared from DA strain rats treated with 
2x5mg/kg 0X34 and compared to those from a naive DA strain rat in a cytotoxicity 
assay using the 51Chromium labelled NK-sensitive Y3 cells. Figure 5.17 shows that 
non-specific cellular cytotoxicity is minimally affected in this model. An 
interpretation of these findings is given at the end of the chapter.
5.6.2 Comparison of the depleting effect of 0X 55 and 0X 34 in DA 
strain rats
As has been demonstrated 0X55 is less effective at prolonging allograft 
survival than 0X34 even at higher doses (0X55 lOmg/kg given days-1, 0 relative to 
transplant produces permanent engraftment in 2 of 6 rats). We hypothesised that this 
difference in efficacy can be explained by a difference in the ability of the two mAb
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to cause cellu lar depletion. Figure 5.18 shows the frequencies o f  B cells and T cell 
subsets in PBLs o f  6 DA rats treated  w ith 0 X 5 5  at the above dose on day 1 
com pared with the depletion obtained in 6 DA rats treated with 0 X 3 4  (2x5mg/kg).
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Figure 5.17 Effect of 0X34 therapy on NK cell function
Non-specific cellu lar cytotoxicity o f  PBLs from  a DA rat 24 
hours after intravenous adm inistration o f  0 X 3 4  (2x5m g/kg) 
com pared to a naive rat.
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Figure 5.18 Depleting effect of 0X55 therapy
Estim ation o f  subset frequency in PBLs after 24 hours in DA 
rats treated w ith 0 X 3 4  (2x5m g/kg) or 0 X 5 5  (2x l0m g/kg) (n=6 
per group).
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0X55 produces a similar degree of T cell depletion as 0X34 but analysis of T 
cell subsets shows that the CD4 subset is not preferentially depleted. The CD4:CD8 
ratio in the experimental groups used above is shown in Table 5.5.
n=6/group Naive 0X34 (2x5mg/kg) 0X55 (2xl0mg/kg)
CD4: CD8 ratio 3.30 1.28 3.25
Table 5.5 Differential effect of 0X55 therapy on T cell 
subsets
CD4: CD8 ratio in the residual T lymphocyte population in 
PBLs after therapy with 0X34 and 0X55 compared to naive 
animals.
5.6.3 Comparison of the depleting effect of 0X34 with 0X 38 in high 
and low responder strain rats.
In the above experiments relative frequencies of T cell subsets were measured, 
which do not give an indication of total leukocyte depletion. For this reason a further 
series of experiments was performed in which groups of animals were injected 
intravenously with mAb and then tail-bled at set time points. The total circulating 
leukocyte count was then measured by staining with Turck’s solution and 
microscopy as described in materials and methods at time periods beginning at four 
hours after injection. The same sample was then subjected to analysis by flow 
cytometry to define subset frequencies. In these experiments both high and low 
responder strain rats were used to assess any difference in the level of depletion 
obtained. In addition the depletion caused by 0X34 was compared to that produced 
by 0X38. Lewis and DA rats (3 per group) were each injected intravenously with 
0X34 (lOmg/kg) or 0X38 (16mg/kg). Total leukocyte counts are shown in figures
5.19 and 5.20.
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Figure 5.19 Total circulating leukocyte count in DA rats 
treated with 0X34 or 0X38
W hole blood was rem oved from naive or treated DA rats (n=3) 
after therapy with 0 X 3 4  or 0X 38 . Total leukocyte count was 
determ ined by labelling with Turks solution.
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Figure 5.20 Total circulating leukocyte count in Lewis rats 
treated with 0X34 or 0X38.
W hole blood was rem oved from naive or treated  Lewis rats 
(n=3) after therapy with 0 X 3 4  or 0 X 38 . Total leukocyte count 
was determ ined by labelling with Turks solution.
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5.6.3.1 Comparison of the depletion of T cell subsets in DA and Lewis rats 
induced by 0X34 and 0X38
Both mAb cause leukocyte depletion in both rat strains, w ith an apparently 
steeper decline in DA rats. The total leukocyte depletion m asks a predom inant 
depletion o f  CD4 T cells, which is greater in rats treated with 0 X 3 4  than 0 X 3 8  and 
is m aintained for the duration o f the experim ent (figures 5.21 and 5.22). The 
frequency o f  CD8 T cells shows m inim al change in either rat strain treated with 
either m odality, w ith values betw een 16% and 20%. The pattern o f  CD4 T cell 
depletion caused by 0 X 3 4  and 0 X 3 8  is sim ilar in both rat strains. How ever when 
analysed closely CD4 depletion in DA strain rats is consistently greater than in Lewis 
rats (table 5.6), so that approxim ately tw ice the num ber o f  CD4 T cells rem ain after 
0 X 3 4  therapy in Lewis rats.
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Figure 5.21 Depletion of CD4 T cells in DA rats treated with
0X34 or 0X38
C ells were prepared from  DA rats treated with 0 X 3 4  
(2x5m g/kg) or 0 X 3 8  (10,2,2,2m g/kg) and the percentage o f  
CD4 T cells determ ined by labelling with W 3/25.
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Figure 5.22 Depletion of CD4 T cells in Lewis rats treated 
with 0X34 or 0X38
Cells were prepared from Lewis rats treated with 0 X 3 4  
(2x5m g/kg) or 0 X 3 8  (10,2,2,2m g/kg) and the percentage o f  
CD4 T cells determ ined by labelling with W 3/25.
Day Lewis DA P
7 8.2 (5.37) 3 .6 (5 .8 1 ) 0.14
14 7 .6 (4 .66 ) 5 .6 (4 .21 ) 0.25
21 10.3 (4.33) 5 .9 (3 .66 ) 0.19
Table 5.6 Comparison of CD4 number in Lewis and DA rats 
after therapy with 0X34
Residual CD4 T cell percentages (SD) in Lewis and DA strain 
rats (n=3) treated  w ith 0 X 3 4  (2x5m g/kg) (t test for unpaired 
data).
5.6.4 Effect on lymphocyte populations of intravenous CTLAJ g  
therapy.
Fundam ental to an exam ination o f  the m echanism  o f  action o f  CTLA4Ig is an 
estim ation o f  its effect on lym phocyte subset frequencies. To explore this effect 
CTLA4Ig was adm inistered intravenously to two rats at a dose o f  2.5mg/kg. PBLs 
and LNCs were prepared 24 hours later and R73, W 3/25 and 0 X 8  labelling was 
assessed by flow cytometry. The proportion o f  CD4 and CD8 T cells was identical to 
that in a naive animal. CTLA4Ig therapy would be expected to influence
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predominantly the B cell population, which expresses B7. PBLs and LNCs from the 
above two rats were stained with OX12-F1TC to assay the B cell fraction which was 
then compared to the results from naive DA rats. Table 5.7 shows that the B cell 
fraction appears to remain largely unchanged despite CTLAJg therapy at this time 
point.
0X12+ cells Naive (n=6) Treated 1 Treated 2
LNC 24.55 (SD 5.34) 29.2 27.9
PEL 19.69 (SD 4.52) 15.9 19.9
Table 5.7 Estimation of B cell frequency at 24 hours in 
untransplanted DA rats treated with CTLA Jg (2.5mg/kg)
5.6.5 Dose effect on saturation of the CD2 molecule after 0X34  
therapy
Survival data presented in Chapter 3 show that a threshold level of 0X34 
therapy (2x5mg/kg) is required to induce long-term allograft survival, whilst lower 
doses fail to prevent acute allograft rejection. Further evidence detailed in figure 5.16 
shows that the same doses which lead to widely different results in transplant 
experiments produce very similar levels of cellular depletion. We therefore 
investigated the saturation of CD2 molecules using low and high dose 0X34 as an 
alternative explanation for this dose effect. Figure 5.8 shows that LNCs taken from a 
rat 24 hours after administration of 0X34 (2x5mg/kg) show no increased labelling 
with FITC-conjugated rabbit anti-mouse Ig after in vitro incubation with further 
0X34. In contrast LNCs from a rat treated with lower doses of 0X34 (2.5 and 5 
mg/kg) show increased labelling with 0X34 after in vitro culture with 0X34, 
suggesting that the lower dose did not lead to saturation of all 0X34 binding sites 
(figure 5.9). Therefore a small number of unbound CD2 molecules appears sufficient 
to initiate acute allograft rejection.
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5.6.6 Effect of anti-CD2 monoclonal antibody on CD2 expression
The level of CD2 antigen expression shown in figure 5.23 on cells from an 
0X34 treated rat is lower than that of a naive animal (mean channel fluoresence of 
0X34 labelling is 8.94 and 4.28 on LNCs of naive and OX34-treated rats 
respectively), demonstrating that labelling of CD2 molecules with 0X34 in vivo 
leads to down-regulation (modulation) of the CD2 molecule on undepleted cells. In a 
similar manner the ability of 0X55 to cause antigen modulation was assessed. Six 
rats were treated with 0X55 (2xl0mg/kg) and LNCs and PBLs harvested after 24 
hours. These cells were labelled with FITC-conjugated rabbit anti-mouse Ig either 
with or without prior incubation with 0X55 in vitro to assess saturation of CD2 
molecules with 0X55 mAb in addition to antigenic modulation. A very different 
pattern of modulation is seen with 0X55 compared to 0X34 (figure 5.24). 
Incomplete saturation of CD2 molecules is obtained at this dose of 0X55. This 
finding is inconsistent, with two of the six rats showing complete saturation of CD2 
molecules, however 0X34 at a similar dose uniformly saturates CD2 molecules at 
this time point. Secondly intravenous 0X55 induces a greater degree of antigenic 
modulation than 0X34.
5.6.7 CD2 modulation induced by in vitro culture with monoclonal 
antibody
In order to investigate the modulation of the CD2 molecule in the absence of 
cellular depletion PBLs and LNCs were taken from a rat and the T cell fraction 
purified as described in materials and methods. Purified T cells were then suspended 
in culture medium at 37°C for 18 hours with mAb at 20jug/ml. Labelling with 0X34 
was then detected in a similar manner using FITC conjugated rabbit anti-mouse 
antibody. 0X34 caused a more profound modulation of the CD2 molecule in vitro
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w ith  little labelling w ith m ouse antibody detectable after 18 hours incubation (figure 
5.23).
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Figure 5.23 0X34 mAb-mediated modulation of the CD2 
molecule
LNCs were prepared from a naive DA rat (top), a sim ilar rat 24 
hours after intravenous injection o f  0 X 3 4  (lO m g/kg) (m iddle) 
and LNCs from a naive rat were incubated with 0 X 3 4  (20jul) in 
vitro for 18 hours at 37°C (bottom ). N aive cells were incubated 
with 0 X 3 4  to establish normal CD2 expression; all cells were 
then labelled with FITC-conjugated rabbit anti-m ouse antibody.
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Figure 5.24 Expression of the CD2 molecule after 
intravenous therapy with 0X55
LNCs were prepared from  a naive DA rat (top) and a sim ilar rat 
24 hours after intravenous injection o f  0 X 5 5  (20m g/kg) 
(bottom ). Cells w ere labelled  directly with FITC-conjugated 
rabbit anti-m ouse antibody (solid line) or with 0 X 5 5  follow ed 
by FITC-conjugated rabbit anti-m ouse antibody (dotted  line).
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5.7 Effect on lymphocyte populations of combined 0X34
and 0X 38 monoclonal antibody therapy
The combination of 0X34 (2x5mg/kg) and 0X38 (16mg/kg) has been shown 
to be more effective in prolonging allograft survival in the high responder DA to 
Lewis strain combination compared to either monoclonal antibody alone. The above 
evidence shows that both monoclonal antibodies cause T cell depletion, particularly 
of the CD4 subset. We therefore wished to examine the effect of combining both 
antibodies on lymphocyte subsets and in particular to assess the time course of CD4 
and CD8 T cell depletion. A combination of the minimal dose allowing tolerance 
induction in the Lewis-DA combination (0X38 10,2,2,2 mg/kg and 0X34 
2x5mg/kg) produces permanent engraftment in 50% of transplants in the DA to 
Lewis combination. Five animals treated in this way were tail-bled at set time points 
and PBLs were separated for analysis. B cells and CD4 and CD8 T cell subsets were 
identified as described in materials and methods. As can be seen in figure 5.25 the 
antibody combination causes a profound, progressive depletion of T cells, 
particularly the CD4 subset, which reaches a maximum at 14 days. As noted before 
the frequency of CD8 cells initially shows a slight relative increase presumably due 
to more rapid CD4 T cell depletion. Subsequently however the CD8 T cell frequency 
declines, an effect not noted with either modality used as monotherapy. There is an 
initial relative preponderance of B cells to T cells, however the B cell element then 
returns toward a more normal fraction of the lymphocyte population despite 
continued T cell depletion. The remainder of the circulating lymphocyte population 
is then composed of the TCR-ve/CD4-low cell discussed below.
Figure 5.25 Lymphocyte depletion in Lewis rats treated with 
0X34 and 0X38
PBLs were prepared from Lewis rats (n=5) treated with 0 X 3 4  
(2x5m g/kg) and 0 X 3 8  (10,2,2,2m g/kg) and specific subset 
frquencies determ ined by labelling w ith fluorochrom e- 
conjugated 0 X 1 2 , W 3/25 and 0 X 8  (figures denote day post- 
injection).
W hen com pared to the depletion caused by either m onoclonal antibody used 
alone in Lewis rats the antibody com bination induces greater depletion o f  CD4 T 
cells and also appears to cause depletion o f  the CD8 subset. The depletion o f  T cell 
subsets in Lewis rats caused by 0 X 3 4  (2x5m g/kg) and 0 X 3 8  (10,2,2,2m g/kg) 
individually has been described above. Figures 5.26 to 5.28 com pare the depletion o f  
T cell subsets caused by these two regim es in Lewis rats w hen used separately or in 
com bination at days 7 and 14 after intravenous injection in untransplanted rats.
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Figure 5.26 T cell depletion in Lewis rats treated with 0X38, 
0X34 or both modalities
PBLs were prepared from Lewis rats treated with 0 X 3 8  
(10,2,2,2m g/kg), 0 X 3 4  (2x5m g/kg) or both m odalities 
com bined and the T cell frequency determ ined by labelling w ith 
R73-FITC. Day 0 control represents R73 labelling o f  a large 
num ber o f  historical controls.
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Figure 5.27 CD4 T cell depletion in Lewis rats treated with 
0X38, 0X34 or both modalities
PBLs were prepared from Lewis rats treated w ith 0 X 3 8  
(10,2,2,2m g/kg), 0 X 3 4  (2x5m g/kg) or both m odalities 
com bined and the CD 4 T cell frequency determ ined by labelling 
with W 3/25-PE. Day 0 control represents R73 labelling o f  a 
large num ber o f  historical controls.
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Figure 5.28 CD8 T cell population in Lewis rats treated with 
0X38, 0X34 or both modalities
PBLs were prepared from Lewis rats treated with 0 X 3 8  
(10,2,2,2m g/kg), 0 X 3 4  (2x5m g/kg) or both m odalities 
com bined and the CD8 T cell frequency determ ined by labelling 
w ith 0X 8-PE . Day 0 control represents R73 labelling o f  a large 
num ber o f historical controls.
The com bination o f  0 X 3 4  and 0 X 3 8  therefore causes a profound degree o f 
CD4 T cell depletion and also depletes CD8 T cells, an unexpected finding in view 
o f  the inability' o f  0 X 3 4  m onotherapy to deplete CD8 T cells. The degree o f 
depletion caused by the com bination o f  0 X 3 8  and 0 X 3 4  (R73 +ve T cells are 
reduced to <10%  o f  circulating m ononuclear cells by day 14) is m atched by a 
relative proliferation o f  o ther cellu lar elem ents. In contrast to DA strain rats or Lewis 
rats treated  with either m odality alone B-lym phocytes do not predom inate in the 
rem aining lym phocyte population. A population o f  cells is detectable in large 
num bers (approxim ately 40%  o f  circulating m ononuclear cells) during the period o f 
T cell depletion, presum ed to be m onocytes, which is ap T C R -, CD 4+ (low  level) 
and expresses im m unoglobulin K-light chain at lower levels than B-lym phocytes and 
is not labelled by 0 X 3 4  (figure 5.29). This population o f  cells is detectable in both 
DA and Lewis strain rats treated  with 0 X 3 4  and 0 X 3 8  m onotherapy but is present in
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relatively few er num bers (10-15% ) than in Lewis rats treated  both m odalities, 
possibly due to the m ore m arked T cell depletion.
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Figure 5.29 Proportion of monocytes in Lewis rats treated 
with 0X34 and 0X38
Circulating cells were prepared from Lewis rats 14 days after 
therapy with 0 X 3 4  (2x5m g/kg) and 0 X 3 8  (10,2,2,2mg/kg).
Cells were labelled with a) directly-conjugated R73-FITC and 
W 3/25-PE or b) directly-conjugated OX12-FITC (group 
H -35 .2% , group G=42.2% ).
5.7.1 Modulation of leukocyte antigens in Lewis rats by combined 
0X34 and 0X38 monoclonal antibody therapy
It has been noted that both 0 X 3 4  and 0X 5 5  are capable o f  causing m odulation 
o f  their respective cellular ligands, and other experim ents (not shown) indicate that 
0 X 3 8  is also capable o f  inducing m odulation o f  the CD 4 m olecule. Com bining the 
two treatm ents allow s com parison o f  the degree and tim e course o f  antigen 
m odulation and re-expression caused by these two antibodies. PBLs were prepared at 
days 7 and 14 from -tail bled rats treated with both 0 X 3 8  (10,2,2,2m g/kg) and 0 X 3 4  
(2x5mg/kg) and from naive Lewis rats. Cells were then incubated in vitro w ith PBS,
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0 X 3 8  or 0 X 3 4  at saturating concentrations. Labelling with m ouse antibody was then 
detected w ith F1TC conjugated rabbit anti-m ouse antibody (figure 5.30). The 
labelling o f  cells incubated w ith PBS and rabbit anti-m ouse in vitro represents both 
0 X 3 8  and 0 X 3 4  bound to cells after intravenous injection.
% of cells labelling with 
anti-mouse fluorescent 
antibody
peak channel 
fluoresence of labelled 
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Figure 5.30 Differential re-expression of CD2 and CD4 after 
dual therapy with 0X34 and 0X38 in Lewis rats
PBLs were prepared from Lewis rats 7 days after injection with 
both 0 X 3 4  (2x5m g/kg) and 0 X 3 8  (10,2,2,2m g/kg). Cells were 
incubated with either 0 X 3 4  or 0 X 3 8  prior to secondary 
labelling with FITC -conjugated rabbit anti-m ouse antibody.
As can be seen from figure 5.30 reincubating PBLs from a treated anim al at 
day 7 with 0 X 3 4  did not increase labelling with rabbit anti-m ouse F1TC, suggesting 
that CD2 m olecules are still saturated with 0 X 3 4  at this point. In contrast re- 
m cubating with 0 X 3 8  m arkedly increased the percentage o f  cells labelled with rabbit 
anti-m ouse to approxim ately 45%. C learly by day 7 CD4 m olecules are no longer 
saturated with 0 X 3 8  mAb. The com bination o f  m onoclonal antibodies therefore 
appears to cause saturation and m odulation o f  CD2 and CD4 m olecules, w ith the 
CD4 m olecule being re-expressed by day 7 whilst CD2 is still saturated and 
m odulated, and rem ains so at day 14. Curiously despite the increased proportion o f 
PBLs taken at day 7 from a treated  Lewis rat labelling with 0 X 3 8  the m ean peak 
channel fluorescence rem ains low  after re-incubation w ith 0 X 3 8  and rabbit anti­
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mouse FITC (1.9) compared to the mean peak channel fluorescence of naive PBLs 
incubated with 0X38 and rabbit anti-mouse FITC (9.34), suggesting that this cell 
population expresses CD4 at a low level. The large number of cells labelled with 
0X38 (45%) at a time point when T cells are still profoundly depleted (<10%) 
suggests that this increased labelling on in vitro culturing with 0X38 may be due to 
the TCR-ve, CD4-low cell (monocytes) described above.
5.8 Effect on lymphocyte populations of combined CTLAJ g  
and 0X 34 monoclonal antibody therapy
This combination of treatment modalities was also effective in inducing 
permanent allograft survival in the high responder DA to Lewis strain combination.
In a similar manner to above the depleting effect of this treatment regime was 
assessed. Six Lewis rats receiving DA transplants were treated intravenously with 
0X34 (2xl0mg/kg) pre-operatively and CTLAJg (2.5mg/kg) two days post- 
operatively. Animals were tail-bled at set time points and lymphocyte subsets 
assayed in the standard manner. Of this cohort of six rats five permanently accepted 
their allografts whilst one rat rejected its graft at day 13. An analysis of total 
circulating leukocyte count reveals that permanent engraftment is associated with 
prolonged leukocyte depletion whereas graft rejection is associated with leukocyte 
proliferation (figure 5.31).
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Figure 5.31 Total circulating leukocyte count in Lewis rats 
treated with 0X34 and CTLA4Ig.
W hole blood was rem oved from transplanted Lewis rats after 
therapy with 0 X 3 4  (2x l0m g/kg) and CTLA4Ig (2.5mg/kg). 
Total leukocyte count was determ ined by labelling w ith Turks 
solution.
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Figure 5.32 Lymphocyte subset frequencies in transplanted 
Lewis rats (n=5) treated with 0X34 and CTLA4Ig
Lym phocyte subset frequencies were determ ined in PBLs o f  
transplanted Lewis rats (n=5) treated with 0 X 3 4  (2x l0m g/kg) 
and CTLA4Ig (2.5m g/kg) at various tim e points after therapy. 
Frequencies were determ ined by labelling w ith directly 
conjugated W 3/25, OX8 and 0X 12 .
An analysis o f  lym phocyte subsets in rats that accepted their allografts shows 
that in a sim ilar m anner to the other regim es explored above the com bination o f
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0X34 (2xl0mg/kg) and CTLA4g (2.5mg/kg) causes a predominant depletion of 
CD4 T cells and a relative dominance of the B cell subset (figure 5.31).
5.8.1 Comparative CD4 T cell depletion in Lewis rats after 0X34- 
based regimes
It is notable in these experiments that CD4 T cells are profoundly depleted 
(<5% of circulating lymphocytes), to a greater degree than obtained by 0X34 as 
monotherapy. This greater depletion may be accounted for by the higher dose of 
0X34 used (2xl0mg/kg compared to 2x5mg/kg). This is unlikely however because 
as demonstrated above intravenous 0X34 at a dose of 2x5mg/kg induces ligand 
saturation with unbound monoclonal antibody still circulating in the serum at day 
seven. The increased depletion must therefore be a consequence of CTLA4g therapy, 
although levels are not as low as those obtained by combining 0X34 with 0X38. 
Depletion also appears to be more long lasting with the 0X34 and CTLAJg 
combination, which may be a consequence of abrogation of the anti-globulin 
response as outlined in Section 5.5.4.
Day post­
injection
0X34 
(2x5mg/kg) n=3
OX34(2x5mg/kg)+ 
0X38(10,2,2,2mg/kg) 
n=5
0X34(2x1 Omg/kg)+ 
CTLA4Ig(2.5mg/kg) 
n=5
1 2.15(0.5)
7 8.2 (5.37) 1.34 (0.42)
14 7.6 (4.67) 1.02 (0.33)
21 10.33 (4.3) 2.9(1.11)
40 26.23 (2.85) 2.38 (0.77)
65 21.36 (2.70)
Table 5.8 Comparison of CD4 T cell depletion by 0X34- 
based regimes
Residual percentage of CD4 T cells in Lewis rats after treatment 
with monoclonal antibody regimes (SD).
In this treatment regime the CD2 molecule remains partially modulated from 
the cell surface for the duration of cellular labelling with 0X34 (>40 days), in a
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similar manner to that seen when 0X34 is used as monotherapy or in combination 
with 0X38.
5.9 Conclusions and discussion of results
5.9.1 CD2 antigen expression in lymphocyte subsets
Figure 5.1 demonstrates the extent of CD2 labelling by 0X34 on cells from 
lymphoid organs. 0X34 labels LNCs and PBLs to a similar degree (there is 
consistently a marginally greater proportion of CD2+ cells in peripheral blood than 
lymph nodes). CD2 is expressed on a lower number of splenocytes due to the 
spleen’s relatively greater number of B cells. Thymocytes are shown universally to 
express CD2. The broad peak of 0X34 labelling by these cells reflects the increased 
expression of CD2 with advancing maturity of thymocytes. Figure 5.3 confirms that 
0X34 and 0X12 mAb label mutually exclusive subsets of lymphocytes. The 
possible exception to this is the small ‘tail’ of the lymphocyte cluster amongst 
splenocytes which is 0X34+ and OX 12+. These cells may represent monocytes, 
which express CD2 at a low level in addition to immunoglobulin light-chain (143). 
Figure 5.2 shows that CD2 is expressed on all ap  TCR+ lymphocytes (labelled with 
R73). There is also a small cluster of CD2+ cells (highest in the spleen) which are ap  
TCR-. This population represents either NK cells, y8 T cells or a combination of the 
two types. Human (131) and mouse NK (154) cells are known to express the CD2 
molecule, whereas work in the rat has only identified CD2 on leukaemic cell lines 
with NK-like activity (171). Whilst murine yST cells express CD2 (349), no data is 
available regarding CD2 expression on y5T cells in the rat. Amongst T cells CD2 is 
expressed equally by CD4+ and CD8+ cells (figure 5.4). This finding is important in
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view of the preferential depletion of CD4 T cells by 0X34, which cannot therefore 
be explained in terms of lower labelling of CD8+ cells by 0X34. Figure 5.5 
demonstrates that peritoneal macrophages are labelled with 0X34 to a lesser degree 
than T lymphocytes, which may represent non-specific labelling by Fc receptors.
5.9.2 B7 antigen expression on activated, but not tolerant B cells
Figure 5.6 shows that, as expected, resting lymphocytes are not labelled with 
CTLAjIg. Similarly labelling of B7 is not detected in a rat undergoing acute allograft 
rejection at day 7, but is detectable by day 50 in a cohort of rats with late rejection of 
their allografts after therapy with 0X34 and CTLAjIg. This late expression is not in 
keeping with the reported upregulation of B7 48 hours after alloactivation as 
discussed in the introduction (102). Cells were not tested for B7 expression at other 
time points during the rejection response so the normal pattern of B7 expression by B 
cells has not been defined. However at the time points tested (days 21,40 and 150) 
no upregulation of B7 is noted in Lewis animals with surviving grafts after therapy 
with 0X34 and CTLAjIg or in tolerant Lewis rats after therapy with 0X34 and 
0X38 (figure 5.7). Whilst this cannot be interpreted as a mechanism of tolerance in 
these animals as the full details of B7 expression have not been defined in this 
project the failure of upregulation of B7 on tolerant cells of transplanted animals is 
consistent with their failure of IL2 secretion on in vitro restimulation in the MLR.
5.9.3 Distribution of 0X 34 monoclonal antibody after intravenous 
administration
This section describes the pharmacokinetics of 0X34 after intravenous 
administration and compares the mechanisms of elimination of mAb in DA and
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Lewis strain rats. The kinetics of elimination of 0X34 are also examined in Lewis 
rats treated with combination therapy.
Figure 5.8 shows that 0X34 administered at 2x5mg/kg (the minimal dose that 
induces permanent allograft survival in DA strain rats) saturates all CD2 ligands on 
LNCs. Similar saturation of 0X34 binding sites was obtained with splenocytes and 
PBLs. Thymocytes however are labelled at a lower level after 0X34 therapy at this 
dose. This suggests the presence of a blood-thymus barrier to the passage of 0X34 
after intravenous administration, which either prevents or delays the passage of 
0X34 molecules. Figure 5.9 shows that lower doses of 0X34 (2.5 and 5mg/kg) that 
fails to induce permanent allograft survival in DA strain rats also fails to saturate all 
CD2 molecules. Evidence is demonstrated in Section 5.6.1.4 that anti-CD2 mAb 
therapy-mediated T cell depletion at early time points after administration is not dose 
dependent. It is possible therefore that incomplete saturation of CD2 molecules after 
sub-optimal therapy with 0X34 is sufficient to allow depletion of some labelled 
cells, whilst the remaining unbound CD2 molecules on undepleted T cells retain the 
functional capability to initiate graft rejection in these animals.
5.9.4 Elimination of mAb in high and low responder strain rats.
These experiments explored two hypotheses:
1) That the increased efficacy in transplant experiments of both 0X34 and 
0X38 in DA compared to Lewis rats is related to a more prolonged 
duration of action of both mAb in the DA strain.
2) That 0X34 mAb has a longer duration of action than 0X38 after in 
vivo therapy in both strains.
Table 5.1 provides evidence in favour of both of these hypotheses. Both 0X34 
and 0X38 are eliminated more quickly by Lewis than DA strain rats, and this
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elimination is associated with the generation of an anti-globulin reaction in Lewis 
rats (demonstrated in figure 5.11). It is notable however that both 0X34 and 0X38 
are eliminated from the serum of Lewis rats before the antiglobulin response is 
detectable. This does not preclude the involvement of neutralising anti-mouse 
antibody in these rats however, as the initial antibody produced will be bound to 
0X34 or 0X38 in rat serum and therefore not detectable in this assay. An 
antiglobulin response was not detectable in OX34-treated DA rats despite the 
preponderance of the B cell fraction noted in Section 5.6.1.3 (figure 5.10). Both IgG 
and IgM were tested for in these experiments (except at day 21, when IgM was not 
tested for due to unavailability of the conjugated antibody). No TgM production was 
detected by either rat strain. The inability of DA strain rats to generate an anti­
globulin response is interesting in view of their ability to eliminate both mAb tested 
in these experiments. The half-life of native IgG is in the region of 20 days; DA rats 
have completely eliminated both 0X34 and 0X38 from the circulation 21 days after 
their administration. This suggests that DA strain rats have an alternative means of 
eliminating foreign mAb; this may involve modulation and internalisation of the 
mAb by T cells or may be an Fc-mediated effect of macrophages, as we have 
demonstrated the ability of rat Fc receptors to recognise mouse Fc (although the 
different rates of elimination of 0X34 and 0X38 argue against this). In these 
experiments all mAb are eliminated from the circulation more rapidly than from the 
cell surface. This is to be expected, as mAb remaining in the circulation would be 
able to label CD2 molecules re-expressed on the cell surface after modulation.
Also noted in these experiments is that 0X38 is eliminated more rapidly than 
0X34 by both Lewis and DA strains. Both mAb were administered at the optimum 
dose used in transplant experiments (0X34, lOmg/kg; 0 X 3 8 ,16mg/kg) and the time 
taken for their elimination is the reverse of the dose used. In Lewis rats the
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elimination of mAb is associated with the earlier production of anti-OX38 IgG (day 
14) than anti-OX34 IgG (day 21). These findings raise two further questions:
1) Is 0X38 more immunogenic than 0X34, despite sharing the same 
isotype?
2) How is 0X38 eliminated more rapidly than 0X34 in DA rats (in which 
an anti-globulin response is not detectable)?
Evidence presented in Section 5.7 shows that circulating monocytes are 
labelled by 0X38 but not 0X34, despite the ability of peritoneal macrophages to 
label with 0X34. It is therefore possible that 0X38 is bound by macrophages leading 
to preferential processing and facilitation of a B cell response. In support of this 
hypothesis is the marked proliferation of monocytes noted in Lewis rats treated with 
0X34 and 0X38, in which 0X38, but not 0X34, is eliminated rapidly from the cell 
surface. Both mAb are of IgG2a isotype, so are likely to be processed by 
macrophages at a similar rate by Fc-mediated mechanisms. Another explanation is 
that 0X34 induces a greater suppression of CD4-derived T cell help required for an 
active immune response by more profound CD4 T cell depletion. The different rate 
of elimination of the two mAb by DA strain rats however cannot be explained in 
terms of anti-globulin. In these animals therefore 0X34 must persist longer than 
0X38 due to a greater suppression of CD4 T cell-derived help by 0X34 for an active 
immunological process which does not involve antibody.
5.9.5 Elimination of mAb in high responder strain rats treated with 
0X 34 and CTLAJ g
Table 5.1 shows that Lewis rats injected with 0X34 normally develop an anti­
globulin response to mouse protein. Coadministration of CTLAdg to these animals 
prevents the development of either an IgM or IgG response to the antibody, and leads
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to its prolonged circulation (table 5.3). In this cohort of six rats, five failed to 
generate anti-globulin, had persistent circulation of 0X34 mAb and cellular 
depletion and went on to permanent graft survival. These rats were able to eliminate 
0X34 by means other than the production of anti-globulin, although this elimination 
was delayed to between 40 and 65 days. As other experiments have shown that 
CTLAdg does not cause depletion of T cells (Section 5.6.4), this prolonged depletion 
must be due to the persistence of 0X34 in the circulation. It is interesting that 
elimination of 0X34 by Lewis rats treated in this way takes longer than in DA rats 
treated with 0X34 alone, in both of which groups 0X34 is cleared without anti­
globulin. This adds weight to the theory that an alternative active process is 
responsible for clearing antibody in these animals, which is also sensitive to the 
immunosuppressive effects of 0X34 and CTLAJg.
The abrogation of the antiglobulin response to mouse mAb by CTLAJg is in 
keeping with the reported dependence of T cell-B cell interactions on functional 
CD28-B7 costimulation. The importance of CD28 costimulation in IL4 secretion 
(122-124) and the ability of blockade of CD28 by CTLAdg to prevent IL4 release 
and antibody production (116, 127, 129) has been discussed at length in the 
introduction.
5.9.6 Monoclonal antibody mediated cellular depletion
The following sections discuss in detail the effects on lymphocyte populations 
of intravenous administration of the anti-CD2 mAb 0X34 and 0X55, the anti-CD4 
mAb 0X38 and CTLAdg and compare these effects in DA and Lewis strain rats.
A notable effect of mAb treatment is depletion of T cells from all lymphocyte 
compartments. Figure 5.13 shows that the frequency of T cells amongst LNCs and 
PBLs of DA rats falls from approximately 70% to a minimum of 24% after 7 days. A
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similar degree of depletion is noted in splenocytes, but depletion was not assessed in 
the thymus. The larger part of the cellular depletion appears to occur within the first 
24 hours of administration; there is also however a progressive loss of T cells over 
the next seven days in these experiments. Experiments described in figures 5.19 and
5.20 using measurement of the total circulating leukocyte count confirms that 
depletion of leukocytes in the circulation begins within the first four hours after 
administration of antibody. The finding that there is a progressive loss of T cells after 
an initial sharp fall is difficult to explain. During the period of progressive 
lymphocyte loss there is excess mAb in the circulation and complete saturation of 
CD2 molecules on circulating lymphocytes. The late depletion of a small number of 
T cells may therefore be due to an intrinsic resistance to depletion by these cells.
This is in keeping with the finding that in all of our experiments using mAb alone 
and in combination total depletion of target cells is never achieved. There must 
therefore be a small subset of cells that is resistant to depletion, although this 
resistance can be overcome with continued exposure. The presence of an anti-CD4 
mAb resistant CD4 T cell population has been recorded previously (260, 350). An 
alternative explanation for the progressive loss of T cells during a period of mAb 
excess is that the process of cellular depletion requires engagement of the mouse 
mAb with host Fc receptors, and these Fc receptors are initially saturated so that 
further depletion requires expression of further Fc receptors. Indeed evidence is 
presented in this thesis that a host Fc-mediated mechanism is involved in an 
interaction with 0X34 to deliver a negative signal to CD4 T cells in in vitro 
experiments.
The recovery of the T cell population after mAb-mediated depletion appears to 
be slow, in that 100 days after administration of 0X34 to DA rats T cells are still 
depleted despite the elimination of circulating mAb by day 21. In the introduction to
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this thesis evidence has been presented that in rodents lymphopoiesis is driven 
mainly by the thymus, rather than by expansion of peripheral cells (210). A possible 
explanation for prolonged depletion therefore is that, despite the presence of the 
blood-thymus barrier described above (which provides an incomplete barrier to the 
passage of antibody), mAb are able to persist for longer within the thymus and able 
to exert a more long lasting effect.
The reduction in the T cell fraction is matched by a relative preponderance of B 
cells shown in figure 5.15. The B cell fraction may have increased because of either:
1) A simple reduction in the T cell number, so that B cells form a larger 
percentage of the remaining cells
2) A combination of reduction in the T cell number with proliferation of B 
cells.
Figures 5.19 and 5.20 describe the findings of experiments where the total 
circulating leukocyte count in rats treated with 0X34 and 0X38 was compared to the 
subset frequencies measured by flow cytometry. The dramatic fall in the T cell 
number is accompanied by a smaller fall in circulating leukocyte count, suggesting 
that other components of the leukocyte series are proliferating as T cells are depleted. 
In addition figure 5.15 shows that the non-B, non-T cell fraction remains constant 
after 0X34 therapy, so that the larger fraction of B cells is unlikely to be explained 
by a simple reduction in the number of T cells. However it is not possible to 
conclude categorically that the B cell fraction proliferates after 0X34 therapy as 
absolute numbers of lymphocyte subsets have not been measured.
5.9.7 Differential depletion of T cell subsets by anti-CD2 mAb
In Section 5.3 it was demonstrated that the CD2 molecule is expressed equally 
on CD4 and CD8 T cells. If depletion of 0X34 labelled cells is exclusively an Fc-
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mediated phenomenon then depletion of these two subsets of cells could be expected 
to be equal. However figure 5.14 demonstrates that 0X34 preferentially depletes the 
CD4 subset, so that after therapy there are fewer CD4 than CD8 T cells. In a DA rat 
treated with 0X34 the frequency of CD4 T cells falls from 54% and 53% to 14% and 
5% in LNCs and PBLs respectively 12 days after administration. During the same 
period the frequency of CD8 cells changes from 14% and 16% in a naive animal to 
15% and 12% in a treated animal in the same compartments. The CD8 compartment 
therefore appears to remain largely unchanged by 0X34 therapy. However because 
of the fall in numbers of CD4 T cells it is impossible from this data to conclude that 
0X34 has no effect on CD8 T cells, but its effect is far less than on CD4 T cells. 
Factors within the CD2-expressing cell therefore appear to be crucial in the 
mechanism of mAb-mediated depletion.
In contrast to this figure 5.14 provides evidence that factors outside the cell 
also influence mAb-mediated depletion. Figure 5.13 shows a similar level of total T 
cell depletion in lymph nodes and peripheral blood whilst figure 5.11 shows that the 
preferential depletion of CD4 T cells is more marked amongst PBLs (the CD4: CD8 
ratio falls from 3.5 to 0.9 and 0.4 in LNCs and PBLs respectively). As we have 
demonstrated that LNCs are saturated with mAb 24 hours after administration of 
intravenous 0X34, this disparity in depleting effect cannot be explained by the 
greater access of PBLs to mAb in the serum. Furthermore lymphocytes continually 
circulate between different lymphocyte compartments, so that a dynamic equilibrium 
is established between CD4 and CD8 T cells moving freely between compartments 
and the continued depletion of T cell subsets at different rates within those two 
compartments. The difference in degree of CD4 depletion between the two 
compartments may therefore be due to the greater access of circulating PBLs to 
effector mechanisms (for example in the spleen or liver). This finding provides
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evidence that factors outside the cell are also important in the mechanism of T cell 
depletion. A possible resolution of the apparently conflicting evidence of these two 
graphs is that T cells are depleted by Fc-mediated mechanisms that are specific for 
the CD4 T cell.
5.9.8 Dose effect in mAb-mediated depletion
Figure 5.16 demonstrates that over the dose range tested relative depletion of 
lymphocyte subsets is equal after 24 hours. The lower doses tested (2.5 and 5mg/kg) 
fail to saturate all CD2 binding sites and also do not lead to permanent allograft 
survival when given to transplanted rats. A number of conclusions can be drawn 
from this:
1) Saturation of all binding sites is not necessary for mAb-mediated depletion
2) The initial level of cellular depletion is not a crucial determinant of long-term 
allograft survival.
Whilst the initial level of cellular depletion may not be a determinant of 
prolonged graft survival it remains plausible that the duration of depletion is 
important. The evidence of prolonged depletion caused by mAb combinations 
supports this theory. According to this model of tolerance induction therefore the size 
of the initial dose is important not for its initial effect on lymphocyte numbers but 
because it allows longer circulation of mAb and longer cellular depletion. This then 
allows the development of a tolerant regime in the rat, and the period of cellular 
depletion required for tolerance induction is longer in Lewis than DA strain rats.
5.9.9 Comparison of depleting effects of 0X 34 and 0X 55
Evidence has been presented that 0X55 produces a similar total level of T cell 
depletion as 0X34. In the data shown in figure 5.18 total T cell count falls from
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approximately 70% of PBLs in a naive animal to 39% 24 hours after administration 
of 0X34. In a similar time span in animals treated with 0X55 the total T cell count 
falls to 34%. Despite this similarity in total depletion 0X55 does not preferentially 
deplete CD4 T cells in the same manner as 0X34 (the CD4.CD8 ratio in 0X55 
treated rats is 3.25, similar to that of a naive animal). There is therefore much 
stronger evidence that 0X55 is able to deplete CD8 T cells than 0X34 (the 
frequency of CD8 T cells falls from 16% to 8% in 0X55 treated rats). The difference 
in effect between 0X34 and 0X55 may be explained by the following possibilities:
1) The different isotypes of the two mAb may direct different effector 
functions in lymphocyte depletion
2) The different epitopes on the CD2 molecule bound by the mAb may 
dictate the response of the lymphocyte to mAb binding (0X34 labels the 
CD48-binding domain of CD2 whereas 0X55 labels an epitope at the base 
of domain 1 (135))
3) Differences in binding kinetics of the two mAb may lead to a different 
response to binding by the lymphocyte as it has been shown that 10-fold 
higher concentrations of 0X55 than 0X34 are required to saturate CD2- 
binding sites, suggesting that 0X55 has lower affinity for the CD2 
molecule (298).
No evidence is presented in this thesis in support of any mechanism to 
distinguish between the depleting effects of 0X34 and 0X55. However there is a 
common thread of indirect evidence in all the data presented in this thesis that an Fc- 
mediated dominant negative signal is involved in the effect of 0X34, and the 
gateway of this signal appears to be the ligand-binding domain of the CD2 molecule 
expressed on a CD4 T cell.
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5.9.10 Comparison of the depleting effects of 0X34 and 0X 38 in DA
and Lewis rats
The potent effect of 0X34 in depleting CD4 T cells is seen when its effect is 
compared directly with the depleting anti-CD4 mAb 0X38. Figures 5.21 and 5.22 
show that in both Lewis and DA strain rats 0X34 produces a greater degree of 
depletion than 0X38. In addition the trend is for both mAb to produce greater 
depletion in DA than Lewis strain rats, although the difference is small and does not 
reach statistical significance. It is unlikely therefore that a difference in mAb- 
mediated depletion is sufficient explanation for the difference in allograft survival in 
the two strains.
5.9.11 Assessment of the depleting effect of CTLA J g
In comparison to the gross effects that anti-CD2 and anti-CD4 mAb have on 
lymphocyte populations CTLAJg has no detectable impact in these assays. This is to 
be expected as earlier studies have shown only low-level labelling of activated B 
cells by CTLAJg, so lymphocyte depletion will not occur in a naive rat. Table 5.7 
shows that the B cell fraction is unaltered by CTLAdg therapy. The possibility 
remains however that activated B cells or APC are adversely affected by labelling 
with CTLATg, although this phenomenon has not been explored in this thesis.
5.9.12 The effect of anti-CD2 mAb on NK cells
The effect of 0X34 therapy on NK cell numbers and function in these 
experiments can only be inferred indirectly due to the absence of a specific NK cell 
marker in the rat. The size of the NK cell subset can be estimated by measuring the 
non-B, non-T cell fraction, which contains both NK cells and y8T cells. In a naive rat
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this subset forms approximately 10% of PBLs (R73-/OX12- cells, see figure 5.15) 
and also forms a distinct subset demonstrable by flow cytometry as the cluster of 
cells which is 0X34+ but R73-. In the FACS image displayed in Section 5.3 the 
number of cells labelled with 0X34 after in vitro culture is therefore 5% greater than 
the total number of apT  cells labelled with R73. Four findings are described in the 
text from which the fate of NK cells and y8T cells after 0X34 therapy can be 
deduced:
1) The size of the non-B, non-T cell compartment remains constant despite 
0X34 therapy (figure 5.15)
2) The total number of residual cells after 0X34 therapy which are labelled 
with 0X34 equals the number of cells labelled with R73 (Table 5.4)
3) There is no reduction in NK cell activity after 0X34 therapy (figure 5.17)
4) There is a small population of cells in a naive rat which is 0X34+ but 
R73- (figure 5.2).
These findings lead directly to a number of conclusions:
1) The total number of NK cells plus y8T cells remains approximately 
constant,
2) In an OX34-treated animal the only cells that remain labelled with 0X34 
are apT  cells (ie any other cellular compartment which expresses CD2 
must either be completely depleted by 0X34 therapy or not label with 
0X34),
3) NK cells are not functionally depleted.
The only explanation that accounts for this series of findings is that NK cells 
are not labelled by 0X34 and therefore remain undepleted and that y8T cells are 
completely depleted by 0X34 therapy and are therefore not detectable. The evidence 
that rat NK cells express the CD2 molecule is based on assays of leukaemic cell
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cultures (171), these findings suggest however that rat NK cells are not labelled with 
0X34.
5.9.13 Anti-CD2 monoclonal antibody mediated ligand saturation
The data in this section demonstrate that 0X34 administered at a dose which 
induces permanent allograft survival in DA rats also saturates CD2 ligands 
immediately after intravenous injection. In contrast a lower dose (2.5mg/kg) which 
does not prevent acute allograft rejection also fails to saturate all 0X34 binding sites 
after intravenous injection. This therefore leaves unbound CD2 molecules which 
appear to retain the functional capability to participate in the generation of the 
allograft response. This is an important finding in view of the equal levels of T cell 
depletion obtained by high and low dose 0X34 therapy, and suggests two distinct 
roles for the CD2 molecule. Evidence has been presented that the CD2 molecule can 
provide a pathway for delivery of a ‘negative signal’ to CD4 T cells resulting in cell 
depletion. The findings reported in this section show that undepleted T cells after 
0X34 therapy are unable to generate a rejection response if their CD2 molecules 
remain saturated with 0X34 whereas a similar number of undepleted T cells 
retaining unbound CD2 molecules after lower dose therapy are able to participate in 
the generation of immunological rejection. This suggests a role for the CD2 molecule 
in the allo-immune response distinct from its role as a mediator of negative signals. 
These findings demonstrate a plurality of functions for the CD2 molecule, with the 
dominant effect being determined by the conditions of ligand engagement.
The inability of 0X55 to induce saturation of CD2 molecules at the high dose 
of 2xl0mg/kg may be explained by the requirement for ten-fold greater 
concentration of 0X55 than 0X34 to induce ligand saturation (298).
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5.9.14 Effect of 0X34 monoclonal antibody on CD2 expression
The data demonstrated in figure 5.23 show that 0X34 saturation of CD2 
molecules leads to antigenic modulation of undepleted cells. This modulation of the 
CD2 molecule may explain the inability of these remaining cells to mount an 
immune response. It is noteable however that 0X55 induces almost total modulation 
of the CD2 molecule, despite being a less potent antibody in terms of cellular 
depletion and tolerance induction than 0X34 (Sido et al noted a comparable degree 
of modulation by 0X34 and 0X55, which was however more prolonged for 0X34 
(303)). This suggests that both mechanisms may be important aspects of anti-CD2 
mAb-mediated immunosuppression. We have demonstrated that cellular depletion 
alone is insufficient to prevent acute allograft rejection when a low dose of 0X34 is 
used, and evidence has been presented here that 0X55 can induce near total 
modulation of the CD2 molecule yet is an inefficient treatment in transplant models, 
inducing permanent allograft survival in only two of six transplanted rats. A 
hypothesis which encompasses both of these mechanisms is that a degree of cellular 
depletion is required to prevent allograft rejection and the undepleted cells are in 
some way disabled by saturation with anti-CD2 mAb and by modulation of the CD2 
molecule.
Figure 5.23 reveals that in contrast to expected results CD2 modulation by 
0X34 is more marked after in vitro incubation than in vivo administration. This is 
unexpected as published work has shown antigen modulation to be an Fc-mediated 
event which requires the presence of monocytes (216-218), which are abundant in in 
vivo systems, and this finding contradicts published work showing equal in vitro and 
in vivo CD2 modulation by 0X34 (303). This provides a further confounding 
observation in attempts to explain the depleting effect of mAb. We have shown that:
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1) Fc-dependent processes are probably involved in in vivo cellular 
depletion and that rat NK cells (and therefore macrophages) can 
recognise mouse Fc
2) Fc-dependent ligand modulation occurs normally in in vitro assays.
Despite these findings lymphocytes can be cultured in in vitro assays with
0X34 mAb and suffer Fc-dependent modulation of CD2 yet appear to survive and 
proliferate as normal and secrete cytokines when stimulated by mitogen. Two 
theories may be invoked to explain this paradox:
1) The unexpectedly profound degree of CD2 modulation induced by 
0X34 in in vitro cultures may ironically prevent delivery of a negative 
signal via the CD2 molecule and therefore allow survival of the cells in 
culture.
2) There may be a feature of the Fc-mediated signal which is specific to an 
intact animal to explain the apparent health of OX34-treated 
lymphocytes in culture. The crucial step may involve contact between 
antibody-coated lymphocytes and fixed-tissue macrophages in the liver 
and spleen.
Furthermore these results demonstrate that lymphocytes can be activated in 
vitro by allogeneic cells despite complete modulation of the CD2 molecule. This 
result also contradicts the in vivo finding that unbound CD2 molecules provide a 
crucial accessory function in allosensitisation to a solid organ allograft, as saturating 
doses of 0X34 prevent acute graft rejection. Allosensitisation differs in these two 
systems however as T cell numbers are greatly reduced in an OX34-treated rat.
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5.9.15 Effect of combined 0X 34 and 0X 38 therapy on lymphocyte
populations
The survival data described in Chapter 3 have shown this mAb combination to 
be very effective at inducing transplant tolerance in the high responder Lewis strain. 
Attempts were therefore made to define the effects of combined therapy on 
lymphocyte populations. The mAb combination produces a very profound degree of 
CD4 T cell depletion with the CD4 level reduced to 1% of the lymphocyte 
population by day 14. In a similar manner to 0X34 when used alone the depletion of 
CD4 cells is progressive, increasing with time. Our earlier observation that mAb- 
mediated depletion is not dose dependent suggests that the effect of combined 0X34 
and 0X38 therapy is synergistic at the level of T cell depletion. It has been shown in 
our work that 0X34 alone does not deplete all CD4 T cells and similarly reports 
using 0X38 in the rat do not achieve 100% reduction of all T cells (234). Both anti- 
CD4 (211) and anti-CD2 mAb (172,174-178) are capable of transmitting negative 
signals to T cells. Synergistic T cell lysis in this model may be explained by 
undepleted T cells becoming susceptible to cell death on receiving additional 
negative signals. The mAb combination also has unexpected effects on other 
lymphocyte subsets. The CD8 population also appears to be depleted by the mAb 
combination. This is unexpected as neither modality used alone has any detectable 
effect on CD8 cells. This effect may be spurious and reflect proliferation of other 
cellular elements within the circulation. This combination of mAb induces 
proliferation of a cellular subset not identified in large numbers in other transplant 
experiments. These cells are characterised by the low expression of CD4 and K-light 
chain typical of monocytes. The proliferation of monocytes in these animals may be 
a response to the profound CD4 T cell depletion, and their presence does not 
compromise the function of the allograft. It seems likely that the presence of these
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cells in such large numbers (40% of circulating lymphocytes) accounts for the 
apparent decline in the numbers of CD8 T cells.
5.9.16 Effect of combined QX34 and 0X 38 on lymphocyte antigen 
expression
It has been noted that 0X34 and 0X38 are able to induce saturation and 
modulation of the CD2 and CD4 molecules after intravenous administration. 
Combining the two modalities in a single animal allows comparison of the kinetics of 
modulation of both molecules. As can be seen in figure 5.30, seven days after 
administering the combined therapy, all 0X34 binding sites on OX34-treated rats 
remain saturated, and the peak channel fluorescence remains low in keeping with the 
modulation of the CD2 molecule. In contrast reincubation of these cells with 0X38 
leads to further labelling of CD4 molecules, so that 50% of the cell population are 
labelled with FITC-conjugated anti-mouse antibody, compared to <10% of cells 
taken directly from a treated animal (where T cells are depleted to <10% of 
circulating lymphocytes). Furthermore the peak channel fluorescence of these 
labelled cells is much lower than that of naive cells labelled with 0X38. These two 
findings suggest that the re-expressed 0X38 binding sites seven days after 0X38 
therapy are not on T cells, but are more likely to be on cells of the monocyte- 
macrophage series. This rapid processing of 0X38 by monocytes may account for 
the enhanced ability of Lewis rats to generate anti-globulins to 0X38 compared to 
0X34.
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5.9.17 Effect of combined 0X 34 and CTLAJg on lymphocyte
populations and antigen expression
This section describes a number of findings. Firstly the combination of mAb 
produces both more profound and more long-lasting depletion of CD4 T cells than 
0X34 when used alone. The more prolonged depletion has been accounted for by the 
abrogation of the anti-globulin response described in Section 5.5.4. More difficult to 
explain is the more profound depletion of CD4 T cells seen with this combination, as 
CTLAJg does not cause cellular depletion (see Section 5.6.4). A possible 
explanation for the synergistic depletion caused by 0X34 and 0X38 is that a 
combination of two mAb in close proximity to the T cell receptor, both of which are 
capable of causing depletion, leads to increased cell death. This phenomenon has 
been described before in the context of anti-CD4 mAb (206) and is discussed in the 
introduction. In contrast CTLAJg has been shown not to cause T cell depletion, so 
that synergistic lysis cannot be adduced as an explanation for the profound depletion 
noted. An alternative explanation is likely to involve apoptosis. As discussed in the 
introduction signalling via the CD28 molecule has been shown to be able to inhibit 
apoptosis induced by both y-irradiation (114) and anti-CD3 (115) mAb. Our work 
has demonstrated that a dominant effect of 0X34 in animal systems is a CD2- 
mediated negative signal on CD4 T cells. The enhanced effect of combining the two 
therapies may therefore be explained by CTLAJg preventing the CD28-mediated 
pathway of rescue from apoptosis induced by 0X34 binding to CD2.
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6 Analysis of alloreactivitv in transplanted animals
treated with anti-CD2 monoclonal antibody
6.1 Study objective
This section outlines investigations performed to explore aspects of the 
immune environment in animals with long surviving allografts, in order to explore 
the mechanism of action of OX34-based immunosuppressive regimes.
6.1.1 Assessment of transplant tolerance.
As survival data shows anti-CD2 mAb is effective at prolonging allograft 
survival in the low responder strain combination. We have also devised two new 
strategies to induce permanent allograft survival in high responder Lewis rats by 
combining anti-CD2 mAb with anti-CD4 mAb and CTLAJg. Various mechanisms 
may be involved in allowing permanent engraftment of tissue grafts in rodents 
including both graft adaptation by loss of immunogenic APC and development of 
true transplant tolerance. Before analysing alloreactivity in transplanted animals it is 
necessary therefore to demonstrate that transplanted animals have become tolerant to 
donor tissue by performing second donor-specific and third party allografts.
6.1.2 Analysis of mechanisms of transplant tolerance.
Having demonstrated donor specific tolerance in two of the transplant models 
under study (third party grafts were not successfully performed in the DA-Lewis 
model treated with 0X34 and CTLAJg due to insufficient numbers of surviving
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animals) we then turned to in vitro experiments to further examine the mechanisms 
of tolerance. Transplant tolerance is maintained by three principal mechanisms:
1) Clonal deletion of alloreactive cells
2) Clonal anergy
3) Immune regulation.
We explored features of the immune environment in tolerant animals and 
attempted to find evidence for the above mechanisms by performing the following 
experiments:
1) Measurement of proliferation of lymphocytes from tolerant animals on in 
vitro stimulation by splenocytes from donor strain and third-party animals.
2) Analysis of cytokine production by lymphocytes stimulated as above.
3) Analysis of antigen-specific cellular cytotoxicity.
4) Analysis of antigen-specific cytotoxic antibody production.
5) Microscopy of explanted hearts.
6.2 Study design
1) To assess the state of responsiveness of animals with permanently surviving 
allografts animals were retransplanted after a period exceeding one hundred days 
with a second allograft placed in the neck as described in materials and methods. The 
criterion for allograft rejection is cessation of beating as for primary grafts.
2) To assess mechanisms of alloreactivity in tolerant animals MLRs were 
performed in which LNCs from tolerant and naive rats were incubated with either 
medium alone, medium containing Con A, donor-strain splenocytes or third party 
PVG splenocytes. Proliferation was measured by incorporation of thymidine after 72 
hours of culture by the standard method. Results from different experiments can be 
expressed numerically using the proliferation index (PI), which takes into account
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background proliferation of cells in medium alone. A direct comparison can then be 
made between cells from different groups of animals analysed at different time 
points. Supernatants of these reactions were retained for comparative assessment of 
cytokine (IL2 and ylFN) production by cells from tolerant and naive animals.
3) Direct assessment of alloreactivity in high responder Lewis rats with 
permanently surviving allografts was performed by assessing the production of 
cytotoxic T cells and cytotoxic antibody in tolerant animals. These measurements 
were performed in the rats treated with 0X34 and 0X38, the model in which donor- 
specific tolerance has been proved. Allo-CTL production was measured in tolerant 
rats more than 100 days post-transplant only, as measurements at earlier time points 
would involve sacrificing rats before tolerance has been established and whilst the 
animals are still depleted of T cells (comparison of CTL induction between T cell 
depleted and naive rats would yield little useful information). Splenocytes were 
prepared from mAb treated, tolerant rats, unmodified rats undergoing acute allograft 
rejection (ten days post-transplant) and from naive rats. Strain-specific and third 
party splenocyte ConA blasts were prepared as above and labelled with 51Cr for use 
as target cells. lOOpl serial dilutions of effectors (starting 2xl07/ml) in serum-free 
culture medium were incubated with lOOjul target cells containing 104 blasts in V- 
bottomed plates. Incubations were for 4 hours in 5% CO2 at 37°C. 100ml culture 
supernatant was then harvested for estimation of y-emission.
4) Cytotoxic antibody activity was also measured in tolerant Lewis rats 100 
days post transplant. Serum was prepared from tolerant rats, unmodified rats 
undergoing acute allograft rejection (seven days post-transplant) and from naive rats 
by tail-bleeding and centrifugation. Serum was heat-inactivated by heating in a water 
bath for 30 mins at 56°C. Strain-specific and third-party target cells were prepared 
from splenocytes as described above. 50jul of tripling dilutions of serum in culture
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medium were added to V-bottomed plates followed by 50pl of target cells containing 
5 x 104 blasts. After incubation for 30 mins in 5% CO2 at 37°C lOOjul of reconstituted 
guinea-pig complement was added to each well and the plates were then incubated 
for a further one hour. Control wells contained 1) targets in medium alone 2) targets 
+ 150jul Triton and 3) targets plus complement alone. Plates were then centrifuged 
briefly to deposit cells and lOOpl of supernatant harvested for estimation of y- 
emission as previously.
5) The presence of IgG and IgM antibody was also measured by a flow 
cytometric technique at the same time point. DA strain LNCs were used as target 
cells and incubated with serial dilutions of serum from tolerant animals. Production 
of anti-DA IgG and IgM was then detected by secondary labelling with mouse anti- 
rat IgG and IgM fluorescent antibody. Mean channel fluorescence of the T cell peak 
was measured for each sample. Serum was also taken from transplanted rats treated 
with 0X34 and 0X38 at days seven and forty post-transplant to ensure detection of 
earlier peaks of antibody production.
6.3 Demonstration of transplant tolerance.
Firstly DA strain rats which had been treated with 0X34 prior to transplanting 
with Lewis strain hearts were retransplanted with donor specific Lewis hearts or third 
party PVG hearts. As can be seen in figure 6.1 donor strain hearts are accepted whilst 
third party PVG grafts are rejected, although at a slower tempo than in naive animals.
In a similar manner Lewis rats treated with 0X34 and 0X38 prior to 
transplanting with DA strain hearts were also rechallanged with donor specific and 
third party grafts (third party grafts were not successfully performed in the DA- 
Lewis model treated with 0X34 and CTLAJg due to insufficient number of
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surviving anim als). Again donor specific tolerance was dem onstrated with third party 
grafts being rejected at a tem po closer to that expected in a naive anim al (figure 6.2).
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Figure 6.1 Survival of second transplants in DA strain rats 
treated with 0X34 (2x5mg/kg) preoperatively
A nim als were retransplanted with either donor-specific Lewis 
hearts (n=4) or third party PVG hearts (n=3). (Lewis v PVG 
p<0.1, logrank test).
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Figure 6.2 Survival of second transplants in Lewis strain 
rats treated with 0X34 and 0X38
Tolerant rats treated with 0 X 3 4  (2x l0m g/kg) and 0 X 3 8  
(10,2,2,2m g/kg) preoperatively were retransplanted with either 
donor-specific DA hearts (n=4) or third-party PVG hearts (n=3) 
(DA v PVG p<0.05, logrank test).
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6.4 Analysis of mechanisms of transplant tolerance in DA
strain rats
Having demonstrated donor specific tolerance in two of the transplant models 
under study we then turned to in vitro experiments to further examine the 
mechanisms of tolerance.
6.4.1 Assessment of alloreactivitv of lymphocytes from DA strain 
rats treated with 0X 34 on in vitro stimulation.
As DA strain rats treated with 0X34 (2x5mg/kg) with long-term surviving 
Lewis allografts failed to reject a further Lewis allograft we performed mixed 
lymphocyte reactions to assess if this unresponsiveness could be demonstrated in 
vitro. Two series of experiments were performed, and cells from tolerant DA strain 
rats were consistently able to proliferate on stimulation with donor strain cells. 
Figure 6.3 shows the results comparing the proliferation of five tolerant and three 
naive rats in a single experiment.
6.4.2 Analysis of cytokine production in mixed lymphocyte reactions 
using tolerant DA strain responders
Further evidence for alloresponsive cells amongst lymphocytes from DA rats 
made tolerant to transplanted Lewis strain hearts by pre-operative 0X34 therapy was 
sought by analysing cytokine production in the above mixed lymphocyte reactions. 
Supernatants from the first experiment were retained and the production of the 
cytokines IL2 and yLFN was assayed by the methods described in materials and 
methods. Figure 6.4 shows an analysis of 1L2 and yLFN present in supernatants of an 
MLR using Lewis strain splenocytes as stimulators and naive and tolerant DA strain
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LNCs as responder cells. In this experiment cells from both tolerant and naive 
animals proliferate less on stimulation with Lewis strain cells than with PVG strain 
cells, and cells from tolerant animals are more responsive to all stimuli.
These results are in agreement with the proliferation data and suggest that 
despite the tolerant DA strain rats inability to reject a donor strain heart, lymphocytes 
from these animals are still able to respond to donor antigen in vitro, by cellular 
proliferation and cytokine production.
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ConA Medium Lewis PVG
Figure 6.3 Proliferation of cells from naive and tolerant DA 
rats after therapy with 0X34 on in vitro stimulation with 
donor antigen
M ean thym idine incorporation from a single experim ent o f 
naive DA LNCs and DA rats transplanted with Lewis allografts 
after pre-operative therapy with 0 X 3 4  (2x5mg/kg). Stim ulator 
cells are donor-specific Lewis and third-party PVG strain 
splenocytes. Control wells contain responder cells plus ConA or 
responder cells alone.
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Figure 6.4 Production of Thi cytokines by cells from tolerant 
and naive DA rats on in vitro stimulation with donor antigen
Analysis o f  IL2 and ylFN concentration in supernatant o f  a 
single MLR using LNCs from naive DA rats and DA rats 
transplanted with Lewis allografts after pre-operative therapy 
with 0X 34 . Stim ulator cells are Lewis splenocytes; differences 
are not significant.
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6.4.3 Assessment of alloreactivity of lymphocytes from DA strain 
rats treated with CTLAJg on in vitro stimulation.
Long-term allograft survival o f  DA strain rats treated  with CTLA4Ig and 
transplanted with Lewis strain hearts has been achieved in this project although true 
tolerance was not dem onstrated by perform ing second grafts. A ttem pts w ere m ade 
how ever to dem onstrate donor-specific hyporesponsiveness by M LR in a sim ilar 
m anner to DA strain rats treated with the 0 X 3 4  protocol.
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Figure 6.5 Proliferation of cells from naive and tolerant DA 
rats after therapy with CTLA4Ig on in vitro stimulation with 
donor antigen
M ean thym idine incorporation from a single experim ent o f  
naive DA LNCs and LNCs from DA rats transplanted with 
Lewis allografts after post-operative therapy with CTLAftg 
(2.5m g/kg) Stim ulator cells are Lewis and third-party PVG 
strain splenocytes. Control wells contain responder cells plus 
ConA or responder cells alone.
As can be seen in figure 6.5 donor-specific hyporesponsiveness is not 
dem onstrated in D A  rats treated with CTLAftg. In contrast to the findings w ith DA 
rats treated with the 0 X 3 4  protocol (figure 6.3) both tolerant and naive rats respond 
to a greater degree to Lewis than to PVG strain stim ulators.
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6.4.4 Proliferative responses of tolerant Lewis rats treated with 
QX34 and 0X38.
O f the two m odels o f  perm anent engraftm ent developed using high responder 
Lewis rats transplant tolerance has been dem onstrated in Lewis rats treated  with 
0 X 3 4  and 0 X 3 8  only. In a sim ilar m anner to above the ability o f  LNCs from  
tolerant rats to respond to donor and third party strain splenocytes was assessed in 
M LR experim ents. Three sets o f  experim ents were perform ed using LNCs from a 
total o f  seven tolerant Lewis rats, six naive rats and three unm odified Lewis rats 
undergoing acute rejection o f  DA strain allografts. The proliferation indices were 
calculated for each group after three days o f  culture to allow  com parisons across 
experim ents and the results are dem onstrated in figure 6.6.
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Figure 6.6 Proliferation of cells from tolerant Lewis rats 
after therapy with 0X34 and 0X38 on in vitro stimulation 
with donor antigen
M ean proliferation indices from three M LR experim ents using 
LNCs from Lewis rats tolerant to DA allografts after therapy 
with 0 X 3 4  (2x5m g/kg) and 0 X 3 8  (16m g/kg) and naive and 
rejecting control Lewis rats. P roliferation Index = (specific 
proliferation/proliferation in m edium ).
These results dem onstrate that lym phocytes from tolerant Lewis rats treated 
with 0 X 3 4  and 0 X 3 8  are able to proliferate norm ally to DA splenocytes in the
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MLR. Again lym phocytes from rats undergoing acute allograft rejection dem onstrate 
m ore dynam ic proliferative responses to both stim uli.
6.4.5 Cytokine production by lymphocytes from tolerant Lewis rats 
treated with QX34 and QX38,
Supernatants from the above reactions w ere retained to  assess the production o f  
the cytokines 1L2 and ylFN by lym phocytes from tolerant, naive and rejecting rats. 
Figure 6.7 shows the concentration o f  IL2 in supernatants from the M LR 
experim ents shown in figure 6.6 plus those o f  a further experim ent (values for PI 
could not be calculated in this experim ent as cells containing m edium  alone were not 
included). Supernatants from these four experim ents w ere retained and used in IL2 
bioassays in two groups, the m eans o f  which are dem onstrated. The experim ent was 
repeated using the sam e supernatants, with identical results.
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Figure 6.7 Production of IL2 by cells from tolerant Lewis 
rats after therapy with 0X34 and 0X38 on in vitro 
stimulation with donor antigen
IL2 concentration in supernatants o f  M LRs using cells from 
naive rats, Lewis rats tolerant to DA allografts after therapy w ith 
0 X 3 4  (2x5m g/kg) and 0 X 3 8  (16m g/kg) and Lewis rats 
rejecting a DA strain allograft. DA strain splenocytes used as 
stim ulators. Supernatants taken from four separate experim ents 
(tolerant v naive p=0.015, t test for unpaired data).
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This experim ent dem onstrates that lym phocytes from tolerant Lewis rats 
produce less 1L2 on in vitro stim ulation with donor-type antigen than do naive rats, 
despite show ing normal levels o f  proliferation. As dem onstrated in proliferation 
assays cells from rats undergoing an acute rejection process show an enhanced IL2 
response after in vitro stim ulation with donor antigen. To assess if  this paralysis o f  
IL2 production by cells from transplanted anim als is specific to stim ulation w ith 
donor antigen, supernatants w ere harvested from one MLR, in w hich cells from 
tolerant Lewis rats were stim ulated with donor-type DA cells and third party' PVG 
cells, and assayed for IL2 in the sam e manner.
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Figure 6.8 Production of IL2 by cells from tolerant Lewis 
rats after therapy with 0X34 and 0X38 on in vitro 
stimulation with donor antigen and third party antigen
M ean IL2 concentration in supernatant o f  single M LR using 
LNCs from tolerant Lewis rats after therapy with 0 X 3 4  
(2x5m g/kg) and 0 X 3 8  (16m g/kg) on in vitro stim ulation with 
donor type DA splenocytes or third party PVG splenocytes.
Figure 6.8 dem onstrates that in a sam ple o f  the anim als assayed in figure 6.7 
IL2 production by cells from tolerant anim als dem onstrate dim inished IL2 
production on stim ulation by both donor type and third party antigen.
In a sim ilar m anner the ability o f  cells from tolerant anim als to produce ylFN 
on in vitro stim ulation was m easured. The reduced IL2 elaboration by cells from 
tolerant Lewis rats was not reproduced for ylFN, the production o f  which was sim ilar
6.211
by cells from all sources m easured (ylFN production was not m easured for cells from 
anim als rejecting their allografts) (figure 6.9).
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Figure 6.9 Production of ylFN by cells from tolerant Lewis 
rats on in vitro stimulation with donor antigen
M ean ylFN concentration in supernatants o f  two MLR 
experim ents using LNCs from tolerant Lewis rats after therapy 
w ith 0 X 3 4  (2x5m g/kg) and 0 X 3 8  (16m g/kg) on in vitro 
stim ulation with donor type DA splenocytes.
6.4.6 Proliferative responses of tolerant Lewis rats treated with 
QX34 and CTLAJ g
Long-term survival o f  DA allografts in Lewis rats was obtained by using a 
com bination o f  0 X 3 4  and CTLA4Ig at varying doses. True transplant tolerance was 
not dem onstrated how ever in this model by perform ing donor specific second 
allografts but investigations were perform ed on cells from  rats with long surviving 
grafts to investigate features o f  the im m une environm ent in these anim als. By using 
standard MLR experim ents the ability o f  LNCs from rats with long surviving 
allografts to respond to donor and third party strain splenocytes was assessed. Two 
separate experim ents were perform ed using LNCs from a total o f  five engrafted 
Lewis rats, two naive rats and two unm odified Lewis rats undergoing acute rejection
Naive n=4 Tolerant n =6
Responding cell type
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o f  DA strain allografts. The proliferation indices were calculated for each group to 
allow  com parisons across experim ents and the results are dem onstrated in figure
6 . 10 .
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Figure 6.10 Proliferation of cells from Lewis rats with long 
surviving grafts after therapy with 0X34 and CTLAJg on 
in vitro stimulation with donor antigen
M ean relative proliferation o f  tw o experim ents using LNCs 
from naive Lewis rats, Lewis rats undergoing rejection o f  a DA 
allograft and perm anently engrafted Lewis rats after treatm ent 
w ith 0 X 3 4  (10 or 20 mg/kg) and CTLAftg (2.5m g/kg) on 
stim ulation with donor-specific and third party splenocytes.
This graph dem onstrates that lym phocytes from engrafted Lewis rats treated 
with 0 X 3 4  and CTLAftg proliferate to a broadly sim ilar degree as those o f  naive 
Lewis rats after stim ulation by DA splenocytes in the M LR, in a sim ilar fashion to 
the other m odels o f  allograft survival assessed in this project. These results 
dem onstrate that an alloreactive T cell repertoire persists in all experim ental anim als 
exam ined in this project, excluding clonal deletion as a m echanism  o f  tolerance.
Supernatants from a single MLR in which cells from transplanted rats treated  
w ith 0 X 3 4  and CTLA4Ig were stim ulated w ith donor type splenocytes were assessed 
for IL2 production. Very low  levels o f  IL2 were noted in these supernatants that did 
not allow  discrim ination betw een samples.
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6.5 Analysis of allo-specific effector mechanisms in tolerant 
Lewis rats after therapy with 0X 34 and 0X38.
The presence of alloreactive T cells in tolerant Lewis rats transplanted with DA 
allografts has been established by proliferation assay. As has been outlined in the 
introduction this assay is not a precise replica of transplant alloimmunity as the 
stimulating cell (DA splenocytes in these experiments) differs from the stimulating 
cell in the transplant model (DA myocytes). We therefore wished to establish if allo- 
sensitised cells are present in tolerant animals.
6.5.1 Assessment of allospeciflc CTL in tolerant Lewis rats.
Firstly we assessed the ability of tolerant Lewis rats treated with this regime to 
generate specific anti-DA cytotoxic lymphocytes. Splenocytes were prepared from 
six tolerant Lewis rats >100 days post transplant treated with 0X34 and 0X38 and 
four Lewis rats 14 days after the onset of acute allograft rejection of an unmodified 
DA allograft. Both groups of cells were used as effectors as described in materials 
and methods. Con A treated DA and PVG strain splenocytes were used as target 
cells. As can be seen in figure 6.11 tolerant Lewis rats generate specific cellular 
cytotoxicity to DA strain targets, but to a lesser degree than rejecting rats. As 
expected neither group of rats show specific cytotoxicity to third party PVG strain 
targets.
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Figure 6.11 Generation of donor-specific allo-CTL by 
tolerant Lewis rats treated with 0X34 and 0X38
M ean % specific cytotoxicity (DA targets) and non-specific 
cytotoxicity (PVG targets) o f  splenocytes from unm odified 
Lewis rats 10 days after transplant o f  a DA allograft (n=4) and 
Lewis rats tolerant to DA allografts after pre-operative therapy 
with 0 X 3 4  (2x5m g/kg) and 0 X 3 8  (16m g/kg)(n=6).
6.5.2 Assessment of alloantibody production by tolerant Lewis rats 
after therapy with 0X34 and 0X38.
In a sim ilar m anner and using the sam e rats as a source o f  serum we assessed 
the production o f  specific cytotoxic antibody in tolerant and rejecting rats. Naive 
Lewis rats were also used as a source o f unm odified serum for use as a negative 
control. Serial dilutions o f  serum  were then incubated with MCr labelled DA strain 
blasts and guinea pig serum  used as a source o f  com plem ent as described in m aterials 
and methods. As can be seen in figure 6.12 the six tolerant Lewis rats tested in this 
way produce no dem onstrable cytotoxic antibody.
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Figure 6.12 Generation of donor-specific cytotoxic 
alloantibody by tolerant Lewis rats treated with 0X34 and 
0X38
M ean % specific cytotoxicity (DA targets) o f  serum from 
unm odified Lewis rats 10 days after transplant o f  a DA allograft 
(n=4), from naive Lewis rats and from Lewis rats tolerant to DA 
allografts after pre-operative therapy with 0 X 3 4  (2x5m g/kg) 
and 0 X 3  8 (16m g/kg)(n=6).
The absence o f  specific antibody m ediated cytotoxicity can be explained by 
either the absence o f  specific antibody or by peripheral m echanism s o f  im m une 
regulation involving com peting antibody isotypes. We therefore investigated the 
presence, in addition to the function, o f  specific alloantibody by a flow cytom etric 
m ethod in rejecting and tolerant Lewis rats. Serum was taken from four unm odified 
Lewis rats seven days after receiving a DA strain allograft and com pared to serum  
from  tolerant Lewis rats 100 days post-transplant treated w ith 0 X 3 4  and 0 X 3 8  
preoperatively. Serial dilutions o f  serum  were incubated with DA strain LNCs before 
labelling with specific m ouse anti-rat IgG and IgM and analysis by FACS. Figures 
6.13 and 6.14 show  that tolerant Lewis rats fail to produce anti-DA strain antibody o f 
IgM or IgG class.
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Figure 6.13 Generation of donor-specific alloantibody of 
IgM subclass by tolerant Lewis rats treated with 0X34 and 
0X38
Flow cytom etric analysis o f  serum  from  Lewis rats tolerant to 
DA strain allografts (>100 days post transplant) after 
preoperative treatm ent with 0 X 3 4  (lO m g/kg total) and 0 X 3 8  
(16m g/kg total) and serum  from unm odified Lewis rats seven 
days after receiving a DA cardiac allograft. DA target cells were 
labelled with FITC-conjugated m ouse anti-rat IgM antibody 
after incubation with test serum.
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Figure 6.14 Generation of donor-specific alloantibody of IgG 
subclass by tolerant Lewis rats treated with 0X34 and 0X38
Flow cytom etric analysis o f  serum  from  Lewis rats tolerant to 
DA strain allografts (>100 days post transplant) after 
preoperative treatm ent with 0 X 3 4  (lO m g/kg total) and 0 X 3 8  
(16m g/kg total) and serum  from unm odified Lewis rats seven 
days after receiving a DA cardiac allograft. DA target cells w ere 
labelled with FITC-conjugated m ouse anti-rat IgG antibody after 
incubation w ith test serum
6.217
Specific im m unological tolerance in this m odel is therefore associated with 
abrogation o f  the alloantibody response to the graft in long-term  recipients. 
Experim ents were also perform ed with serum  from transplanted Lewis rats treated as 
above using neat serum  harvested seven and forty days post transplant, to  ensure 
detection o f  an early IgM or IgG peak. Very low levels o f  specific anti-DA antibody 
are dem onstrable at all tim e points in to lerant rats (figure 6.15).
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Figure 6.15 Generation of donor-specific alloantibody of IgG 
and IgM subclass by tolerant Lewis rats treated with 0X34 
and 0X38 during the induction of transplant tolerance
M ean channel fluorescence o f  DA target cells incubated with 
serum  from Lewis rats transplanted w ith DA allografts and 
treated with 0 X 3 4  and 0 X 3 8  taken at 7 (n=3), 40 (n=3) and 150 
( n ^ )  days post-transplant com pared to unm odified Lewis rats 
(n=4) 14 days post-transplant. Target cells are labelled with 
FITC-conjugated m ouse anti-rat IgM and IgG antibody.
6.6 C onclusions and d iscussion  o f  results
6.6.1 Demonstration of transplant tolerance
Tolerance to donor tissue has been dem onstrated for the DA to Lewis model 
treated pre-operatively with 0 X 3 4  (2x5m g) and 0 X 3 8  (10,2,2,2m g/kg). In the Lewis 
to DA m odel treated with 0 X 3 4  alone (2x5m g/kg pre-operatively) three o f  four
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retransplanted animals accepted a second donor type allograft whilst all rejected a 
third party allograft; the logrank test for these data is very close to significance. 
Transplant tolerance in Lewis rats treated with 0X34 and 0X38 however can be 
concluded by:
1) The persistence of a strong, palpable heart beat
2) The microscopic appearance of minimal tissue damage
3) The absence of detectable alloantibody in transplanted Lewis rats
The observation that tolerant rats of both strains reject third-party allografts at a 
slower tempo than naive rats suggests the presence of continued immunosuppression 
in treated rats. This observation is supported by the continued depletion of CD4 T 
cells more than 100 days after therapy with 0X34 in DA strain rats. Furthermore 
MLR experiments reported in this section suggest a depressed response of LNCs 
from tolerant Lewis rats treated with 0X34 and 0X38 against both donor specific 
and third-party alloantigen in terms of proliferation and cytokine production, 
although the small number of animals used does not allow the demonstration of 
statistical significance. As noted in the text tolerance in Lewis rats treated with 0X34 
and CTLA4lg was not successfully demonstrated due to technical difficulties with the 
procedure of cervical transplantation.
6.6.2 Analysis of proliferative responses in transplanted rats.
In contrast to the response of DA and Lewis rats to second donor and third 
party allografts, donor type hyporesponsiveness is not demonstrated in MLR 
experiments for any of the models under study, since LNCs from successfully 
transplanted rats are consistently able to proliferate on stimulation with donor type 
cells. Estimates of relative proliferation between LNCs from naive and transplanted 
animals against donor and third party splenocytes are difficult to draw from MLR
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experiments as the pattern of proliferation differs between experiments performed 
under identical conditions. A safe conclusion from these experiments however is that 
cells from tolerant animals are able to respond to donor strain lymphocytes in vitro 
(‘split tolerance’). The only other consistent observation from the MLR experiments 
performed is that cells from sensitised animals (undergoing acute allograft rejection) 
produce greater degrees of proliferation on in vitro stimulation with donor type 
antigen than cells from either naive or tolerant animals.
6.6.3 Analysis of cytokine production in MLR experiments
IL2 and ylFN production by cells from 0X34 treated DA strain rats with long 
surviving Lewis allografts on stimulation with Lewis splenocytes was measured in 
the supernatant of one MLR. No difference was noted in cytokine production 
between cells from naive and transplanted animals, in keeping with their similar 
degree of proliferation. In contrast a striking difference was noted in IL2 production 
between cells from naive Lewis rats and Lewis rats tolerant to DA allografts after 
therapy with 0X34 and 0X38 on stimulation with DA splenocytes. This was not 
matched by a similar reduction in ylFN production. This difference in IL2 production 
by tolerant cells may be either stimulator cell-type specific or may represent a 
generalised reduction in DL2 production by cells from animals treated with 0X34 and 
0X38. To address this question supernatants from a single MLR only in which the 
cells from two naive Lewis rats and two tolerant rats were stimulated by PVG 
splenocytes was also assessed for IL2 production (figure 6.8). Unfortunately this 
MLR produced supernatant with the highest IL2 content on stimulation with both 
strains of splenocyte stimulator cell. Although tolerant Lewis LNCs produced less 
IL2 on stimulation by both types of stimulator cell, adequate numbers of experiments
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were not performed to reliably discriminate between donor-specific 
hyporesponsiveness and a persistent global suppression of T cell function.
No reliable comment can be made regarding cytokine concentration in MLRs 
using cells from Lewis rats treated with 0X34 and CTLAJg.
6.6.4 Analysis of effector mechanisms in tolerant Lewis rats after 
therapy with 0X 34 and 0X38
The results of experiments assessing effector mechanisms in tolerant Lewis rats 
show a dichotomy between humoral and cellular alloresponses. Tolerant rats are 
clearly able to generate cytotoxic T cells directed against alloantigen, although to a 
lesser degree than rats undergoing acute allograft rejection. The controls used in this 
experiment (figure 6.11) are unmodified Lewis rats 10 days post-transplant, a time 
point where cellular responses may be expected to be very high. The lower level of 
cytotoxicity found in cells from tolerant Lewis rats may represent either a lower titre 
of allo-reactive CTL or impaired lysis by CTL.
Very low levels of antibody-mediated cytotoxicity are generated by these 
Lewis rats, in contrast to the high levels of cytotoxic alloantibody found in serum 
from rejecting animals. Analysis of alloantibody class in tolerant Lewis rats reveals 
that no IgM is present, although very low levels of T-dependent IgG directed at DA 
antigen are present. This antibody is however only detectable during the maintenance 
phase of immune-tolerance (>100 days) and is absent during the induction phase 
(measured at days 7 and 40). The inability of Lewis rats treated with this 
combination of mAb to generate either an IgG or IgM antibody response despite the 
presence of large numbers of B cells suggests that in Lewis rats both classes of 
antibody are T cell dependent, and also that a degree of B cell tolerance has 
developed in Lewis rats during the prolonged period of T cell depletion.
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7 Summary
The starting point of this discussion is the observation made in Chapter 3 on 
the efficacy of anti-CD2 mAb in transplant models either when used alone in low 
responder strain rats or in combination with other modalities in high responder strain 
rats. The subsequent two chapters contain the bulk of the experimental work of this 
project which aims to investigate the mechanism by which anti-CD2 mAb acts as an 
immunosuppressive agent in rat experiments. These investigations therefore 
concentrate on the mechanisms of induction, rather than maintenace, of transplant 
tolerance and seek to compare these mechanisms to those of the established 
immunosuppressive agents anti-CD4 mAb and CTLAJg. The final chapter begins to 
explore the mechanisms of the maintenance of transplant tolerance in DA and Lewis 
rats, although the investigation of tolerance mechanisms is a secondary aim of this 
project. This chapter will bring together findings from each of the sections of the 
thesis to give an overview of the biological effects and mechanisms of anti-CD2 
mAb.
7.1 The in vivo properties of anti-CD2 mAb
The ability of 0X34 to induce permanent allograft survival in DA strain rats 
but not in Lewis rats is described, and the related anti-CD2 mAb 0X55 is noted to be 
less potent than 0X34. An analysis of timing and dose of 0X34 administration 
reveals that post-operative therapy is ineffective at reversing graft rejection and that a 
‘threshold’ dose of 0X34 (2x5mg/kg) is required to prevent acute allograft rejection, 
with lower doses having minimal impact on allograft survival. After intravenous 
administration 0X34 induces a marked depletion of CD4 T cells to similar levels in
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both Lewis and DA strain rats, so that differential levels of depletion do not explain 
the difference in graft survival seen in the two strains. The depletion of CD4 T cells 
by 0X34 is greater than that induced by the depleting anti-CD4 antibody 0X38, 
whilst little effect is detectable on CD8 T cells, despite equal expression of CD2 by 
the two subsets. The anti-CD2 mAb 0X55 induces a similar overall level of 
depletion of T cells but depletes CD4 and CD8 T cells equally.
Further examination of the cellular depletion induced by 0X34 shows that the 
level of CD4 T cell depletion differs between the vascular and lymphatic 
compartments, suggesting that an external factor more accessible in the vascular 
compartment contributes to the depletion process. Furthermore the depletion of T 
cells is progressive over a period of weeks, during which time there is excess mAb in 
the circulation. This may be due to saturation of Fc receptors on fixed tissue 
macrophages in the liver and spleen limiting the depletion of antibody-coated cells.
The T cell population recovers slowly after administration of 0X34 mAb and 
depletion of T cells continues for at least 100 days, whilst the mAb is eliminated 
from the circulation by day 21. The depletion of CD4 T cells induced by 0X34 is 
accompanied by a relative preponderance of the B cell fraction, whilst the ‘null’ cell 
(OX12-/R73-) fraction remains constant in size. In keeping with this the lytic 
function of NK cells is not reduced by 0X34 therapy.
Acute graft rejection in these models requires unbound CD2 molecules as 
0X34 therapy at the dose which induces permanent allograft survival saturates all 
0X34 binding sites 24 hours after administration, and induces modulation of the 
CD2 molecule from the surface of undepleted cells. The less potent mAb 0X55 
induces greater modulation of the CD2 molecule than 0X34, suggesting that 
modulation is not a crucial aspect of the immunosuppressive effect of anti-CD2 
mAb. Analysis of the effects of low dose 0X34 therapy (2.5mg/kg) reveals that a
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similar level of T cell depletion is obtained as by high dose therapy but without 
saturation of 0X34 binding sites. This demonstrates that saturation of the CD2 
molecule is not necessary to induce depletion of T cells. The ability of rats treated 
with low dose 0X34 to mount an acute rejection response also suggests that the 
remaining unbound CD2 molecules are involved in allosensitisation. The CD2 
molecule is therefore able to act as an accessory molecule in the alloimmune 
response to an organ graft, but can also become a gateway for transmission of a 
negative signal when labelled with 0X34 mAb.
The differential effect of 0X34 therapy on graft survival in Lewis and DA 
strain rats may relate to the fact that Lewis rats are able to generate an anti-globulin 
response to 0X34 mAb leading to its early elimination from the circulation. Despite 
the preponderance of the B cell fraction noted in DA strain rats after 0X34 therapy 
these animals eliminate 0X34 by mechanisms not involving humoral immunity.
7.2 The in vitro properties of anti-CD2 mAb
Having demonstrated potent effects of 0X34 mAb in rat experiments in terms 
of graft survival and cellular depletion, we then explored its effect in in vitro assays 
to define its mechanism of action. In contrast to anti-CD4 mAb and CTLA4g, which 
have predictable and potent effects on in vitro correlates of alloimmunity, anti-CD2 
mAb has only subtle effects, which make a stark contrast with the findings noted 
above.
In MLR experiments we have shown that both the anti-CD4 mAb 0X38 and 
CTLAJg are able to inhibit proliferation whilst neither 0X34 nor 0X55 have a 
consistent effect. In proliferation experiments using anti-TCR antibody, where 
costimulatory signals are less crucial in activation, anti-CD4 mAb is partially able to 
inhibit T cell activation while CTLAftg and anti-CD2 mAb have no effect. Analysis
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of the production of the cytokines IL2 and ylFN in these proliferation assays shows 
that both anti-CD4 mAb and CTLA4g are able to inhibit cytokine production in a 
similar manner to their inhibition of proliferation. Anti-CD2 mAb has minimal 
impact on cytokine production in these assays. Anti-CD2 mAb therefore does not 
inhibit T cell activation either by influencing signal 1 or signal 2 in the manner of 
anti-CD4 mAb and CTLAJg. Furthermore lymphocytes can be cultured with 0X34 
in viiro without undergoing cell death on the scale seen after intravenous 
administration. The exception to this is when cells are cultured with 0X34 fixed to 
the walls of a culture plate, which has a negative impact on cell survival. This 
suggests that physical anchoring of the 0X34 mAb may be important in its effect. 
The greater depletion of 0X34 in the vascular compartment may be a result of 0X34 
binding via Fc receptors to fixed tissue macrophages.
According to the above results CD2 modulation by anti-CD2 mAb is unable to 
prevent in vitro allosensitisation despite the role of the CD2 molecule in sensitisation 
to an organ graft in an intact animal. This suggests that undepleted cells have other 
accessory pathways which can augment T cell activation in the absence of CD2. 
Further experiments were then performed to examine if the effect of anti-CD2 mAb 
lies in the generation of effector functions in MLR experiments. 0X34 was noted to 
inhibit the in vitro generation of allo-CTL, but to a lesser degree than 0X38. In a 
similar manner 0X34 is able to prevent the amplification of NK cells in MLR bulk 
cultures. Assessment of lysis by CTL and NK cells showed that 0X34 is unable to 
inhibit the effector arm of cellular cytotoxicity. These observations show that despite 
the inability of 0X34 therapy to prevent allosensitisation in terms of proliferation 
and Thi cytokine release it is still able to inhibit the provision of helper signals for 
CTL induction and NK cell amplification.
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In an attempt to explain the depleting effect of mAb, in vitro experiments 
showed that neither 0X34 nor 0X38 are able to fix rat complement, excluding 
complement mediated lysis as a mechanism of depletion. The preferential depletion 
of CD4 T cells by 0X34 is more marked within the vascular compartment suggesting 
that factors outside the cell are also important in T cell lysis. In support of a role for 
Fc-mediated functions is the observation that both 0X55 (IgG 1) and 0X34 (IgG2a) 
can act as opsonins to promote the activity of NK cells in in vitro assays.
The difference in survival between cells exposed to 0X34 in vivo and in vitro 
indicates that the proliferation assays described above do not accurately reproduce 
biological events within an intact animal and therefore limited conclusions can be 
drawn from these assays.
7.3 Combination therapy in high responder Lewis strain 
rats
Survival data show that 0X34, 0X38 and CTLA^g are only able to prolong 
allograft survival in Lewis rats, but a combination of 0X34 with either of the other 
two reagents allows the induction of permanent allograft survival. This interaction is 
probably synergistic because high doses of 0X34 and 0X38 in other treatment 
regimes do not show an improved effect over low dose therapy. An exploration of 
the mechanisms involved in the induction of tolerance in these regimes shows that a 
combination of treatment modalities causes more profound CD4 T cell depletion than 
0X34 does alone. Anti-CD4 mAb has also been shown to transmit negative signals 
to T cells and the proportion of cells which are resistant to cell death induced by a 
single mAb may be susceptible to a combination of effects. The increased depletion 
seen in animals treated with 0X34 and CTLAJg may be due to blockade of the B7
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molecule by CTLAJg, which has been shown to promote cell death by apoptosis. 
Another effect of CTLA^g in the Lewis model is to prevent the generation of an 
anti-globulin response, thereby allowing prolonged circulation of 0X34 and cellular 
depletion. The CD2 molecule remains modulated from the cell surface of the few 
remaining CD4 T cells for the duration of circulation of 0X34 in Lewis rats treated 
with either regime.
An anlysis of the mechanisms involved in the maintenance of transplant 
tolerance in these regimes shows no evidence for the induction of anergy. Cells 
removed from both DA and Lewis rats with long surviving allografts retain the 
ability to proliferate in in vitro culture when stimulated by donor cells. It is noteable 
however that cells from a tolerant Lewis rat treated with 0X34 and 0X38 show 
deficient IL2 production when stimulated in vitro. This may be a long-term effect of 
mAb-induced immunosuppression. Estimation of effector functions in tolerant Lewis 
rats treated with 0X34 and 0X38 shows an almost complete abrogation of the 
humoral response to graft antigens and a reduction in cytotoxic T cell activity 
compared to that of a rejecting, unmodified control rat.
7.4 Final synopsis
Previous publications which have reported experience with anti-CD2 mAb in 
the mouse suggest a mechanism of action which involves the modulation of the CD2 
molecule without cellular depletion (292, 304), the inhibition of costimulatory 
signals in T cell activation (291) and the induction of a Th2 phenotype amongst 
alloreactive cells (289). More recent studies in the rat (300, 301, 303) have advanced 
a similar mechanism for the effect of mAb to the rat CD2 molecule. However the 
mouse CD2 molecule shows fundamental differences to the rat CD2 molecule in 
terms of:
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1) Its distribution on B as well as T cells (352)
2) The presence of allotypic variants (287)
These differences suggest that the molecule may also function in a different 
manner and respond differently to anti-CD2 mAb. In keeping with this is our 
observation that whilst anti-CD2 mAb is ineffective when used as monotherapy in 
the mouse and has a synergistic action with anti-CD3 mAb (296), anti-CD2 mAb has 
a reverse pattern of effects in the rat, as it is effective in a low responder strain when 
used as monotherapy and shows no synergy of action with anti-CD3 mAb. The 
results reported in this thesis therefore do not support a construction based on the 
inhibition of costimulation but rather suggest that the principle mechanism of action 
of 0X34 mAb is the transmission of a negative signal via the CD48-binding domain 
of the CD2 molecule on CD4 T cells using an Fc-mediated interaction with a host 
cell. This results in death of the mAb-bound cell and consequent disabling of 
immune responses. The following novel observations presented in this thesis support 
this proposition:
1) Intravenous 0X34 therapy causes profound and long lasting depletion of 
CD4 T cells (greater than that caused by 0X38)
2) Depletion is not caused by complement fixation
3) 0X34 labels CD4 and CD8 T cells equally yet only depletes CD4 T cells
4) OX34-mediated death of CD4 T cells occurs more readily within the 
vascular than the lymphatic compartment, despite saturation o f binding 
sites in both compartments
5) Depletion of T cells is progressive in the presence of excess 0X34 in the 
serum of treated rats
6) 0X34 mAb in solution in in vitro lymphocyte cultures causes more 
marked modulation of the CD2 molecule than after intravenous
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administration in an intact animal yet has minimal impact on T cell 
activation and cytokine release in the MLR or after stimulation with anti- 
TCRmAb
7) Rat Fc-receptors recognise mouse Fc, and 0X34 acts as an opsonin on NK 
target cells
8) 0X55 mAb causes more profound modulation of the CD2 molecule than 
0X34 yet is less effective in transplant models
9) 0X55 mAb causes less cellular depletion and does not discriminate 
between CD4 and CD8 T cells
10) Coadministration of CTLAJg with 0X34 exaggerates the depletion of 
CD4 T cells (blockade of B7 is known to promote apoptosis)
11) Coadministration of 0X38 with 0X34 also exaggerates the depletion of 
CD4 T cells (anti-CD4 mAb can also act by delivery of a negative signal)
12) The more profound and prolonged depletion of CD4 T cells induced by 
these combination regimes is associated with permanent allograft survival 
in high responder rats.
In contrast results presented in this thesis provide little evidence that 0X34 
mAb acts by inducing hyporesponsiveness through blockade of costimulatory signals 
in the classic manner described by Bretscher and Cohn (90).
7.4.1 Future pospects
Two broad areas of research arise from this thesis which are worthy of further 
study. The potent ability of 0X34 to deliver negative signals and cause T cell 
depletion could be corroborated by analysis of apoptosis both in vivo and in vitro by 
assays of DNA fragmentation. The nature of the host agent responsible for 
cooperating with CD2-mediated apoptosis could be investigated by using radio-
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labelled 0X34 to determine the site of T cell lysis. Attempts could also be made to 
saturate host Fc receptors with Fc fragments to assess their involvement in this 
process.
The findings reported in the tolerant Lewis rats after therapy with 0X34 and 
0X38 are unusual and merit further study. Particularly interesting are the related 
findings of abnormal DL2 production by cells from tolerant animals and the failure of 
upregulation of B7 expression by these cells. These findings suggest that tolerance in 
these animals may be due to an abnormality of the IL2 pathway, a finding which has 
been noted before in the context of tolerance induced by DST (277). This finding 
could be pursued further by a more extensive analysis of B7 expression in these 
animals and by assessment of isolated graft infiltrating cells.
8.230
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